The data behind the atlas
Twenty-five views of anti-cancer nephrotoxicity, drawn from the citation-grounded catalog: a phenotype-similarity map, the growing evidence base, onset timing, FAERS reporting signals, renal anatomy, several clinical cross-tabs, the field's co-authorship structure, the regimen pairs that compound kidney risk, and a browsable explorer of any agent's nearest phenotype analogs.
Phenotype & similarity
What kind of kidney injury each agent causes, and which agents resemble each other.
Every anti-cancer agent placed so that nearness means a similar kidney-injury phenotype — computed from the full set of kidney injuries each agent carries, nephron segments, severity, drug class, and a small approval-era term that keeps identical fingerprints apart. Neighborhoods emerge on their own: platinum tubular injury, anti-VEGF glomerular disease, checkpoint-inhibitor interstitial nephritis. Dot size scales with FAERS reporting volume. Filter by injury; tap a profiled agent to open it.
- Acute Tubular Necrosis: Actinium 225 PSMA, BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib), Binimetinib, Carboplatin, Cisplatin, Cobimetinib, Datopotamab deruxtecan (Dato-DXd), Disitamab vedotin, Encorafenib, Enfortumab vedotin, Gallium nitrate, Ibandronate, Iobenguane I-131, Lenalidomide, Lurbinectedin, Melphalan flufenamide (melflufen), Nedaplatin, Pentostatin, Plicamycin (mithramycin), Procarbazine, Raltitrexed, Samarium-153 lexidronam, Sonidegib, Telisotuzumab vedotin (Teliso-V), Trabectedin, Trastuzumab deruxtecan, Vemurafenib, Zoledronic acid
- Acute Interstitial Nephritis: Atezolizumab, Avelumab, Bicalutamide, Cadonilimab, Cemiplimab, Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab), Cosibelimab, Dabrafenib, Dostarlimab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Relatlimab, Retifanlimab, Sugemalimab, Tislelizumab, Toripalimab
- Thrombotic Microangiopathy: 5-Fluorouracil, Bortezomib, Busulfan, Carfilzomib, Carmofur (HCFU), Doxifluridine, Gemcitabine, Ixazomib, Mitomycin C, Moxetumomab pasudotox, Oxaliplatin, Tegafur-uracil (UFT), Trastuzumab emtansine (T-DM1), promacta
- Glomerular Injury / Proteinuria: Belantamab mafodotin, Bevacizumab, Dasatinib, Doxorubicin, Erlotinib, Everolimus, Gefitinib, Interferon-α, Ivonescimab, Olverembatinib, Pamidronate, Pazopanib, Sirolimus, Temsirolimus, mTOR inhibitors (everolimus · temsirolimus)
- Electrolyte Disturbance: Abiraterone, Amivantamab, Amsacrine, Avutometinib, Cetuximab, Dactinomycin (actinomycin D), Darolutamide, Defactinib, Denosumab, Erdafitinib, Fedratinib, Furmonertinib, Futibatinib, Gedatolisib, Imatinib, Inavolisib, Infigratinib, Lanreotide, Mechlorethamine, Mitotane, Necitumumab, Nirogacestat, Octreotide, Panitumumab, Pemigatinib, Relacorilant, Strontium-89 chloride, Sunvozertinib, Teniposide, Vinflunine
- Fanconi Syndrome: Azacitidine, Ifosfamide, Streptozocin
- Crystal / Obstructive Nephropathy: Bendamustine, Cladribine, Cytarabine, Decitabine, Etoposide, Fludarabine, Hydroxyurea, Idarubicin, Methotrexate (high-dose), Mitoxantrone, Nelarabine, Obinutuzumab, Odronextamab, Pirtobrutinib, Pralatrexate, Rituximab, Sonrotoclax, Venetoclax
- Hypertension: Acalabrutinib, Asciminib, Axitinib, Cabozantinib, Copanlisib, Enzalutamide, Fruquintinib, Ibrutinib, Lenvatinib, Leuprolide, Nintedanib, Niraparib, Ponatinib, Pralsetinib, Ramucirumab, Regorafenib, Ripretinib, Selpercatinib, Sorafenib, Sunitinib, Tivozanib, VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib), Vandetanib, Ziv-aflibercept
- Prerenal / Hemodynamic AKI: Adagrasib, Afamitresgene autoleucel (Afami-cel), Afatinib, Alpelisib, Altretamine (hexamethylmelamine), Anitocabtagene autoleucel, Arsenic trioxide, Asparaginase, Avapritinib, Belzutifan, Bleomycin, Blinatumomab, Brentuximab vedotin, CAR-T cell therapy, Cabazitaxel, Camizestrant, Capecitabine, Capivasertib, Casdatifan, Catumaxomab, Ceritinib, Ciltacabtagene autoleucel, Clofarabine, Dacarbazine, Daratumumab, Daraxonrasib, Denileukin diftitox, Dinutuximab, Docetaxel, Dordaviprone, Duvelisib, Elacestrant, Elotuzumab, Elranatamab, Enasidenib, Epcoritamab, Eribulin, Estramustine, Gemtuzumab ozogamicin, Gilteritinib, Glasdegib, Glofitamab, Iberdomide, Ibritumomab tiuxetan, Idecabtagene vicleucel, Idelalisib, Imetelstat, Inotuzumab ozogamicin, Interleukin-2 (high-dose), Irinotecan, Isatuximab, Ivosidenib, Lifileucel, Linvoseltamab, Lisocabtagene maraleucel, Loncastuximab tesirine, Midostaurin, Mirdametinib, Mirvetuximab soravtansine, Mobocertinib, Mogamulizumab, Mosunetuzumab, Naxitamab, Neratinib, Nilotinib, Obecabtagene autoleucel (Obe-cel), Olutasidenib, Paclitaxel, Pacritinib, Pegaspargase, Pexidartinib, Pivekimab sunirine, Polatuzumab vedotin, Pomalidomide, Quizartinib, Radium-223 dichloride, Revumenib, Ruxolitinib, Sacituzumab govitecan, Selumetinib, Sevabertinib, Sotorasib, Tafasitamab, Tagraxofusp, Talquetamab, Tarlatamab, Tasonermin, Tazemetostat, Tebentafusp, Teclistamab, Thalidomide, Tisotumab vedotin, Topotecan, Tovorafenib, Trametinib, Tretinoin (ATRA), Trifluridine/tipiracil, Vepdegestrant, Zanidatamab, Zanubrutinib, Zenocutuzumab, Zidesamtinib, Ziftomenib, Zolbetuximab
- SIADH / Hyponatremia: Chlorambucil, Cyclophosphamide, Lazertinib, Melphalan, Osimertinib, Selinexor, Tamoxifen, Temozolomide, Vinblastine, Vincristine, Vinorelbine, Vismodegib
- Hemorrhagic Cystitis: Thiotepa
- Pseudo-AKI: Abemaciclib, Alectinib, Bosutinib, Brigatinib, Capmatinib, Ensartinib, Entrectinib, Imlunestrant, Larotrectinib, Lorlatinib, Momelotinib, Olaparib, Palbociclib, Repotrectinib, Ribociclib, Rucaparib, Talazoparib, Taletrectinib, Tepotinib, Tucatinib, Vimseltinib, Vorasidenib, Zongertinib, saruparib
- Renal Cysts: Crizotinib
- Chronic Interstitial Nephropathy: Carmustine (BCNU), Fotemustine, Lomustine (CCNU), Lutetium-177 Dotatate, Lutetium-177 PSMA-617 (vipivotide), Nimustine (ACNU), Pemetrexed
300 agents · dot size = FAERS reporting volume, for the 283 agents openFDA returns reports for. The remaining 17 are drawn as hollow rings: every static-catalog agent is queried, so a ring means openFDA came back empty — a withdrawn drug, a non-US approval, a 2025 launch, or a catalog entry that names a whole class and has no generic name to query; a recently added agent may simply lack a stored lookup yet. Position = clinical-toxicity similarity (2-D MDS). A small deterministic jitter keeps agents with identical fingerprints from stacking — treat fine nearest-neighbor ordering as approximate.
The focused companion to the map (fig 1): pick an agent and see the six agents whose kidney-injury phenotype sits closest — nearer the center means a tighter match. The chips name why each pair pulls together: a shared signature injury, nephron segment, class family, or severity band.
Nearest analogs of Pembrolizumab
Open Pembrolizumab →Acute Interstitial Nephritis · Checkpoint inhibitors · Moderate
- Nivolumab70%Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
- Toripalimab68%Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
- Cosibelimab67%Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
- Sugemalimab66%Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
- Penpulimab66%Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
- Tislelizumab64%Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
Distance from the center = phenotype similarity (closer is a tighter match), ranked by the exact clinical-fingerprint distance the map's 2-D MDS approximates — injury signature (weight 0.48), nephron target (0.23), severity (0.11), class family (0.11), and a 0.07 approval-era term that breaks ties between otherwise-identical fingerprints. That last term is small but not nothing: it decides which neighbors appear when several agents share a signature, anatomy, severity and class. Click a neighbor to recenter and walk the neighborhood; the list links to each profile. Similarity is a phenotype resemblance, not a shared mechanism or an interchangeability claim.
The kidney-injury combinations that strike the same agent, ranked by how many agents carry each exact set. The dot column under each bar shows which injuries are in that combination — the multi-way overlaps a pairwise chord can only hint at. A set-size bar to the left of each injury row totals how often that injury appears across these combinations, for comparison against any single set.
- 32 agents: Electrolyte Disturbance + Prerenal / Hemodynamic AKI
- 22 agents: Electrolyte Disturbance + Crystal / Obstructive Nephropathy + Prerenal / Hemodynamic AKI
- 11 agents: Acute Tubular Necrosis + Electrolyte Disturbance + Prerenal / Hemodynamic AKI
- 11 agents: Prerenal / Hemodynamic AKI + Pseudo-AKI
- 9 agents: Thrombotic Microangiopathy + Glomerular Injury / Proteinuria + Hypertension
- 9 agents: Acute Tubular Necrosis + Prerenal / Hemodynamic AKI
- 8 agents: Electrolyte Disturbance + SIADH / Hyponatremia
- 8 agents: Acute Tubular Necrosis + Electrolyte Disturbance + Crystal / Obstructive Nephropathy + Prerenal / Hemodynamic AKI
- 5 agents: Electrolyte Disturbance + Prerenal / Hemodynamic AKI + SIADH / Hyponatremia
- 5 agents: Acute Tubular Necrosis + Electrolyte Disturbance
- 5 agents: Thrombotic Microangiopathy + Electrolyte Disturbance + Prerenal / Hemodynamic AKI
- 4 agents: Glomerular Injury / Proteinuria + Hypertension
- 4 agents: Acute Interstitial Nephritis + Glomerular Injury / Proteinuria
- 3 agents: Acute Tubular Necrosis + Crystal / Obstructive Nephropathy
- Acute Tubular Necrosis: 36 agents across the shown combinations
- Acute Interstitial Nephritis: 4 agents across the shown combinations
- Thrombotic Microangiopathy: 14 agents across the shown combinations
- Glomerular Injury / Proteinuria: 17 agents across the shown combinations
- Electrolyte Disturbance: 96 agents across the shown combinations
- Crystal / Obstructive Nephropathy: 33 agents across the shown combinations
- Hypertension: 13 agents across the shown combinations
- Prerenal / Hemodynamic AKI: 103 agents across the shown combinations
- SIADH / Hyponatremia: 13 agents across the shown combinations
- Pseudo-AKI: 11 agents across the shown combinations
Top 14 injury combinations among profiled agents · top bar = agents with exactly that set · connected dots = injuries in the combination · left set-size bar = total agents across these combinations carrying that injury (each agent counted once).
Every profiled agent as a row; the 14 kidney injuries as columns. A colored tick means the agent carries that injury. Rows are grouped by drug class, so agents in a family light up the same injury columns. Tap a column header to isolate an injury.
| Agent | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other targeted agents · 45 | ||||||||||||||
| Adagrasib | Glomerular Injury / Proteinuria | Prerenal / Hemodynamic AKI (signature) | Pseudo-AKI | |||||||||||
| Afamitresgene autoleucel (Afami-cel) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Anitocabtagene autoleucel | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Arsenic trioxide | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Belzutifan | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Bortezomib | Thrombotic Microangiopathy (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Carfilzomib | Acute Tubular Necrosis | Thrombotic Microangiopathy (signature) | Glomerular Injury / Proteinuria | Hypertension | ||||||||||
| Casdatifan | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Daraxonrasib | Thrombotic Microangiopathy | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Defactinib | Electrolyte Disturbance (signature) | |||||||||||||
| Denileukin diftitox | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Dordaviprone | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Enasidenib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Gallium nitrate | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Glasdegib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Iberdomide | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Imetelstat | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Ivosidenib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Ixazomib | Thrombotic Microangiopathy (signature) | |||||||||||||
| Lenalidomide | Acute Tubular Necrosis (signature) | Thrombotic Microangiopathy | Fanconi Syndrome | |||||||||||
| Lifileucel | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Moxetumomab pasudotox | Thrombotic Microangiopathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Niraparib | Hypertension (signature) | Pseudo-AKI | ||||||||||||
| Nirogacestat | Electrolyte Disturbance (signature) | Fanconi Syndrome | ||||||||||||
| Olaparib | Thrombotic Microangiopathy | Pseudo-AKI (signature) | ||||||||||||
| Olutasidenib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Pomalidomide | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| promacta | Thrombotic Microangiopathy (signature) | |||||||||||||
| Relacorilant | Electrolyte Disturbance (signature) | Hypertension | ||||||||||||
| Revumenib | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Rucaparib | Pseudo-AKI (signature) | |||||||||||||
| saruparib | Pseudo-AKI (signature) | |||||||||||||
| Selinexor | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia (signature) | |||||||||||
| Sonidegib | Acute Tubular Necrosis (signature) | |||||||||||||
| Sonrotoclax | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Sotorasib | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Tagraxofusp | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Talazoparib | Pseudo-AKI (signature) | |||||||||||||
| Tazemetostat | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Thalidomide | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Tretinoin (ATRA) | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Venetoclax | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Vismodegib | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Vorasidenib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Ziftomenib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Alkylating agents · 21 | ||||||||||||||
| Altretamine (hexamethylmelamine) | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Bendamustine | Thrombotic Microangiopathy | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | |||||||||||
| Busulfan | Thrombotic Microangiopathy (signature) | |||||||||||||
| Carmustine (BCNU) | Thrombotic Microangiopathy | Chronic Interstitial Nephropathy (signature) | ||||||||||||
| Chlorambucil | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Cyclophosphamide | SIADH / Hyponatremia (signature) | Hemorrhagic Cystitis | ||||||||||||
| Dacarbazine | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Estramustine | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Fotemustine | Acute Tubular Necrosis | Electrolyte Disturbance | Chronic Interstitial Nephropathy (signature) | |||||||||||
| Ifosfamide | Acute Tubular Necrosis | Electrolyte Disturbance | Fanconi Syndrome (signature) | Hemorrhagic Cystitis | ||||||||||
| Lomustine (CCNU) | Chronic Interstitial Nephropathy (signature) | |||||||||||||
| Lurbinectedin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | |||||||||||
| Mechlorethamine | Electrolyte Disturbance (signature) | Crystal / Obstructive Nephropathy | ||||||||||||
| Melphalan | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Melphalan flufenamide (melflufen) | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | ||||||||||||
| Nimustine (ACNU) | Acute Tubular Necrosis | Electrolyte Disturbance | Chronic Interstitial Nephropathy (signature) | |||||||||||
| Procarbazine | Acute Tubular Necrosis (signature) | Acute Interstitial Nephritis | ||||||||||||
| Streptozocin | Acute Tubular Necrosis | Electrolyte Disturbance | Fanconi Syndrome (signature) | |||||||||||
| Temozolomide | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Thiotepa | Hemorrhagic Cystitis (signature) | |||||||||||||
| Trabectedin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | ||||||||||||
| Antimetabolites · 20 | ||||||||||||||
| 5-Fluorouracil | Thrombotic Microangiopathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Azacitidine | Acute Tubular Necrosis | Electrolyte Disturbance | Fanconi Syndrome (signature) | Pseudo-AKI | ||||||||||
| Capecitabine | Thrombotic Microangiopathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Carmofur (HCFU) | Thrombotic Microangiopathy (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Cladribine | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Clofarabine | Acute Tubular Necrosis | Glomerular Injury / Proteinuria | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Cytarabine | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | ||||||||||
| Decitabine | Thrombotic Microangiopathy | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Doxifluridine | Thrombotic Microangiopathy (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Fludarabine | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Gemcitabine | Thrombotic Microangiopathy (signature) | Glomerular Injury / Proteinuria | Hypertension | Hemorrhagic Cystitis | ||||||||||
| Hydroxyurea | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Methotrexate (high-dose) | Acute Tubular Necrosis | Crystal / Obstructive Nephropathy (signature) | ||||||||||||
| Nelarabine | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Pemetrexed | Acute Tubular Necrosis | Electrolyte Disturbance | SIADH / Hyponatremia | Chronic Interstitial Nephropathy (signature) | ||||||||||
| Pentostatin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | SIADH / Hyponatremia | |||||||||||
| Pralatrexate | Acute Tubular Necrosis | Crystal / Obstructive Nephropathy (signature) | ||||||||||||
| Raltitrexed | Acute Tubular Necrosis (signature) | Crystal / Obstructive Nephropathy | ||||||||||||
| Tegafur-uracil (UFT) | Thrombotic Microangiopathy (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Trifluridine/tipiracil | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Checkpoint inhibitors · 18 | ||||||||||||||
| Atezolizumab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | SIADH / Hyponatremia | Hemorrhagic Cystitis | ||||||||||
| Avelumab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Cadonilimab | Acute Interstitial Nephritis (signature) | |||||||||||||
| Cemiplimab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab) | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | |||||||||||
| Cosibelimab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | |||||||||||
| Dostarlimab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Durvalumab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Ipilimumab | Acute Interstitial Nephritis (signature) | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Prerenal / Hemodynamic AKI | Chronic Interstitial Nephropathy | |||||||||
| Ivonescimab | Acute Interstitial Nephritis | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Hypertension | Prerenal / Hemodynamic AKI | |||||||||
| Nivolumab | Acute Tubular Necrosis | Acute Interstitial Nephritis (signature) | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | SIADH / Hyponatremia | Chronic Interstitial Nephropathy | ||||||||
| Pembrolizumab | Acute Interstitial Nephritis (signature) | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Electrolyte Disturbance | Hemorrhagic Cystitis | Chronic Interstitial Nephropathy | ||||||||
| Penpulimab | Acute Tubular Necrosis | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | ||||||||||
| Relatlimab | Acute Interstitial Nephritis (signature) | |||||||||||||
| Retifanlimab | Acute Interstitial Nephritis (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Sugemalimab | Acute Tubular Necrosis | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | ||||||||||
| Tislelizumab | Acute Interstitial Nephritis (signature) | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Prerenal / Hemodynamic AKI | ||||||||||
| Toripalimab | Acute Interstitial Nephritis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | |||||||||||
| Monoclonal antibodies (other) · 16 | ||||||||||||||
| Amivantamab | Acute Interstitial Nephritis | Electrolyte Disturbance (signature) | ||||||||||||
| Cetuximab | Glomerular Injury / Proteinuria | Electrolyte Disturbance (signature) | ||||||||||||
| Daratumumab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Dinutuximab | Thrombotic Microangiopathy | Hypertension | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Elotuzumab | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Isatuximab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Mogamulizumab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Naxitamab | Hypertension | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Necitumumab | Electrolyte Disturbance (signature) | |||||||||||||
| Obinutuzumab | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Panitumumab | Glomerular Injury / Proteinuria | Electrolyte Disturbance (signature) | ||||||||||||
| Rituximab | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Tafasitamab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Zanidatamab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Zenocutuzumab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Zolbetuximab | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Antibody-drug conjugates · 16 | ||||||||||||||
| Belantamab mafodotin | Glomerular Injury / Proteinuria (signature) | |||||||||||||
| Brentuximab vedotin | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Datopotamab deruxtecan (Dato-DXd) | Acute Tubular Necrosis (signature) | Glomerular Injury / Proteinuria | ||||||||||||
| Disitamab vedotin | Acute Tubular Necrosis (signature) | |||||||||||||
| Enfortumab vedotin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | |||||||||||
| Gemtuzumab ozogamicin | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Inotuzumab ozogamicin | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Loncastuximab tesirine | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Mirvetuximab soravtansine | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Pivekimab sunirine | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Polatuzumab vedotin | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Sacituzumab govitecan | Acute Tubular Necrosis | Acute Interstitial Nephritis | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Telisotuzumab vedotin (Teliso-V) | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | ||||||||||||
| Tisotumab vedotin | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Trastuzumab deruxtecan | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Fanconi Syndrome | |||||||||||
| Trastuzumab emtansine (T-DM1) | Thrombotic Microangiopathy (signature) | Glomerular Injury / Proteinuria | Hypertension | |||||||||||
| Anti-angiogenic (VEGF) · 15 | ||||||||||||||
| Axitinib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Bevacizumab | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Hypertension | |||||||||||
| Cabozantinib | Glomerular Injury / Proteinuria | Hypertension (signature) | ||||||||||||
| Fruquintinib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Lenvatinib | Glomerular Injury / Proteinuria | Hypertension (signature) | ||||||||||||
| Nintedanib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Pazopanib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Hypertension | |||||||||||
| Ramucirumab | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Regorafenib | Glomerular Injury / Proteinuria | Hypertension (signature) | ||||||||||||
| Sorafenib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Electrolyte Disturbance | Hypertension (signature) | ||||||||||
| Sunitinib | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Tivozanib | Glomerular Injury / Proteinuria | Hypertension (signature) | ||||||||||||
| Vandetanib | Glomerular Injury / Proteinuria | Electrolyte Disturbance | Hypertension (signature) | |||||||||||
| VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib) | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Ziv-aflibercept | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria | Hypertension (signature) | |||||||||||
| Other kinase inhibitors · 14 | ||||||||||||||
| Avapritinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Fedratinib | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Furmonertinib | Electrolyte Disturbance (signature) | |||||||||||||
| Gilteritinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Midostaurin | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Momelotinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Pacritinib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Pexidartinib | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Pralsetinib | Hypertension (signature) | Prerenal / Hemodynamic AKI | Pseudo-AKI | |||||||||||
| Quizartinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Ripretinib | Hypertension (signature) | |||||||||||||
| Ruxolitinib | Thrombotic Microangiopathy | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Selpercatinib | Glomerular Injury / Proteinuria | Hypertension (signature) | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | Pseudo-AKI | |||||||||
| Vimseltinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| ALK / ROS1 / MET / TRK inhibitors · 13 | ||||||||||||||
| Alectinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Brigatinib | Hypertension | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | |||||||||||
| Capmatinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Ceritinib | Prerenal / Hemodynamic AKI (signature) | Pseudo-AKI | ||||||||||||
| Crizotinib | Electrolyte Disturbance | Pseudo-AKI | Renal Cysts (signature) | |||||||||||
| Ensartinib | Electrolyte Disturbance | Pseudo-AKI (signature) | Renal Cysts | |||||||||||
| Entrectinib | Pseudo-AKI (signature) | |||||||||||||
| Larotrectinib | Pseudo-AKI (signature) | |||||||||||||
| Lorlatinib | Glomerular Injury / Proteinuria | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | |||||||||||
| Repotrectinib | Pseudo-AKI (signature) | |||||||||||||
| Taletrectinib | Pseudo-AKI (signature) | |||||||||||||
| Tepotinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Zidesamtinib | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Hormonal / endocrine · 13 | ||||||||||||||
| Abiraterone | Electrolyte Disturbance (signature) | Hypertension | ||||||||||||
| Bicalutamide | Acute Interstitial Nephritis (signature) | |||||||||||||
| Camizestrant | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Darolutamide | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Elacestrant | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Enzalutamide | Electrolyte Disturbance | Hypertension (signature) | ||||||||||||
| Imlunestrant | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Lanreotide | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Leuprolide | Hypertension (signature) | |||||||||||||
| Mitotane | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Octreotide | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Tamoxifen | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia (signature) | |||||||||||
| Vepdegestrant | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Bispecifics / T-cell engagers · 12 | ||||||||||||||
| Blinatumomab | Acute Tubular Necrosis | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Catumaxomab | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Elranatamab | Acute Tubular Necrosis | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Epcoritamab | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Glofitamab | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Linvoseltamab | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Mosunetuzumab | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Odronextamab | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Talquetamab | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Tarlatamab | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Tebentafusp | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Teclistamab | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| BRAF / MEK inhibitors · 11 | ||||||||||||||
| Avutometinib | Acute Tubular Necrosis | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Binimetinib | Acute Tubular Necrosis (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib) | Acute Tubular Necrosis (signature) | Acute Interstitial Nephritis | Electrolyte Disturbance | Fanconi Syndrome | Pseudo-AKI | |||||||||
| Cobimetinib | Acute Tubular Necrosis (signature) | Acute Interstitial Nephritis | ||||||||||||
| Dabrafenib | Acute Tubular Necrosis | Acute Interstitial Nephritis (signature) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | |||||||||
| Encorafenib | Acute Tubular Necrosis (signature) | Acute Interstitial Nephritis | ||||||||||||
| Mirdametinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Selumetinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Tovorafenib | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Trametinib | Acute Interstitial Nephritis | Glomerular Injury / Proteinuria | Hypertension | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Vemurafenib | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Fanconi Syndrome | Chronic Interstitial Nephropathy | ||||||||||
| EGFR / HER2 inhibitors · 11 | ||||||||||||||
| Afatinib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Erlotinib | Acute Tubular Necrosis | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Prerenal / Hemodynamic AKI | ||||||||||
| Gefitinib | Acute Interstitial Nephritis | Glomerular Injury / Proteinuria (signature) | Hemorrhagic Cystitis | |||||||||||
| Lazertinib | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Mobocertinib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Neratinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Osimertinib | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | Pseudo-AKI | |||||||||||
| Sevabertinib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Sunvozertinib | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | |||||||||||
| Tucatinib | Pseudo-AKI (signature) | |||||||||||||
| Zongertinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Microtubule inhibitors · 8 | ||||||||||||||
| Cabazitaxel | Prerenal / Hemodynamic AKI (signature) | Hemorrhagic Cystitis | ||||||||||||
| Docetaxel | Thrombotic Microangiopathy | Prerenal / Hemodynamic AKI (signature) | Hemorrhagic Cystitis | |||||||||||
| Eribulin | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Paclitaxel | Glomerular Injury / Proteinuria | Prerenal / Hemodynamic AKI (signature) | Hemorrhagic Cystitis | |||||||||||
| Vinblastine | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Vincristine | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Vinflunine | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | |||||||||||
| Vinorelbine | Electrolyte Disturbance | SIADH / Hyponatremia (signature) | ||||||||||||
| Radiopharmaceuticals · 8 | ||||||||||||||
| Actinium 225 PSMA | Acute Tubular Necrosis (signature) | |||||||||||||
| Ibritumomab tiuxetan | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Iobenguane I-131 | Acute Tubular Necrosis (signature) | Glomerular Injury / Proteinuria | Hypertension | Chronic Interstitial Nephropathy | ||||||||||
| Lutetium-177 Dotatate | Thrombotic Microangiopathy | Chronic Interstitial Nephropathy (signature) | ||||||||||||
| Lutetium-177 PSMA-617 (vipivotide) | Electrolyte Disturbance | Chronic Interstitial Nephropathy (signature) | ||||||||||||
| Radium-223 dichloride | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Samarium-153 lexidronam | Acute Tubular Necrosis (signature) | |||||||||||||
| Strontium-89 chloride | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Antitumor antibiotics · 7 | ||||||||||||||
| Bleomycin | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Dactinomycin (actinomycin D) | Electrolyte Disturbance (signature) | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI | |||||||||||
| Doxorubicin | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Hemorrhagic Cystitis | |||||||||||
| Idarubicin | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Mitomycin C | Thrombotic Microangiopathy (signature) | Glomerular Injury / Proteinuria | Hemorrhagic Cystitis | |||||||||||
| Mitoxantrone | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | Hemorrhagic Cystitis | ||||||||||
| Plicamycin (mithramycin) | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | ||||||||||||
| BCR-ABL inhibitors · 7 | ||||||||||||||
| Asciminib | Hypertension (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Bosutinib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Dasatinib | Glomerular Injury / Proteinuria (signature) | |||||||||||||
| Imatinib | Acute Tubular Necrosis | Electrolyte Disturbance (signature) | Fanconi Syndrome | |||||||||||
| Nilotinib | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Olverembatinib | Glomerular Injury / Proteinuria (signature) | Hypertension | Prerenal / Hemodynamic AKI | Pseudo-AKI | ||||||||||
| Ponatinib | Thrombotic Microangiopathy | Hypertension (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| PI3K / AKT inhibitors · 7 | ||||||||||||||
| Alpelisib | Acute Tubular Necrosis | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Capivasertib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Copanlisib | Hypertension (signature) | |||||||||||||
| Duvelisib | Acute Interstitial Nephritis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Gedatolisib | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Idelalisib | Acute Interstitial Nephritis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Inavolisib | Electrolyte Disturbance (signature) | |||||||||||||
| CAR-T cell therapy · 5 | ||||||||||||||
| CAR-T cell therapy | Acute Tubular Necrosis | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| Ciltacabtagene autoleucel | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Idecabtagene vicleucel | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Lisocabtagene maraleucel | Acute Tubular Necrosis | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | ||||||||||
| Obecabtagene autoleucel (Obe-cel) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Cytokines & enzymes · 5 | ||||||||||||||
| Asparaginase | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Interferon-α | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | ||||||||||||
| Interleukin-2 (high-dose) | Electrolyte Disturbance | Prerenal / Hemodynamic AKI (signature) | SIADH / Hyponatremia | |||||||||||
| Pegaspargase | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Tasonermin | Acute Tubular Necrosis | Prerenal / Hemodynamic AKI (signature) | ||||||||||||
| Topoisomerase inhibitors · 5 | ||||||||||||||
| Amsacrine | Electrolyte Disturbance (signature) | Crystal / Obstructive Nephropathy | ||||||||||||
| Etoposide | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Irinotecan | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Teniposide | Electrolyte Disturbance (signature) | Prerenal / Hemodynamic AKI | ||||||||||||
| Topotecan | Prerenal / Hemodynamic AKI (signature) | |||||||||||||
| Platinum agents · 4 | ||||||||||||||
| Carboplatin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | SIADH / Hyponatremia | Hemorrhagic Cystitis | ||||||||||
| Cisplatin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | Fanconi Syndrome | Prerenal / Hemodynamic AKI | SIADH / Hyponatremia | Hemorrhagic Cystitis | ||||||||
| Nedaplatin | Acute Tubular Necrosis (signature) | Electrolyte Disturbance | ||||||||||||
| Oxaliplatin | Acute Tubular Necrosis | Thrombotic Microangiopathy (signature) | ||||||||||||
| mTOR inhibitors · 4 | ||||||||||||||
| Everolimus | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | Electrolyte Disturbance | |||||||||||
| mTOR inhibitors (everolimus · temsirolimus) | Acute Tubular Necrosis | Thrombotic Microangiopathy | Glomerular Injury / Proteinuria (signature) | |||||||||||
| Sirolimus | Acute Tubular Necrosis | Glomerular Injury / Proteinuria (signature) | ||||||||||||
| Temsirolimus | Glomerular Injury / Proteinuria (signature) | Electrolyte Disturbance | ||||||||||||
| Bisphosphonates & bone · 4 | ||||||||||||||
| Denosumab | Electrolyte Disturbance (signature) | |||||||||||||
| Ibandronate | Acute Tubular Necrosis (signature) | Glomerular Injury / Proteinuria | Electrolyte Disturbance | |||||||||||
| Pamidronate | Glomerular Injury / Proteinuria (signature) | |||||||||||||
| Zoledronic acid | Acute Tubular Necrosis (signature) | Fanconi Syndrome | ||||||||||||
| FGFR inhibitors · 4 | ||||||||||||||
| Erdafitinib | Electrolyte Disturbance (signature) | |||||||||||||
| Futibatinib | Electrolyte Disturbance (signature) | |||||||||||||
| Infigratinib | Electrolyte Disturbance (signature) | Crystal / Obstructive Nephropathy | ||||||||||||
| Pemigatinib | Electrolyte Disturbance (signature) | |||||||||||||
| BTK inhibitors · 4 | ||||||||||||||
| Acalabrutinib | Crystal / Obstructive Nephropathy | Hypertension (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Ibrutinib | Acute Tubular Necrosis | Acute Interstitial Nephritis | Glomerular Injury / Proteinuria | Hypertension (signature) | Prerenal / Hemodynamic AKI | |||||||||
| Pirtobrutinib | Electrolyte Disturbance | Crystal / Obstructive Nephropathy (signature) | Prerenal / Hemodynamic AKI | |||||||||||
| Zanubrutinib | Electrolyte Disturbance | Crystal / Obstructive Nephropathy | Prerenal / Hemodynamic AKI (signature) | |||||||||||
| CDK4/6 inhibitors · 3 | ||||||||||||||
| Abemaciclib | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | ||||||||||||
| Palbociclib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | |||||||||||
| Ribociclib | Electrolyte Disturbance | Prerenal / Hemodynamic AKI | Pseudo-AKI (signature) | |||||||||||
300 profiled agents × 14 injuries · tick = injury present · outlined tick = the agent's signature injury.
Agents by their worst-case severity against whether the injury reverses. The severe × often-irreversible cell is the highest-stakes group.
| Severity | Reversiblecolumn total: 204 | Partially reversiblecolumn total: 39 | Often irreversiblecolumn total: 6 | Variablecolumn total: 43 |
|---|---|---|---|---|
| Severe, row total 13 | Severe, Reversible: 1 agent (8% of row) | Severe, Partially reversible: 5 agents (38% of row) | Severe, Often irreversible: 3 agents (23% of row) | Severe, Variable: 4 agents (31% of row) |
| Moderate, row total 136 | Moderate, Reversible: 75 agents (55% of row) | Moderate, Partially reversible: 33 agents (24% of row) | Moderate, Often irreversible: 3 agents (2% of row) | Moderate, Variable: 25 agents (18% of row) |
| Mild, row total 143 | Mild, Reversible: 128 agents (90% of row) | Mild, Partially reversible: 1 agent (1% of row) | Mild, Often irreversible: 0 agents (0% of row) | Mild, Variable: 14 agents (10% of row) |
Agent counts per severity × reversibility · color depth scales within the grid · column totals above each outcome.
For the agents carrying a specific renal dose action: which class family forces it, and whether the action is a CrCl-banded reduction or an outright avoid. The antimetabolites lead the reduce-by-CrCl column; radiopharmaceuticals and antibody-drug conjugates sit only under avoid.
| Class family | Reduce dose by kidney functioncolumn total: 52 | Avoid or contraindicated in impairmentcolumn total: 17 | Dose calculated from GFRcolumn total: 1 | Caution — no defined thresholdcolumn total: 6 |
|---|---|---|---|---|
| Antimetabolites, row total 15 | Antimetabolites, Reduce dose by kidney function: 10 agents (67% of row) | Antimetabolites, Avoid or contraindicated in impairment: 2 agents (13% of row) | Antimetabolites, Dose calculated from GFR: 0 agents (0% of row) | Antimetabolites, Caution — no defined threshold: 3 agents (20% of row) |
| Other targeted agents, row total 10 | Other targeted agents, Reduce dose by kidney function: 6 agents (60% of row) | Other targeted agents, Avoid or contraindicated in impairment: 1 agent (10% of row) | Other targeted agents, Dose calculated from GFR: 0 agents (0% of row) | Other targeted agents, Caution — no defined threshold: 3 agents (30% of row) |
| Alkylating agents, row total 8 | Alkylating agents, Reduce dose by kidney function: 5 agents (63% of row) | Alkylating agents, Avoid or contraindicated in impairment: 3 agents (38% of row) | Alkylating agents, Dose calculated from GFR: 0 agents (0% of row) | Alkylating agents, Caution — no defined threshold: 0 agents (0% of row) |
| Antitumor antibiotics, row total 4 | Antitumor antibiotics, Reduce dose by kidney function: 2 agents (50% of row) | Antitumor antibiotics, Avoid or contraindicated in impairment: 2 agents (50% of row) | Antitumor antibiotics, Dose calculated from GFR: 0 agents (0% of row) | Antitumor antibiotics, Caution — no defined threshold: 0 agents (0% of row) |
| Hormonal / endocrine, row total 4 | Hormonal / endocrine, Reduce dose by kidney function: 3 agents (75% of row) | Hormonal / endocrine, Avoid or contraindicated in impairment: 1 agent (25% of row) | Hormonal / endocrine, Dose calculated from GFR: 0 agents (0% of row) | Hormonal / endocrine, Caution — no defined threshold: 0 agents (0% of row) |
| Other kinase inhibitors, row total 4 | Other kinase inhibitors, Reduce dose by kidney function: 3 agents (75% of row) | Other kinase inhibitors, Avoid or contraindicated in impairment: 1 agent (25% of row) | Other kinase inhibitors, Dose calculated from GFR: 0 agents (0% of row) | Other kinase inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| Platinum agents, row total 4 | Platinum agents, Reduce dose by kidney function: 3 agents (75% of row) | Platinum agents, Avoid or contraindicated in impairment: 0 agents (0% of row) | Platinum agents, Dose calculated from GFR: 1 agent (25% of row) | Platinum agents, Caution — no defined threshold: 0 agents (0% of row) |
| Topoisomerase inhibitors, row total 4 | Topoisomerase inhibitors, Reduce dose by kidney function: 3 agents (75% of row) | Topoisomerase inhibitors, Avoid or contraindicated in impairment: 1 agent (25% of row) | Topoisomerase inhibitors, Dose calculated from GFR: 0 agents (0% of row) | Topoisomerase inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| ALK / ROS1 / MET / TRK inhibitors, row total 3 | ALK / ROS1 / MET / TRK inhibitors, Reduce dose by kidney function: 3 agents (100% of row) | ALK / ROS1 / MET / TRK inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | ALK / ROS1 / MET / TRK inhibitors, Dose calculated from GFR: 0 agents (0% of row) | ALK / ROS1 / MET / TRK inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| Bisphosphonates & bone, row total 3 | Bisphosphonates & bone, Reduce dose by kidney function: 2 agents (67% of row) | Bisphosphonates & bone, Avoid or contraindicated in impairment: 1 agent (33% of row) | Bisphosphonates & bone, Dose calculated from GFR: 0 agents (0% of row) | Bisphosphonates & bone, Caution — no defined threshold: 0 agents (0% of row) |
| Anti-angiogenic (VEGF), row total 2 | Anti-angiogenic (VEGF), Reduce dose by kidney function: 2 agents (100% of row) | Anti-angiogenic (VEGF), Avoid or contraindicated in impairment: 0 agents (0% of row) | Anti-angiogenic (VEGF), Dose calculated from GFR: 0 agents (0% of row) | Anti-angiogenic (VEGF), Caution — no defined threshold: 0 agents (0% of row) |
| BCR-ABL inhibitors, row total 2 | BCR-ABL inhibitors, Reduce dose by kidney function: 2 agents (100% of row) | BCR-ABL inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | BCR-ABL inhibitors, Dose calculated from GFR: 0 agents (0% of row) | BCR-ABL inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| Cytokines & enzymes, row total 2 | Cytokines & enzymes, Reduce dose by kidney function: 1 agent (50% of row) | Cytokines & enzymes, Avoid or contraindicated in impairment: 1 agent (50% of row) | Cytokines & enzymes, Dose calculated from GFR: 0 agents (0% of row) | Cytokines & enzymes, Caution — no defined threshold: 0 agents (0% of row) |
| EGFR / HER2 inhibitors, row total 2 | EGFR / HER2 inhibitors, Reduce dose by kidney function: 1 agent (50% of row) | EGFR / HER2 inhibitors, Avoid or contraindicated in impairment: 1 agent (50% of row) | EGFR / HER2 inhibitors, Dose calculated from GFR: 0 agents (0% of row) | EGFR / HER2 inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| Microtubule inhibitors, row total 2 | Microtubule inhibitors, Reduce dose by kidney function: 2 agents (100% of row) | Microtubule inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | Microtubule inhibitors, Dose calculated from GFR: 0 agents (0% of row) | Microtubule inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| Radiopharmaceuticals, row total 2 | Radiopharmaceuticals, Reduce dose by kidney function: 0 agents (0% of row) | Radiopharmaceuticals, Avoid or contraindicated in impairment: 2 agents (100% of row) | Radiopharmaceuticals, Dose calculated from GFR: 0 agents (0% of row) | Radiopharmaceuticals, Caution — no defined threshold: 0 agents (0% of row) |
| Antibody-drug conjugates, row total 1 | Antibody-drug conjugates, Reduce dose by kidney function: 0 agents (0% of row) | Antibody-drug conjugates, Avoid or contraindicated in impairment: 1 agent (100% of row) | Antibody-drug conjugates, Dose calculated from GFR: 0 agents (0% of row) | Antibody-drug conjugates, Caution — no defined threshold: 0 agents (0% of row) |
| BTK inhibitors, row total 1 | BTK inhibitors, Reduce dose by kidney function: 1 agent (100% of row) | BTK inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | BTK inhibitors, Dose calculated from GFR: 0 agents (0% of row) | BTK inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| CDK4/6 inhibitors, row total 1 | CDK4/6 inhibitors, Reduce dose by kidney function: 1 agent (100% of row) | CDK4/6 inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | CDK4/6 inhibitors, Dose calculated from GFR: 0 agents (0% of row) | CDK4/6 inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| FGFR inhibitors, row total 1 | FGFR inhibitors, Reduce dose by kidney function: 1 agent (100% of row) | FGFR inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | FGFR inhibitors, Dose calculated from GFR: 0 agents (0% of row) | FGFR inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
| PI3K / AKT inhibitors, row total 1 | PI3K / AKT inhibitors, Reduce dose by kidney function: 1 agent (100% of row) | PI3K / AKT inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row) | PI3K / AKT inhibitors, Dose calculated from GFR: 0 agents (0% of row) | PI3K / AKT inhibitors, Caution — no defined threshold: 0 agents (0% of row) |
Counts the agents FLAGGED as needing a renal change (not all 292) · each agent carries exactly one action and one family, so it lands in one cell · color depth scales within the grid · column totals above each action. Source: renal-dose-adjustments, verified against FDA labels.
Anatomy & mechanism
Where in the nephron the damage lands.
Where each drug class strikes the nephron. Rows are class families, columns are nephron segments; a cell's depth of color is how many agents in that class the catalog files under that segment (each agent is bucketed into one primary segment). Most agents whose signature is prerenal or hemodynamic AKI, which injures no segment structurally, are filed under the vasculature, so that column mixes endothelial injury with perfusion risk. Read down a column for the agents filed under one structure, across a row for a class's anatomical footprint.
| Drug class family | Glomeruluscolumn total: 25 | Vasculature / Endotheliumcolumn total: 137 | Proximal Tubulecolumn total: 60 | Distal Tubule / Collecting Ductcolumn total: 28 | Interstitiumcolumn total: 23 | Tubular Lumencolumn total: 18 | Bladder / Urotheliumcolumn total: 1 |
|---|---|---|---|---|---|---|---|
| Other targeted agents | Other targeted agents, Glomerulus: 0 agents | Other targeted agents, Vasculature / Endothelium: 27 agents | Other targeted agents, Proximal Tubule: 9 agents | Other targeted agents, Distal Tubule / Collecting Duct: 3 agents | Other targeted agents, Interstitium: 0 agents | Other targeted agents, Tubular Lumen: 2 agents | Other targeted agents, Bladder / Urothelium: 0 agents |
| Alkylating agents | Alkylating agents, Glomerulus: 0 agents | Alkylating agents, Vasculature / Endothelium: 4 agents | Alkylating agents, Proximal Tubule: 7 agents | Alkylating agents, Distal Tubule / Collecting Duct: 4 agents | Alkylating agents, Interstitium: 4 agents | Alkylating agents, Tubular Lumen: 1 agent | Alkylating agents, Bladder / Urothelium: 1 agent |
| Antimetabolites | Antimetabolites, Glomerulus: 0 agents | Antimetabolites, Vasculature / Endothelium: 9 agents | Antimetabolites, Proximal Tubule: 3 agents | Antimetabolites, Distal Tubule / Collecting Duct: 0 agents | Antimetabolites, Interstitium: 1 agent | Antimetabolites, Tubular Lumen: 7 agents | Antimetabolites, Bladder / Urothelium: 0 agents |
| Checkpoint inhibitors | Checkpoint inhibitors, Glomerulus: 1 agent | Checkpoint inhibitors, Vasculature / Endothelium: 0 agents | Checkpoint inhibitors, Proximal Tubule: 0 agents | Checkpoint inhibitors, Distal Tubule / Collecting Duct: 0 agents | Checkpoint inhibitors, Interstitium: 16 agents | Checkpoint inhibitors, Tubular Lumen: 0 agents | Checkpoint inhibitors, Bladder / Urothelium: 0 agents |
| Monoclonal antibodies (other) | Monoclonal antibodies (other), Glomerulus: 0 agents | Monoclonal antibodies (other), Vasculature / Endothelium: 10 agents | Monoclonal antibodies (other), Proximal Tubule: 0 agents | Monoclonal antibodies (other), Distal Tubule / Collecting Duct: 4 agents | Monoclonal antibodies (other), Interstitium: 0 agents | Monoclonal antibodies (other), Tubular Lumen: 2 agents | Monoclonal antibodies (other), Bladder / Urothelium: 0 agents |
| Anti-angiogenic (VEGF) | Anti-angiogenic (VEGF), Glomerulus: 11 agents | Anti-angiogenic (VEGF), Vasculature / Endothelium: 4 agents | Anti-angiogenic (VEGF), Proximal Tubule: 0 agents | Anti-angiogenic (VEGF), Distal Tubule / Collecting Duct: 0 agents | Anti-angiogenic (VEGF), Interstitium: 0 agents | Anti-angiogenic (VEGF), Tubular Lumen: 0 agents | Anti-angiogenic (VEGF), Bladder / Urothelium: 0 agents |
| Antibody-drug conjugates | Antibody-drug conjugates, Glomerulus: 1 agent | Antibody-drug conjugates, Vasculature / Endothelium: 10 agents | Antibody-drug conjugates, Proximal Tubule: 4 agents | Antibody-drug conjugates, Distal Tubule / Collecting Duct: 0 agents | Antibody-drug conjugates, Interstitium: 0 agents | Antibody-drug conjugates, Tubular Lumen: 0 agents | Antibody-drug conjugates, Bladder / Urothelium: 0 agents |
| Hormonal / endocrine | Hormonal / endocrine, Glomerulus: 0 agents | Hormonal / endocrine, Vasculature / Endothelium: 5 agents | Hormonal / endocrine, Proximal Tubule: 1 agent | Hormonal / endocrine, Distal Tubule / Collecting Duct: 6 agents | Hormonal / endocrine, Interstitium: 1 agent | Hormonal / endocrine, Tubular Lumen: 0 agents | Hormonal / endocrine, Bladder / Urothelium: 0 agents |
| ALK / ROS1 / MET / TRK inhibitors | ALK / ROS1 / MET / TRK inhibitors, Glomerulus: 0 agents | ALK / ROS1 / MET / TRK inhibitors, Vasculature / Endothelium: 5 agents | ALK / ROS1 / MET / TRK inhibitors, Proximal Tubule: 8 agents | ALK / ROS1 / MET / TRK inhibitors, Distal Tubule / Collecting Duct: 0 agents | ALK / ROS1 / MET / TRK inhibitors, Interstitium: 0 agents | ALK / ROS1 / MET / TRK inhibitors, Tubular Lumen: 0 agents | ALK / ROS1 / MET / TRK inhibitors, Bladder / Urothelium: 0 agents |
| Other kinase inhibitors | Other kinase inhibitors, Glomerulus: 0 agents | Other kinase inhibitors, Vasculature / Endothelium: 11 agents | Other kinase inhibitors, Proximal Tubule: 1 agent | Other kinase inhibitors, Distal Tubule / Collecting Duct: 1 agent | Other kinase inhibitors, Interstitium: 0 agents | Other kinase inhibitors, Tubular Lumen: 0 agents | Other kinase inhibitors, Bladder / Urothelium: 0 agents |
| Bispecifics / T-cell engagers | Bispecifics / T-cell engagers, Glomerulus: 0 agents | Bispecifics / T-cell engagers, Vasculature / Endothelium: 11 agents | Bispecifics / T-cell engagers, Proximal Tubule: 0 agents | Bispecifics / T-cell engagers, Distal Tubule / Collecting Duct: 0 agents | Bispecifics / T-cell engagers, Interstitium: 0 agents | Bispecifics / T-cell engagers, Tubular Lumen: 1 agent | Bispecifics / T-cell engagers, Bladder / Urothelium: 0 agents |
| EGFR / HER2 inhibitors | EGFR / HER2 inhibitors, Glomerulus: 2 agents | EGFR / HER2 inhibitors, Vasculature / Endothelium: 4 agents | EGFR / HER2 inhibitors, Proximal Tubule: 2 agents | EGFR / HER2 inhibitors, Distal Tubule / Collecting Duct: 3 agents | EGFR / HER2 inhibitors, Interstitium: 0 agents | EGFR / HER2 inhibitors, Tubular Lumen: 0 agents | EGFR / HER2 inhibitors, Bladder / Urothelium: 0 agents |
| BRAF / MEK inhibitors | BRAF / MEK inhibitors, Glomerulus: 0 agents | BRAF / MEK inhibitors, Vasculature / Endothelium: 4 agents | BRAF / MEK inhibitors, Proximal Tubule: 6 agents | BRAF / MEK inhibitors, Distal Tubule / Collecting Duct: 0 agents | BRAF / MEK inhibitors, Interstitium: 1 agent | BRAF / MEK inhibitors, Tubular Lumen: 0 agents | BRAF / MEK inhibitors, Bladder / Urothelium: 0 agents |
| Microtubule inhibitors | Microtubule inhibitors, Glomerulus: 0 agents | Microtubule inhibitors, Vasculature / Endothelium: 4 agents | Microtubule inhibitors, Proximal Tubule: 0 agents | Microtubule inhibitors, Distal Tubule / Collecting Duct: 4 agents | Microtubule inhibitors, Interstitium: 0 agents | Microtubule inhibitors, Tubular Lumen: 0 agents | Microtubule inhibitors, Bladder / Urothelium: 0 agents |
| Antitumor antibiotics | Antitumor antibiotics, Glomerulus: 1 agent | Antitumor antibiotics, Vasculature / Endothelium: 1 agent | Antitumor antibiotics, Proximal Tubule: 2 agents | Antitumor antibiotics, Distal Tubule / Collecting Duct: 0 agents | Antitumor antibiotics, Interstitium: 0 agents | Antitumor antibiotics, Tubular Lumen: 3 agents | Antitumor antibiotics, Bladder / Urothelium: 0 agents |
| BCR-ABL inhibitors | BCR-ABL inhibitors, Glomerulus: 2 agents | BCR-ABL inhibitors, Vasculature / Endothelium: 4 agents | BCR-ABL inhibitors, Proximal Tubule: 1 agent | BCR-ABL inhibitors, Distal Tubule / Collecting Duct: 0 agents | BCR-ABL inhibitors, Interstitium: 0 agents | BCR-ABL inhibitors, Tubular Lumen: 0 agents | BCR-ABL inhibitors, Bladder / Urothelium: 0 agents |
| PI3K / AKT inhibitors | PI3K / AKT inhibitors, Glomerulus: 0 agents | PI3K / AKT inhibitors, Vasculature / Endothelium: 5 agents | PI3K / AKT inhibitors, Proximal Tubule: 0 agents | PI3K / AKT inhibitors, Distal Tubule / Collecting Duct: 2 agents | PI3K / AKT inhibitors, Interstitium: 0 agents | PI3K / AKT inhibitors, Tubular Lumen: 0 agents | PI3K / AKT inhibitors, Bladder / Urothelium: 0 agents |
| Radiopharmaceuticals | Radiopharmaceuticals, Glomerulus: 1 agent | Radiopharmaceuticals, Vasculature / Endothelium: 3 agents | Radiopharmaceuticals, Proximal Tubule: 3 agents | Radiopharmaceuticals, Distal Tubule / Collecting Duct: 0 agents | Radiopharmaceuticals, Interstitium: 0 agents | Radiopharmaceuticals, Tubular Lumen: 0 agents | Radiopharmaceuticals, Bladder / Urothelium: 0 agents |
| CAR-T cell therapy | CAR-T cell therapy, Glomerulus: 0 agents | CAR-T cell therapy, Vasculature / Endothelium: 5 agents | CAR-T cell therapy, Proximal Tubule: 0 agents | CAR-T cell therapy, Distal Tubule / Collecting Duct: 0 agents | CAR-T cell therapy, Interstitium: 0 agents | CAR-T cell therapy, Tubular Lumen: 0 agents | CAR-T cell therapy, Bladder / Urothelium: 0 agents |
| Topoisomerase inhibitors | Topoisomerase inhibitors, Glomerulus: 0 agents | Topoisomerase inhibitors, Vasculature / Endothelium: 2 agents | Topoisomerase inhibitors, Proximal Tubule: 1 agent | Topoisomerase inhibitors, Distal Tubule / Collecting Duct: 0 agents | Topoisomerase inhibitors, Interstitium: 0 agents | Topoisomerase inhibitors, Tubular Lumen: 2 agents | Topoisomerase inhibitors, Bladder / Urothelium: 0 agents |
| Cytokines & enzymes | Cytokines & enzymes, Glomerulus: 1 agent | Cytokines & enzymes, Vasculature / Endothelium: 4 agents | Cytokines & enzymes, Proximal Tubule: 0 agents | Cytokines & enzymes, Distal Tubule / Collecting Duct: 0 agents | Cytokines & enzymes, Interstitium: 0 agents | Cytokines & enzymes, Tubular Lumen: 0 agents | Cytokines & enzymes, Bladder / Urothelium: 0 agents |
| Platinum agents | Platinum agents, Glomerulus: 0 agents | Platinum agents, Vasculature / Endothelium: 0 agents | Platinum agents, Proximal Tubule: 4 agents | Platinum agents, Distal Tubule / Collecting Duct: 0 agents | Platinum agents, Interstitium: 0 agents | Platinum agents, Tubular Lumen: 0 agents | Platinum agents, Bladder / Urothelium: 0 agents |
| mTOR inhibitors | mTOR inhibitors, Glomerulus: 4 agents | mTOR inhibitors, Vasculature / Endothelium: 0 agents | mTOR inhibitors, Proximal Tubule: 0 agents | mTOR inhibitors, Distal Tubule / Collecting Duct: 0 agents | mTOR inhibitors, Interstitium: 0 agents | mTOR inhibitors, Tubular Lumen: 0 agents | mTOR inhibitors, Bladder / Urothelium: 0 agents |
| FGFR inhibitors | FGFR inhibitors, Glomerulus: 0 agents | FGFR inhibitors, Vasculature / Endothelium: 0 agents | FGFR inhibitors, Proximal Tubule: 4 agents | FGFR inhibitors, Distal Tubule / Collecting Duct: 0 agents | FGFR inhibitors, Interstitium: 0 agents | FGFR inhibitors, Tubular Lumen: 0 agents | FGFR inhibitors, Bladder / Urothelium: 0 agents |
| BTK inhibitors | BTK inhibitors, Glomerulus: 0 agents | BTK inhibitors, Vasculature / Endothelium: 4 agents | BTK inhibitors, Proximal Tubule: 0 agents | BTK inhibitors, Distal Tubule / Collecting Duct: 0 agents | BTK inhibitors, Interstitium: 0 agents | BTK inhibitors, Tubular Lumen: 0 agents | BTK inhibitors, Bladder / Urothelium: 0 agents |
| Bisphosphonates & bone | Bisphosphonates & bone, Glomerulus: 1 agent | Bisphosphonates & bone, Vasculature / Endothelium: 0 agents | Bisphosphonates & bone, Proximal Tubule: 2 agents | Bisphosphonates & bone, Distal Tubule / Collecting Duct: 1 agent | Bisphosphonates & bone, Interstitium: 0 agents | Bisphosphonates & bone, Tubular Lumen: 0 agents | Bisphosphonates & bone, Bladder / Urothelium: 0 agents |
| CDK4/6 inhibitors | CDK4/6 inhibitors, Glomerulus: 0 agents | CDK4/6 inhibitors, Vasculature / Endothelium: 1 agent | CDK4/6 inhibitors, Proximal Tubule: 2 agents | CDK4/6 inhibitors, Distal Tubule / Collecting Duct: 0 agents | CDK4/6 inhibitors, Interstitium: 0 agents | CDK4/6 inhibitors, Tubular Lumen: 0 agents | CDK4/6 inhibitors, Bladder / Urothelium: 0 agents |
Cell depth scales to the per-grid maximum; column totals sum each segment.
Which nephron structures absorb the most damage. Each ribbon groups agents by their signature injury (left) and carries them to every nephron segment those agents strike (right); ribbon width = agent count. The tallest right-hand nodes are the structures the catalog injures most — hover or tap a node to isolate its flows. A ribbon links an agent group to an anatomy, not a lesion to a segment: an agent's segments cover all of its injuries, so ifosfamide's cystitis reaches the bladder under its Fanconi signature.
- Acute Tubular Necrosis → Glomerulus: 1 agents
- Acute Tubular Necrosis → Vasculature / Endothelium: 3 agents
- Acute Tubular Necrosis → Proximal Tubule: 26 agents
- Acute Tubular Necrosis → Distal Tubule / Collecting Duct: 2 agents
- Acute Tubular Necrosis → Interstitium: 8 agents
- Acute Tubular Necrosis → Tubular Lumen: 6 agents
- Acute Interstitial Nephritis → Glomerulus: 13 agents
- Acute Interstitial Nephritis → Vasculature / Endothelium: 1 agents
- Acute Interstitial Nephritis → Proximal Tubule: 4 agents
- Acute Interstitial Nephritis → Distal Tubule / Collecting Duct: 6 agents
- Acute Interstitial Nephritis → Interstitium: 18 agents
- Thrombotic Microangiopathy → Glomerulus: 7 agents
- Thrombotic Microangiopathy → Vasculature / Endothelium: 13 agents
- Thrombotic Microangiopathy → Proximal Tubule: 1 agents
- Glomerular Injury / Proteinuria → Glomerulus: 15 agents
- Glomerular Injury / Proteinuria → Vasculature / Endothelium: 6 agents
- Glomerular Injury / Proteinuria → Proximal Tubule: 5 agents
- Glomerular Injury / Proteinuria → Interstitium: 1 agents
- Electrolyte Disturbance → Vasculature / Endothelium: 10 agents
- Electrolyte Disturbance → Proximal Tubule: 10 agents
- Electrolyte Disturbance → Distal Tubule / Collecting Duct: 18 agents
- Electrolyte Disturbance → Tubular Lumen: 4 agents
- Fanconi Syndrome → Proximal Tubule: 3 agents
- Fanconi Syndrome → Distal Tubule / Collecting Duct: 1 agents
- Fanconi Syndrome → Bladder / Urothelium: 1 agents
- Crystal / Obstructive Nephropathy → Vasculature / Endothelium: 14 agents
- Crystal / Obstructive Nephropathy → Proximal Tubule: 6 agents
- Crystal / Obstructive Nephropathy → Distal Tubule / Collecting Duct: 2 agents
- Crystal / Obstructive Nephropathy → Tubular Lumen: 18 agents
- Hypertension → Glomerulus: 14 agents
- Hypertension → Vasculature / Endothelium: 23 agents
- Hypertension → Proximal Tubule: 3 agents
- Hypertension → Interstitium: 1 agents
- Prerenal / Hemodynamic AKI → Glomerulus: 6 agents
- Prerenal / Hemodynamic AKI → Vasculature / Endothelium: 101 agents
- Prerenal / Hemodynamic AKI → Proximal Tubule: 23 agents
- Prerenal / Hemodynamic AKI → Distal Tubule / Collecting Duct: 6 agents
- Prerenal / Hemodynamic AKI → Interstitium: 3 agents
- Prerenal / Hemodynamic AKI → Tubular Lumen: 16 agents
- SIADH / Hyponatremia → Vasculature / Endothelium: 1 agents
- SIADH / Hyponatremia → Proximal Tubule: 1 agents
- SIADH / Hyponatremia → Distal Tubule / Collecting Duct: 12 agents
- SIADH / Hyponatremia → Bladder / Urothelium: 1 agents
- Hemorrhagic Cystitis → Bladder / Urothelium: 1 agents
- Pseudo-AKI → Vasculature / Endothelium: 11 agents
- Pseudo-AKI → Proximal Tubule: 23 agents
- Renal Cysts → Proximal Tubule: 1 agents
- Chronic Interstitial Nephropathy → Glomerulus: 1 agents
- Chronic Interstitial Nephropathy → Vasculature / Endothelium: 1 agents
- Chronic Interstitial Nephropathy → Proximal Tubule: 5 agents
- Chronic Interstitial Nephropathy → Interstitium: 7 agents
Ribbon width = agents whose signature injury strikes that segment · left node height = agent-incidences per injury (an agent striking several segments counts in each) · right node height = total agent-incidences per segment.
Evidence & literature
How the evidence base grew, how deep it runs, and who built it.
Every citation record placed by its publication year and its citing drug's signature kidney injury — a reference shared across agents counts once per agent. Band composition shows the field's focus shifting: platinum tubular injury, then anti-VEGF vascular disease, then checkpoint-inhibitor interstitial nephritis. Hover a year; click a band to isolate an injury.
53 years · each citation counted once per citing agent · band thickness = citation records that year
- 1974: 1 citation records
- 1975: 0 citation records
- 1976: 0 citation records
- 1977: 2 citation records
- 1978: 0 citation records
- 1979: 2 citation records
- 1980: 3 citation records
- 1981: 4 citation records
- 1982: 2 citation records
- 1983: 7 citation records
- 1984: 2 citation records
- 1985: 9 citation records
- 1986: 3 citation records
- 1987: 5 citation records
- 1988: 6 citation records
- 1989: 6 citation records
- 1990: 5 citation records
- 1991: 12 citation records
- 1992: 5 citation records
- 1993: 10 citation records
- 1994: 5 citation records
- 1995: 12 citation records
- 1996: 7 citation records
- 1997: 7 citation records
- 1998: 14 citation records
- 1999: 10 citation records
- 2000: 4 citation records
- 2001: 29 citation records
- 2002: 17 citation records
- 2003: 17 citation records
- 2004: 11 citation records
- 2005: 21 citation records
- 2006: 13 citation records
- 2007: 21 citation records
- 2008: 35 citation records
- 2009: 19 citation records
- 2010: 37 citation records
- 2011: 40 citation records
- 2012: 17 citation records
- 2013: 35 citation records
- 2014: 49 citation records
- 2015: 84 citation records
- 2016: 71 citation records
- 2017: 104 citation records
- 2018: 95 citation records
- 2019: 88 citation records
- 2020: 157 citation records
- 2021: 221 citation records
- 2022: 166 citation records
- 2023: 165 citation records
- 2024: 223 citation records
- 2025: 207 citation records
- 2026: 85 citation records
From approval (hollow) to the earliest reference the atlas cites (filled). The bar is how far the curated evidence trails approval, not when the kidney signal first appeared: the atlas favors recent trials and reviews, so an agent whose nephrotoxicity was known at approval can still draw a long bar.
- Mechlorethamine: approved 1949, first atlas citation 2011 (62-year lag) · Electrolyte Disturbance · Alkylating agents
- Methotrexate (high-dose): approved 1953, first atlas citation 2010 (57-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
- Busulfan: approved 1954, first atlas citation 2001 (47-year lag) · Thrombotic Microangiopathy · Alkylating agents
- Mitotane: approved 1970, first atlas citation 2017 (47-year lag) · Electrolyte Disturbance · Hormonal / endocrine
- Chlorambucil: approved 1957, first atlas citation 1999 (42-year lag) · SIADH / Hyponatremia · Alkylating agents
- Thiotepa: approved 1959, first atlas citation 1998 (39-year lag) · Hemorrhagic Cystitis · Alkylating agents
- Vincristine: approved 1963, first atlas citation 2002 (39-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
- Hydroxyurea: approved 1967, first atlas citation 2003 (36-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
- Dactinomycin (actinomycin D): approved 1964, first atlas citation 1996 (32-year lag) · Electrolyte Disturbance · Antitumor antibiotics
- Tamoxifen: approved 1977, first atlas citation 2006 (29-year lag) · SIADH / Hyponatremia · Hormonal / endocrine
- 5-Fluorouracil: approved 1962, first atlas citation 1987 (25-year lag) · Thrombotic Microangiopathy · Antimetabolites
- Irinotecan: approved 1996, first atlas citation 2020 (24-year lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors
- Paclitaxel: approved 1992, first atlas citation 2015 (23-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
- Leuprolide: approved 1985, first atlas citation 2007 (22-year lag) · Hypertension · Hormonal / endocrine
- Melphalan: approved 1964, first atlas citation 1985 (21-year lag) · SIADH / Hyponatremia · Alkylating agents
- Cisplatin: approved 1978, first atlas citation 1998 (20-year lag) · Acute Tubular Necrosis · Platinum agents
- Topotecan: approved 1996, first atlas citation 2015 (19-year lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors
- Doxorubicin: approved 1974, first atlas citation 1991 (17-year lag) · Glomerular Injury / Proteinuria · Antitumor antibiotics
- Cyclophosphamide: approved 1959, first atlas citation 1974 (15-year lag) · SIADH / Hyponatremia · Alkylating agents
- Dacarbazine: approved 1975, first atlas citation 1990 (15-year lag) · Prerenal / Hemodynamic AKI · Alkylating agents
- Vinblastine: approved 1965, first atlas citation 1980 (15-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
- Docetaxel: approved 1996, first atlas citation 2010 (14-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
- Procarbazine: approved 1969, first atlas citation 1983 (14-year lag) · Acute Tubular Necrosis · Alkylating agents
- Plicamycin (mithramycin): approved 1970, first atlas citation 1983 (13-year lag) · Acute Tubular Necrosis · Antitumor antibiotics
- Vinorelbine: approved 1994, first atlas citation 2007 (13-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
- Bortezomib: approved 2003, first atlas citation 2015 (12-year lag) · Thrombotic Microangiopathy · Other targeted agents
- Etoposide: approved 1983, first atlas citation 1995 (12-year lag) · Crystal / Obstructive Nephropathy · Topoisomerase inhibitors
- Idarubicin: approved 1990, first atlas citation 2002 (12-year lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics
- Nimustine (ACNU): approved 1979, first atlas citation 1991 (12-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
- Arsenic trioxide: approved 2000, first atlas citation 2011 (11-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
- Rituximab: approved 1997, first atlas citation 2008 (11-year lag) · Crystal / Obstructive Nephropathy · Monoclonal antibodies (other)
- Interferon-α: approved 1986, first atlas citation 1997 (11-year lag) · Glomerular Injury / Proteinuria · Cytokines & enzymes
- Cytarabine: approved 1969, first atlas citation 1979 (10-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
- Mitomycin C: approved 1974, first atlas citation 1984 (10-year lag) · Thrombotic Microangiopathy · Antitumor antibiotics
- Pamidronate: approved 1991, first atlas citation 2001 (10-year lag) · Glomerular Injury / Proteinuria · Bisphosphonates & bone
- Strontium-89 chloride: approved 1993, first atlas citation 2003 (10-year lag) · Electrolyte Disturbance · Radiopharmaceuticals
- Pegaspargase: approved 1994, first atlas citation 2003 (9-year lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes
- Nilotinib: approved 2007, first atlas citation 2015 (8-year lag) · Prerenal / Hemodynamic AKI · BCR-ABL inhibitors
- Dasatinib: approved 2006, first atlas citation 2013 (7-year lag) · Glomerular Injury / Proteinuria · BCR-ABL inhibitors
- Abemaciclib: approved 2017, first atlas citation 2024 (7-year lag) · Pseudo-AKI · CDK4/6 inhibitors
- Pazopanib: approved 2009, first atlas citation 2016 (7-year lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)
- Mitoxantrone: approved 1987, first atlas citation 1993 (6-year lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics
- Tegafur-uracil (UFT): approved 1984, first atlas citation 1990 (6-year lag) · Thrombotic Microangiopathy · Antimetabolites
- Samarium-153 lexidronam: approved 1997, first atlas citation 2003 (6-year lag) · Acute Tubular Necrosis · Radiopharmaceuticals
- Nelarabine: approved 2005, first atlas citation 2010 (5-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
- Daratumumab: approved 2015, first atlas citation 2020 (5-year lag) · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)
- Octreotide: approved 1988, first atlas citation 1993 (5-year lag) · Electrolyte Disturbance · Hormonal / endocrine
- Ipilimumab: approved 2011, first atlas citation 2016 (5-year lag) · Acute Interstitial Nephritis · Checkpoint inhibitors
- Carmustine (BCNU): approved 1977, first atlas citation 1981 (4-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
- Decitabine: approved 2006, first atlas citation 2010 (4-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
- Bevacizumab: approved 2004, first atlas citation 2008 (4-year lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)
- Crizotinib: approved 2011, first atlas citation 2015 (4-year lag) · Renal Cysts · ALK / ROS1 / MET / TRK inhibitors
- Ribociclib: approved 2017, first atlas citation 2021 (4-year lag) · Pseudo-AKI · CDK4/6 inhibitors
- Cabazitaxel: approved 2010, first atlas citation 2014 (4-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
- Asparaginase: approved 1978, first atlas citation 1982 (4-year lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes
- Denosumab: approved 2010, first atlas citation 2014 (4-year lag) · Electrolyte Disturbance · Bisphosphonates & bone
- Ruxolitinib: approved 2011, first atlas citation 2015 (4-year lag) · Prerenal / Hemodynamic AKI · Other kinase inhibitors
- Bleomycin: approved 1973, first atlas citation 1977 (4-year lag) · Prerenal / Hemodynamic AKI · Antitumor antibiotics
- Carmofur (HCFU): approved 1981, first atlas citation 1985 (4-year lag) · Thrombotic Microangiopathy · Antimetabolites
- Oxaliplatin: approved 2002, first atlas citation 2005 (3-year lag) · Thrombotic Microangiopathy · Platinum agents
- Ifosfamide: approved 1988, first atlas citation 1991 (3-year lag) · Fanconi Syndrome · Alkylating agents
- Lomustine (CCNU): approved 1976, first atlas citation 1979 (3-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
- Gemcitabine: approved 1996, first atlas citation 1999 (3-year lag) · Thrombotic Microangiopathy · Antimetabolites
- Capecitabine: approved 1998, first atlas citation 2001 (3-year lag) · Prerenal / Hemodynamic AKI · Antimetabolites
- Lenvatinib: approved 2015, first atlas citation 2018 (3-year lag) · Hypertension · Anti-angiogenic (VEGF)
- Sirolimus: approved 1999, first atlas citation 2002 (3-year lag) · Glomerular Injury / Proteinuria · mTOR inhibitors
- Cetuximab: approved 2004, first atlas citation 2007 (3-year lag) · Electrolyte Disturbance · Monoclonal antibodies (other)
- Erlotinib: approved 2004, first atlas citation 2007 (3-year lag) · Glomerular Injury / Proteinuria · EGFR / HER2 inhibitors
- CAR-T cell therapy: approved 2017, first atlas citation 2020 (3-year lag) · Prerenal / Hemodynamic AKI · CAR-T cell therapy
- Ponatinib: approved 2012, first atlas citation 2015 (3-year lag) · Hypertension · BCR-ABL inhibitors
- Bosutinib: approved 2012, first atlas citation 2015 (3-year lag) · Pseudo-AKI · BCR-ABL inhibitors
- Niraparib: approved 2017, first atlas citation 2020 (3-year lag) · Hypertension · Other targeted agents
- Palbociclib: approved 2015, first atlas citation 2018 (3-year lag) · Pseudo-AKI · CDK4/6 inhibitors
- Catumaxomab: approved 2009, first atlas citation 2012 (3-year lag) · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagers
- Sorafenib: approved 2005, first atlas citation 2008 (3-year lag) · Hypertension · Anti-angiogenic (VEGF)
- Pemetrexed: approved 2004, first atlas citation 2006 (2-year lag) · Chronic Interstitial Nephropathy · Antimetabolites
- VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib): approved 2006, first atlas citation 2008 (2-year lag) · Hypertension · Anti-angiogenic (VEGF)
- Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab): approved 2014, first atlas citation 2016 (2-year lag) · Acute Interstitial Nephritis · Checkpoint inhibitors
- Trastuzumab emtansine (T-DM1): approved 2013, first atlas citation 2015 (2-year lag) · Thrombotic Microangiopathy · Antibody-drug conjugates
- Brentuximab vedotin: approved 2011, first atlas citation 2013 (2-year lag) · Prerenal / Hemodynamic AKI · Antibody-drug conjugates
- Carfilzomib: approved 2012, first atlas citation 2014 (2-year lag) · Thrombotic Microangiopathy · Other targeted agents
- Ixazomib: approved 2015, first atlas citation 2017 (2-year lag) · Thrombotic Microangiopathy · Other targeted agents
- Lenalidomide: approved 2005, first atlas citation 2007 (2-year lag) · Acute Tubular Necrosis · Other targeted agents
- Thalidomide: approved 2006, first atlas citation 2008 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
- Imatinib: approved 2001, first atlas citation 2003 (2-year lag) · Electrolyte Disturbance · BCR-ABL inhibitors
- BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib): approved 2011, first atlas citation 2013 (2-year lag) · Acute Tubular Necrosis · BRAF / MEK inhibitors
- Ibrutinib: approved 2013, first atlas citation 2015 (2-year lag) · Hypertension · BTK inhibitors
- Tretinoin (ATRA): approved 1995, first atlas citation 1997 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
- Tagraxofusp: approved 2018, first atlas citation 2020 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
- Zoledronic acid: approved 2001, first atlas citation 2003 (2-year lag) · Acute Tubular Necrosis · Bisphosphonates & bone
The 90 longest-lag agents (of those with both an approval year and a dated citation) · hollow = approval · filled = first atlas citation · bar = years to first dated citation · color = signature injury.
Every catalog agent with citation evidence by evidence depth (citations, horizontal) and recency (newest reference, vertical). The crosshairs are the medians — the upper-left quadrant is the frontier (fresh but thin), the lower-right is deep but aging.
300 agents · x = citation count (log) · y = newest citation year · crosshair = medians.
- Cisplatin — 21 citations, newest 2025, Acute Tubular Necrosis
- Lutetium-177 Dotatate — 19 citations, newest 2025, Chronic Interstitial Nephropathy
- Ifosfamide — 16 citations, newest 2026, Fanconi Syndrome
- Atezolizumab — 15 citations, newest 2025, Acute Interstitial Nephritis
- Pembrolizumab — 15 citations, newest 2026, Acute Interstitial Nephritis
- Gemcitabine — 14 citations, newest 2026, Thrombotic Microangiopathy
- Mitomycin C — 13 citations, newest 2025, Thrombotic Microangiopathy
- Lenvatinib — 13 citations, newest 2026, Hypertension
- Sirolimus — 13 citations, newest 2019, Glomerular Injury / Proteinuria
- Carfilzomib — 13 citations, newest 2025, Thrombotic Microangiopathy
- Ipilimumab — 13 citations, newest 2026, Acute Interstitial Nephritis
- Cetuximab — 13 citations, newest 2022, Electrolyte Disturbance
- Carboplatin — 12 citations, newest 2024, Acute Tubular Necrosis
- Doxorubicin — 12 citations, newest 2026, Glomerular Injury / Proteinuria
- Gefitinib — 12 citations, newest 2018, Glomerular Injury / Proteinuria
- Venetoclax — 12 citations, newest 2025, Crystal / Obstructive Nephropathy
- Lutetium-177 PSMA-617 (vipivotide) — 12 citations, newest 2026, Chronic Interstitial Nephropathy
- Everolimus — 12 citations, newest 2025, Glomerular Injury / Proteinuria
- Zoledronic acid — 11 citations, newest 2026, Acute Tubular Necrosis
- Nedaplatin — 11 citations, newest 2023, Acute Tubular Necrosis
- Fludarabine — 11 citations, newest 2017, Crystal / Obstructive Nephropathy
- Ramucirumab — 11 citations, newest 2025, Hypertension
- Durvalumab — 11 citations, newest 2026, Acute Interstitial Nephritis
- Cemiplimab — 11 citations, newest 2026, Acute Interstitial Nephritis
- Selpercatinib — 11 citations, newest 2026, Hypertension
- Abiraterone — 11 citations, newest 2025, Electrolyte Disturbance
- Pentostatin — 11 citations, newest 2013, Acute Tubular Necrosis
- Sorafenib — 11 citations, newest 2021, Hypertension
- Oxaliplatin — 10 citations, newest 2026, Thrombotic Microangiopathy
- Methotrexate (high-dose) — 10 citations, newest 2025, Crystal / Obstructive Nephropathy
- Pemetrexed — 10 citations, newest 2026, Chronic Interstitial Nephropathy
- Interleukin-2 (high-dose) — 10 citations, newest 2011, Prerenal / Hemodynamic AKI
- Streptozocin — 10 citations, newest 2026, Fanconi Syndrome
- Bendamustine — 10 citations, newest 2026, Crystal / Obstructive Nephropathy
- Clofarabine — 10 citations, newest 2020, Prerenal / Hemodynamic AKI
- Cabozantinib — 10 citations, newest 2026, Hypertension
- Regorafenib — 10 citations, newest 2025, Hypertension
- Elranatamab — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
- Enfortumab vedotin — 10 citations, newest 2025, Acute Tubular Necrosis
- Crizotinib — 10 citations, newest 2025, Renal Cysts
- Tretinoin (ATRA) — 10 citations, newest 2025, Prerenal / Hemodynamic AKI
- Docetaxel — 10 citations, newest 2025, Prerenal / Hemodynamic AKI
- Denosumab — 10 citations, newest 2025, Electrolyte Disturbance
- Fruquintinib — 10 citations, newest 2025, Hypertension
- Trabectedin — 10 citations, newest 2019, Acute Tubular Necrosis
- Selinexor — 10 citations, newest 2024, SIADH / Hyponatremia
- Cladribine — 10 citations, newest 2023, Crystal / Obstructive Nephropathy
- Ciltacabtagene autoleucel — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
- Nivolumab — 10 citations, newest 2026, Acute Interstitial Nephritis
- Panitumumab — 10 citations, newest 2026, Electrolyte Disturbance
- Trametinib — 10 citations, newest 2024, Prerenal / Hemodynamic AKI
- Temsirolimus — 10 citations, newest 2016, Glomerular Injury / Proteinuria
- Camizestrant — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
- Bevacizumab — 9 citations, newest 2019, Glomerular Injury / Proteinuria
- CAR-T cell therapy — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
- Lomustine (CCNU) — 9 citations, newest 2019, Chronic Interstitial Nephropathy
- Temozolomide — 9 citations, newest 2025, SIADH / Hyponatremia
- 5-Fluorouracil — 9 citations, newest 2024, Thrombotic Microangiopathy
- Capecitabine — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
- Cytarabine — 9 citations, newest 2023, Crystal / Obstructive Nephropathy
- Plicamycin (mithramycin) — 9 citations, newest 2017, Acute Tubular Necrosis
- Nintedanib — 9 citations, newest 2026, Hypertension
- Necitumumab — 9 citations, newest 2021, Electrolyte Disturbance
- Osimertinib — 9 citations, newest 2026, SIADH / Hyponatremia
- Erlotinib — 9 citations, newest 2024, Glomerular Injury / Proteinuria
- Avelumab — 9 citations, newest 2026, Acute Interstitial Nephritis
- Dostarlimab — 9 citations, newest 2025, Acute Interstitial Nephritis
- Teclistamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
- Epcoritamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
- Lenalidomide — 9 citations, newest 2025, Acute Tubular Necrosis
- Imatinib — 9 citations, newest 2024, Electrolyte Disturbance
- Dasatinib — 9 citations, newest 2025, Glomerular Injury / Proteinuria
- Ponatinib — 9 citations, newest 2025, Hypertension
- Bosutinib — 9 citations, newest 2025, Pseudo-AKI
- Alectinib — 9 citations, newest 2026, Pseudo-AKI
- Brigatinib — 9 citations, newest 2025, Pseudo-AKI
- Encorafenib — 9 citations, newest 2022, Acute Tubular Necrosis
- Binimetinib — 9 citations, newest 2022, Acute Tubular Necrosis
- Pemigatinib — 9 citations, newest 2025, Electrolyte Disturbance
- Ibrutinib — 9 citations, newest 2025, Hypertension
- Arsenic trioxide — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
- Daratumumab — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
- Ribociclib — 9 citations, newest 2026, Pseudo-AKI
- Etoposide — 9 citations, newest 2021, Crystal / Obstructive Nephropathy
- Vincristine — 9 citations, newest 2024, SIADH / Hyponatremia
- Paclitaxel — 9 citations, newest 2024, Prerenal / Hemodynamic AKI
- Cabazitaxel — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
- Ibandronate — 9 citations, newest 2024, Acute Tubular Necrosis
- Enzalutamide — 9 citations, newest 2024, Hypertension
- Idecabtagene vicleucel — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
- Mitoxantrone — 9 citations, newest 2016, Crystal / Obstructive Nephropathy
- Pazopanib — 9 citations, newest 2024, Glomerular Injury / Proteinuria
- Vemurafenib — 9 citations, newest 2021, Acute Tubular Necrosis
- Dabrafenib — 9 citations, newest 2022, Acute Interstitial Nephritis
- Iobenguane I-131 — 9 citations, newest 2025, Acute Tubular Necrosis
- Cyclophosphamide — 8 citations, newest 2023, SIADH / Hyponatremia
- VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib) — 8 citations, newest 2024, Hypertension
- mTOR inhibitors (everolimus · temsirolimus) — 8 citations, newest 2019, Glomerular Injury / Proteinuria
- Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab) — 8 citations, newest 2023, Acute Interstitial Nephritis
- Interferon-α — 8 citations, newest 2025, Glomerular Injury / Proteinuria
- BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib) — 8 citations, newest 2022, Acute Tubular Necrosis
- Melphalan — 8 citations, newest 2025, SIADH / Hyponatremia
- Busulfan — 8 citations, newest 2019, Thrombotic Microangiopathy
- Thiotepa — 8 citations, newest 2024, Hemorrhagic Cystitis
- Pralatrexate — 8 citations, newest 2022, Crystal / Obstructive Nephropathy
- Azacitidine — 8 citations, newest 2024, Fanconi Syndrome
- Ziv-aflibercept — 8 citations, newest 2022, Hypertension
- Afatinib — 8 citations, newest 2024, Prerenal / Hemodynamic AKI
- Blinatumomab — 8 citations, newest 2022, Prerenal / Hemodynamic AKI
- Mosunetuzumab — 8 citations, newest 2024, Prerenal / Hemodynamic AKI
- Ixazomib — 8 citations, newest 2025, Thrombotic Microangiopathy
- Nilotinib — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
- Lorlatinib — 8 citations, newest 2025, Pseudo-AKI
- Olaparib — 8 citations, newest 2026, Pseudo-AKI
- Niraparib — 8 citations, newest 2026, Hypertension
- Capmatinib — 8 citations, newest 2025, Pseudo-AKI
- Tepotinib — 8 citations, newest 2025, Pseudo-AKI
- Enasidenib — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
- Acalabrutinib — 8 citations, newest 2025, Hypertension
- Rituximab — 8 citations, newest 2024, Crystal / Obstructive Nephropathy
- Obinutuzumab — 8 citations, newest 2025, Crystal / Obstructive Nephropathy
- Abemaciclib — 8 citations, newest 2026, Pseudo-AKI
- Palbociclib — 8 citations, newest 2026, Pseudo-AKI
- Vinblastine — 8 citations, newest 2024, SIADH / Hyponatremia
- Leuprolide — 8 citations, newest 2024, Hypertension
- Tarlatamab — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
- Capivasertib — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
- Radium-223 dichloride — 8 citations, newest 2022, Prerenal / Hemodynamic AKI
- Lurbinectedin — 8 citations, newest 2025, Acute Tubular Necrosis
- Moxetumomab pasudotox — 8 citations, newest 2020, Thrombotic Microangiopathy
- Denileukin diftitox — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
- Pegaspargase — 8 citations, newest 2020, Prerenal / Hemodynamic AKI
- Idarubicin — 8 citations, newest 2023, Crystal / Obstructive Nephropathy
- Tislelizumab — 8 citations, newest 2026, Acute Interstitial Nephritis
- Sunitinib — 8 citations, newest 2026, Hypertension
- Naxitamab — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
- Lisocabtagene maraleucel — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
- Gallium nitrate — 8 citations, newest 2003, Acute Tubular Necrosis
- Tasonermin — 8 citations, newest 2000, Prerenal / Hemodynamic AKI
- Disitamab vedotin — 8 citations, newest 2026, Acute Tubular Necrosis
- Anitocabtagene autoleucel — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
- Carmustine (BCNU) — 7 citations, newest 2012, Chronic Interstitial Nephropathy
- Hydroxyurea — 7 citations, newest 2020, Crystal / Obstructive Nephropathy
- Talquetamab — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
- Trastuzumab emtansine (T-DM1) — 7 citations, newest 2026, Thrombotic Microangiopathy
- Bortezomib — 7 citations, newest 2025, Thrombotic Microangiopathy
- Pomalidomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Rucaparib — 7 citations, newest 2026, Pseudo-AKI
- Cobimetinib — 7 citations, newest 2022, Acute Tubular Necrosis
- Erdafitinib — 7 citations, newest 2024, Electrolyte Disturbance
- Belzutifan — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Zanubrutinib — 7 citations, newest 2024, Prerenal / Hemodynamic AKI
- Isatuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Tagraxofusp — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
- Vinorelbine — 7 citations, newest 2024, SIADH / Hyponatremia
- Amivantamab — 7 citations, newest 2025, Electrolyte Disturbance
- Nirogacestat — 7 citations, newest 2024, Electrolyte Disturbance
- Ruxolitinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
- Momelotinib — 7 citations, newest 2026, Pseudo-AKI
- Entrectinib — 7 citations, newest 2024, Pseudo-AKI
- Infigratinib — 7 citations, newest 2025, Electrolyte Disturbance
- Mobocertinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Larotrectinib — 7 citations, newest 2020, Pseudo-AKI
- Estramustine — 7 citations, newest 2015, Prerenal / Hemodynamic AKI
- Alpelisib — 7 citations, newest 2024, Prerenal / Hemodynamic AKI
- Duvelisib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Gilteritinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
- Midostaurin — 7 citations, newest 2023, Prerenal / Hemodynamic AKI
- Asciminib — 7 citations, newest 2026, Hypertension
- Ripretinib — 7 citations, newest 2026, Hypertension
- Tazemetostat — 7 citations, newest 2022, Prerenal / Hemodynamic AKI
- Dinutuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Relatlimab — 7 citations, newest 2026, Acute Interstitial Nephritis
- Trifluridine/tipiracil — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Bleomycin — 7 citations, newest 2021, Prerenal / Hemodynamic AKI
- Octreotide — 7 citations, newest 2024, Electrolyte Disturbance
- Toripalimab — 7 citations, newest 2024, Acute Interstitial Nephritis
- Axitinib — 7 citations, newest 2023, Hypertension
- Pacritinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Avutometinib — 7 citations, newest 2025, Electrolyte Disturbance
- Fedratinib — 7 citations, newest 2020, Electrolyte Disturbance
- Odronextamab — 7 citations, newest 2025, Crystal / Obstructive Nephropathy
- Sonrotoclax — 7 citations, newest 2026, Crystal / Obstructive Nephropathy
- Iberdomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
- Daraxonrasib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
- Pamidronate — 6 citations, newest 2011, Glomerular Injury / Proteinuria
- Decitabine — 6 citations, newest 2023, Crystal / Obstructive Nephropathy
- Nelarabine — 6 citations, newest 2020, Crystal / Obstructive Nephropathy
- Vandetanib — 6 citations, newest 2023, Hypertension
- Glofitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
- Trastuzumab deruxtecan — 6 citations, newest 2026, Acute Tubular Necrosis
- Belantamab mafodotin — 6 citations, newest 2026, Glomerular Injury / Proteinuria
- Thalidomide — 6 citations, newest 2017, Prerenal / Hemodynamic AKI
- Ceritinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Talazoparib — 6 citations, newest 2026, Pseudo-AKI
- Selumetinib — 6 citations, newest 2023, Prerenal / Hemodynamic AKI
- Futibatinib — 6 citations, newest 2024, Electrolyte Disturbance
- Pralsetinib — 6 citations, newest 2025, Hypertension
- Ivosidenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
- Sotorasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Adagrasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Eribulin — 6 citations, newest 2022, Prerenal / Hemodynamic AKI
- Asparaginase — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Tamoxifen — 6 citations, newest 2023, SIADH / Hyponatremia
- Datopotamab deruxtecan (Dato-DXd) — 6 citations, newest 2025, Acute Tubular Necrosis
- Revumenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
- Pirtobrutinib — 6 citations, newest 2024, Crystal / Obstructive Nephropathy
- Lazertinib — 6 citations, newest 2024, SIADH / Hyponatremia
- Repotrectinib — 6 citations, newest 2025, Pseudo-AKI
- Lifileucel — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Quizartinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Ibritumomab tiuxetan — 6 citations, newest 2004, Prerenal / Hemodynamic AKI
- Idelalisib — 6 citations, newest 2021, Prerenal / Hemodynamic AKI
- Copanlisib — 6 citations, newest 2021, Hypertension
- Vismodegib — 6 citations, newest 2023, SIADH / Hyponatremia
- Sonidegib — 6 citations, newest 2023, Acute Tubular Necrosis
- Glasdegib — 6 citations, newest 2023, Prerenal / Hemodynamic AKI
- Neratinib — 6 citations, newest 2022, Prerenal / Hemodynamic AKI
- Olutasidenib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Tafasitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
- Mogamulizumab — 6 citations, newest 2021, Prerenal / Hemodynamic AKI
- Lanreotide — 6 citations, newest 2018, Electrolyte Disturbance
- Mitotane — 6 citations, newest 2025, Electrolyte Disturbance
- Retifanlimab — 6 citations, newest 2025, Acute Interstitial Nephritis
- Linvoseltamab — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
- Pivekimab sunirine — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
- Tivozanib — 5 citations, newest 2021, Hypertension
- Sacituzumab govitecan — 5 citations, newest 2026, Prerenal / Hemodynamic AKI
- Brentuximab vedotin — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
- Irinotecan — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
- Zanidatamab — 5 citations, newest 2025, Prerenal / Hemodynamic AKI
- Imetelstat — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
- Ziftomenib — 5 citations, newest 2026, Prerenal / Hemodynamic AKI
- Avapritinib — 5 citations, newest 2021, Prerenal / Hemodynamic AKI
- Pexidartinib — 5 citations, newest 2023, Prerenal / Hemodynamic AKI
- Loncastuximab tesirine — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
- Vinflunine — 5 citations, newest 2019, Electrolyte Disturbance
- Teniposide — 5 citations, newest 2021, Electrolyte Disturbance
- Darolutamide — 5 citations, newest 2025, Electrolyte Disturbance
- Cosibelimab — 5 citations, newest 2025, Acute Interstitial Nephritis
- Ivonescimab — 5 citations, newest 2025, Glomerular Injury / Proteinuria
- Olverembatinib — 5 citations, newest 2026, Glomerular Injury / Proteinuria
- Vimseltinib — 5 citations, newest 2025, Pseudo-AKI
- Penpulimab — 5 citations, newest 2026, Acute Interstitial Nephritis
- Sugemalimab — 5 citations, newest 2024, Acute Interstitial Nephritis
- Ensartinib — 5 citations, newest 2025, Pseudo-AKI
- Obecabtagene autoleucel (Obe-cel) — 5 citations, newest 2025, Prerenal / Hemodynamic AKI
- Cadonilimab — 5 citations, newest 2026, Acute Interstitial Nephritis
- Polatuzumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Mirvetuximab soravtansine — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Gemtuzumab ozogamicin — 4 citations, newest 2020, Prerenal / Hemodynamic AKI
- Inotuzumab ozogamicin — 4 citations, newest 2023, Prerenal / Hemodynamic AKI
- Topotecan — 4 citations, newest 2022, Prerenal / Hemodynamic AKI
- Tovorafenib — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Mirdametinib — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Sunvozertinib — 4 citations, newest 2024, Electrolyte Disturbance
- Tucatinib — 4 citations, newest 2024, Pseudo-AKI
- Casdatifan — 4 citations, newest 2026, Prerenal / Hemodynamic AKI
- Zongertinib — 4 citations, newest 2025, Pseudo-AKI
- Tisotumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Tebentafusp — 4 citations, newest 2023, Prerenal / Hemodynamic AKI
- Zolbetuximab — 4 citations, newest 2025, Prerenal / Hemodynamic AKI
- Elacestrant — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
- Raltitrexed — 4 citations, newest 2021, Acute Tubular Necrosis
- Elotuzumab — 4 citations, newest 2017, Prerenal / Hemodynamic AKI
- Melphalan flufenamide (melflufen) — 4 citations, newest 2026, Acute Tubular Necrosis
- Procarbazine — 4 citations, newest 2021, Acute Tubular Necrosis
- Catumaxomab — 4 citations, newest 2017, Prerenal / Hemodynamic AKI
- Fotemustine — 4 citations, newest 2015, Chronic Interstitial Nephropathy
- Nimustine (ACNU) — 4 citations, newest 2023, Chronic Interstitial Nephropathy
- Dactinomycin (actinomycin D) — 4 citations, newest 2017, Electrolyte Disturbance
- Mechlorethamine — 4 citations, newest 2021, Electrolyte Disturbance
- Amsacrine — 4 citations, newest 2017, Electrolyte Disturbance
- Tegafur-uracil (UFT) — 4 citations, newest 2021, Thrombotic Microangiopathy
- Doxifluridine — 4 citations, newest 2021, Thrombotic Microangiopathy
- Samarium-153 lexidronam — 4 citations, newest 2014, Acute Tubular Necrosis
- Bicalutamide — 4 citations, newest 2020, Acute Interstitial Nephritis
- Strontium-89 chloride — 4 citations, newest 2021, Electrolyte Disturbance
- Vorasidenib — 4 citations, newest 2026, Pseudo-AKI
- Taletrectinib — 4 citations, newest 2026, Pseudo-AKI
- Inavolisib — 4 citations, newest 2024, Electrolyte Disturbance
- Afamitresgene autoleucel (Afami-cel) — 4 citations, newest 2025, Prerenal / Hemodynamic AKI
- Zidesamtinib — 4 citations, newest 2026, Prerenal / Hemodynamic AKI
- Chlorambucil — 3 citations, newest 2021, SIADH / Hyponatremia
- Altretamine (hexamethylmelamine) — 3 citations, newest 2017, Prerenal / Hemodynamic AKI
- Carmofur (HCFU) — 3 citations, newest 2021, Thrombotic Microangiopathy
- Telisotuzumab vedotin (Teliso-V) — 3 citations, newest 2025, Acute Tubular Necrosis
- Relacorilant — 3 citations, newest 2025, Electrolyte Disturbance
- Sevabertinib — 3 citations, newest 2026, Prerenal / Hemodynamic AKI
- Gedatolisib — 3 citations, newest 2026, Electrolyte Disturbance
- Dacarbazine — 2 citations, newest 2001, Prerenal / Hemodynamic AKI
- Imlunestrant — 2 citations, newest 2025, Pseudo-AKI
- Vepdegestrant — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
- Dordaviprone — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
- Zenocutuzumab — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
- Actinium 225 PSMA — 2 citations, newest 2025, Acute Tubular Necrosis
- Furmonertinib — 2 citations, newest 2026, Electrolyte Disturbance
- Defactinib — 2 citations, newest 2023, Electrolyte Disturbance
- promacta — 1 citations, newest 2010, Thrombotic Microangiopathy
- saruparib — 1 citations, newest 2026, Pseudo-AKI
Published relative risks and odds ratios for kidney-injury associations in cancer therapy, on a log axis with the null line at 1.0. Right of the line is increased risk; left is protective. These are clinical effect sizes from trials and meta-analyses, the complement to the FAERS reporting signals in the section below.
- Panitumumab → Grade 3/4 hypomagnesemia, CRC vs chemo alone: RR 18.29 (7.29–48.41) · Electrolyte Disturbance · PMID 25542231 (opens PubMed in a new tab)
- Severe CRS → CAR-T–associated AKI: OR 16.4 (1.9–138.5) · Prerenal / Hemodynamic AKI · PMID 39506012 (opens PubMed in a new tab)
- Bevacizumab → Nephrotic syndrome: RR 7.78 (1.8–33.62) · Glomerular Injury / Proteinuria · PMID 20538785 (opens PubMed in a new tab)
- Bevacizumab (high dose) → Hypertension: RR 7.5 (4.2–13.4) · Hypertension · PMID 17261421 (opens PubMed in a new tab)
- Cetuximab → Grade 3/4 hypomagnesemia, CRC vs chemo alone: RR 7.14 (3.13–16.27) · Electrolyte Disturbance · PMID 25542231 (opens PubMed in a new tab)
- Anti-EGFR mAb → Any-grade hypomagnesemia, metastatic CRC: OR 6.73 (3.84–11.82) · Electrolyte Disturbance · PMID 19906103 (opens PubMed in a new tab)
- Bevacizumab → High-grade hypertension: RR 5.28 (4.15–6.71) · Hypertension · PMID 20186127 (opens PubMed in a new tab)
- Bevacizumab → High-grade proteinuria: RR 4.79 (2.71–8.46) · Glomerular Injury / Proteinuria · PMID 20538785 (opens PubMed in a new tab)
- Bevacizumab (low dose) → Hypertension: RR 3 (2.2–4.2) · Hypertension · PMID 17261421 (opens PubMed in a new tab)
- Concurrent PPI → Checkpoint-inhibitor AKI: OR 1.84 (1.16–2.9) · Acute Interstitial Nephritis · PMID 38471492 (opens PubMed in a new tab)
- Magnesium prophylaxis → Cisplatin AKI: OR 0.24 (0.19–0.32) (protective) · Acute Tubular Necrosis · PMID 31429065 (opens PubMed in a new tab)
11 estimates · x = effect size (log), null at 1.0 · whisker = 95% CI · colored by the injury each estimate is for. Effect sizes as reported; heterogeneous designs (RCT meta-analyses, cohorts) — not directly comparable across rows.
The rise of onconephrology in the literature: each year's height stacks the clinical PubMed papers matching each of the eight subfield queries behind the contributor atlas — a paper matching two subfields adds to both bands, so the stacked total counts memberships, not distinct papers. The drug-toxicity base gives way to the myeloma/MGRS surge and the checkpoint-inhibitor era. Hover a year; click a band to isolate a subfield.
38 years · a paper may match more than one subfield · band height = papers matching that subfield · 2026 is shaded because the corpus was harvested mid-year — its dip is incomplete indexing, not a decline
- 1990: 165 subfield matches
- 1991: 151 subfield matches
- 1992: 144 subfield matches
- 1993: 156 subfield matches
- 1994: 164 subfield matches
- 1995: 177 subfield matches
- 1996: 176 subfield matches
- 1997: 172 subfield matches
- 1998: 168 subfield matches
- 1999: 177 subfield matches
- 2000: 174 subfield matches
- 2001: 186 subfield matches
- 2002: 164 subfield matches
- 2003: 196 subfield matches
- 2004: 203 subfield matches
- 2005: 244 subfield matches
- 2006: 204 subfield matches
- 2007: 309 subfield matches
- 2008: 284 subfield matches
- 2009: 294 subfield matches
- 2010: 374 subfield matches
- 2011: 386 subfield matches
- 2012: 452 subfield matches
- 2013: 436 subfield matches
- 2014: 523 subfield matches
- 2015: 590 subfield matches
- 2016: 621 subfield matches
- 2017: 605 subfield matches
- 2018: 682 subfield matches
- 2019: 728 subfield matches
- 2020: 997 subfield matches
- 2021: 1,033 subfield matches
- 2022: 976 subfield matches
- 2023: 937 subfield matches
- 2024: 1,061 subfield matches
- 2025: 1,226 subfield matches
- 2026: 1,321 subfield matches
- 2027: 4 subfield matches
- Dispenzieri, Angela and Gertz, Morie A: 76 shared corpus papers
- Dispenzieri, Angela and Leung, Nelson: 64 shared corpus papers
- Dispenzieri, Angela and Lacy, Martha Q: 59 shared corpus papers
- Gertz, Morie A and Lacy, Martha Q: 59 shared corpus papers
- Leung, Nelson and Nasr, Samih H: 59 shared corpus papers
- Dimopoulos, Meletios A and Terpos, Evangelos: 57 shared corpus papers
- Gertz, Morie A and Leung, Nelson: 57 shared corpus papers
- Dispenzieri, Angela and Kumar, Shaji K: 55 shared corpus papers
- Gertz, Morie A and Kumar, Shaji K: 52 shared corpus papers
- Dimopoulos, Meletios A and Kastritis, Efstathios: 50 shared corpus papers
- Kumar, Shaji K and Leung, Nelson: 47 shared corpus papers
- Lacy, Martha Q and Leung, Nelson: 44 shared corpus papers
- Kumar, Shaji K and Lacy, Martha Q: 43 shared corpus papers
- Dispenzieri, Angela and Kyle, Robert A: 42 shared corpus papers
- Kastritis, Efstathios and Terpos, Evangelos: 39 shared corpus papers
- Leung, Nelson and Sethi, Sanjeev: 39 shared corpus papers
- Nasr, Samih H and Sethi, Sanjeev: 38 shared corpus papers
- Fervenza, Fernando C and Sethi, Sanjeev: 37 shared corpus papers
- Gertz, Morie A and Kyle, Robert A: 37 shared corpus papers
- Kyle, Robert A and Leung, Nelson: 35 shared corpus papers
- Kumar, Shaji K and Kyle, Robert A: 32 shared corpus papers
- Kyle, Robert A and Lacy, Martha Q: 31 shared corpus papers
- Fervenza, Fernando C and Leung, Nelson: 30 shared corpus papers
- Merlini, Giampaolo and Palladini, Giovanni: 27 shared corpus papers
- Bridoux, Frank and Leung, Nelson: 23 shared corpus papers
- Cornell, Lynn D and Nasr, Samih H: 23 shared corpus papers
- Fervenza, Fernando C and Nasr, Samih H: 23 shared corpus papers
- Cornell, Lynn D and Leung, Nelson: 21 shared corpus papers
- Cornell, Lynn D and Sethi, Sanjeev: 21 shared corpus papers
- Anderson, Kenneth C and Richardson, Paul G: 19 shared corpus papers
- Bridoux, Frank and Nasr, Samih H: 17 shared corpus papers
- Dispenzieri, Angela and Nasr, Samih H: 17 shared corpus papers
- Gupta, Shruti and Leaf, David E: 16 shared corpus papers
- Herrmann, Sandra M and Leung, Nelson: 14 shared corpus papers
- D'Agati, Vivette D and Nasr, Samih H: 13 shared corpus papers
- Dispenzieri, Angela and Fervenza, Fernando C: 13 shared corpus papers
- Gupta, Shruti and Sise, Meghan E: 13 shared corpus papers
- Dimopoulos, Meletios A and Richardson, Paul G: 12 shared corpus papers
- Fervenza, Fernando C and Gertz, Morie A: 12 shared corpus papers
- D'Agati, Vivette D and Sethi, Sanjeev: 11 shared corpus papers
- Dispenzieri, Angela and Sethi, Sanjeev: 11 shared corpus papers
- Gertz, Morie A and Nasr, Samih H: 11 shared corpus papers
- Kastritis, Efstathios and Merlini, Giampaolo: 11 shared corpus papers
- Perazella, Mark A and Rosner, Mitchell H: 11 shared corpus papers
- D'Agati, Vivette D and Leung, Nelson: 10 shared corpus papers
- Fervenza, Fernando C and Kumar, Shaji K: 10 shared corpus papers
- Fervenza, Fernando C and Lacy, Martha Q: 10 shared corpus papers
- Kastritis, Efstathios and Leung, Nelson: 10 shared corpus papers
- Cornell, Lynn D and Fervenza, Fernando C: 9 shared corpus papers
- Gertz, Morie A and Sethi, Sanjeev: 9 shared corpus papers
- Gupta, Shruti and Herrmann, Sandra M: 9 shared corpus papers
- Gupta, Shruti and Jhaveri, Kenar D: 9 shared corpus papers
- Herrmann, Sandra M and Kitchlu, Abhijat: 9 shared corpus papers
- Kyle, Robert A and Nasr, Samih H: 9 shared corpus papers
- Leaf, David E and Sise, Meghan E: 9 shared corpus papers
- Abudayyeh, Ala and Gupta, Shruti: 8 shared corpus papers
- Dimopoulos, Meletios A and Merlini, Giampaolo: 8 shared corpus papers
- Dispenzieri, Angela and Merlini, Giampaolo: 8 shared corpus papers
- Gupta, Shruti and Kitchlu, Abhijat: 8 shared corpus papers
- Jhaveri, Kenar D and Perazella, Mark A: 8 shared corpus papers
- Lacy, Martha Q and Nasr, Samih H: 8 shared corpus papers
- Merlini, Giampaolo and Wechalekar, Ashutosh D: 8 shared corpus papers
- Palladini, Giovanni and Wechalekar, Ashutosh D: 8 shared corpus papers
- Bridoux, Frank and Dispenzieri, Angela: 7 shared corpus papers
- Fervenza, Fernando C and Kyle, Robert A: 7 shared corpus papers
- Herrmann, Sandra M and Sise, Meghan E: 7 shared corpus papers
- Izzedine, Hassan and Perazella, Mark A: 7 shared corpus papers
- Kastritis, Efstathios and Palladini, Giovanni: 7 shared corpus papers
- Kumar, Shaji K and Nasr, Samih H: 7 shared corpus papers
- Kumar, Shaji K and Sethi, Sanjeev: 7 shared corpus papers
- Leung, Nelson and Merlini, Giampaolo: 7 shared corpus papers
- Abudayyeh, Ala and Herrmann, Sandra M: 6 shared corpus papers
- Abudayyeh, Ala and Kitchlu, Abhijat: 6 shared corpus papers
- Abudayyeh, Ala and Leaf, David E: 6 shared corpus papers
- Cornell, Lynn D and D'Agati, Vivette D: 6 shared corpus papers
- Dimopoulos, Meletios A and Leung, Nelson: 6 shared corpus papers
- Dispenzieri, Angela and Kastritis, Efstathios: 6 shared corpus papers
- Gertz, Morie A and Merlini, Giampaolo: 6 shared corpus papers
- Herrmann, Sandra M and Leaf, David E: 6 shared corpus papers
- Izzedine, Hassan and Jhaveri, Kenar D: 6 shared corpus papers
- Jhaveri, Kenar D and Rosner, Mitchell H: 6 shared corpus papers
- Kastritis, Efstathios and Wechalekar, Ashutosh D: 6 shared corpus papers
- Kyle, Robert A and Sethi, Sanjeev: 6 shared corpus papers
- Azoulay, Elie and Zafrani, Lara: 5 shared corpus papers
- Bridoux, Frank and Kastritis, Efstathios: 5 shared corpus papers
- Bridoux, Frank and Sethi, Sanjeev: 5 shared corpus papers
- Bridoux, Frank and Merlini, Giampaolo: 5 shared corpus papers
- Hutchison, Colin A and Leung, Nelson: 5 shared corpus papers
- Jhaveri, Kenar D and Sise, Meghan E: 5 shared corpus papers
- Kastritis, Efstathios and Kyle, Robert A: 5 shared corpus papers
- Kitchlu, Abhijat and Leaf, David E: 5 shared corpus papers
- Kyle, Robert A and Merlini, Giampaolo: 5 shared corpus papers
- Lacy, Martha Q and Sethi, Sanjeev: 5 shared corpus papers
- Merlini, Giampaolo and Terpos, Evangelos: 5 shared corpus papers
- Richardson, Paul G and Terpos, Evangelos: 5 shared corpus papers
- Abudayyeh, Ala and Jhaveri, Kenar D: 4 shared corpus papers
- Abudayyeh, Ala and Sise, Meghan E: 4 shared corpus papers
- Bridoux, Frank and D'Agati, Vivette D: 4 shared corpus papers
- Bridoux, Frank and Kyle, Robert A: 4 shared corpus papers
- Bridoux, Frank and Hutchison, Colin A: 4 shared corpus papers
- Cornell, Lynn D and Dispenzieri, Angela: 4 shared corpus papers
- Cornell, Lynn D and Gertz, Morie A: 4 shared corpus papers
- D'Agati, Vivette D and Fervenza, Fernando C: 4 shared corpus papers
- Dimopoulos, Meletios A and Palladini, Giovanni: 4 shared corpus papers
- Dispenzieri, Angela and Palladini, Giovanni: 4 shared corpus papers
- Dispenzieri, Angela and Hutchison, Colin A: 4 shared corpus papers
- Fervenza, Fernando C and Herrmann, Sandra M: 4 shared corpus papers
- Gertz, Morie A and Palladini, Giovanni: 4 shared corpus papers
- Gratama, Jan W and Lamers, Cor H J: 4 shared corpus papers
- Gupta, Shruti and Rosner, Mitchell H: 4 shared corpus papers
- Herrmann, Sandra M and Rosner, Mitchell H: 4 shared corpus papers
- Herrmann, Sandra M and Jhaveri, Kenar D: 4 shared corpus papers
- Hutchison, Colin A and Kyle, Robert A: 4 shared corpus papers
- Jhaveri, Kenar D and Leaf, David E: 4 shared corpus papers
- Kastritis, Efstathios and Richardson, Paul G: 4 shared corpus papers
- Kitchlu, Abhijat and Sise, Meghan E: 4 shared corpus papers
- Leung, Nelson and Terpos, Evangelos: 4 shared corpus papers
- Leung, Nelson and Wechalekar, Ashutosh D: 4 shared corpus papers
- Abudayyeh, Ala and Rosner, Mitchell H: 3 shared corpus papers
- Anderson, Kenneth C and Dimopoulos, Meletios A: 3 shared corpus papers
- Anderson, Kenneth C and Kumar, Shaji K: 3 shared corpus papers
- Anderson, Kenneth C and Kyle, Robert A: 3 shared corpus papers
- Bridoux, Frank and Dimopoulos, Meletios A: 3 shared corpus papers
- Bridoux, Frank and Wechalekar, Ashutosh D: 3 shared corpus papers
- Dimopoulos, Meletios A and Dispenzieri, Angela: 3 shared corpus papers
- Dimopoulos, Meletios A and Kumar, Shaji K: 3 shared corpus papers
- Dispenzieri, Angela and Wechalekar, Ashutosh D: 3 shared corpus papers
- Gupta, Shruti and Perazella, Mark A: 3 shared corpus papers
- Herrmann, Sandra M and Sethi, Sanjeev: 3 shared corpus papers
- Kastritis, Efstathios and Kumar, Shaji K: 3 shared corpus papers
- Kitchlu, Abhijat and Leung, Nelson: 3 shared corpus papers
- Kitchlu, Abhijat and Rosner, Mitchell H: 3 shared corpus papers
- Kumar, Shaji K and Merlini, Giampaolo: 3 shared corpus papers
- Kumar, Shaji K and Wechalekar, Ashutosh D: 3 shared corpus papers
- Leung, Nelson and Rosner, Mitchell H: 3 shared corpus papers
- Leung, Nelson and Richardson, Paul G: 3 shared corpus papers
- Marasco, Wayne A and Suarez, Eloah Rabello: 3 shared corpus papers
- Merlini, Giampaolo and Nasr, Samih H: 3 shared corpus papers
- Merlini, Giampaolo and Sethi, Sanjeev: 3 shared corpus papers
- Merlini, Giampaolo and Richardson, Paul G: 3 shared corpus papers
- Abudayyeh, Ala and Leung, Nelson: 2 shared corpus papers
- Anderson, Kenneth C and Terpos, Evangelos: 2 shared corpus papers
- Bridoux, Frank and Jhaveri, Kenar D: 2 shared corpus papers
- Bridoux, Frank and Terpos, Evangelos: 2 shared corpus papers
- Bridoux, Frank and Cornell, Lynn D: 2 shared corpus papers
- Bridoux, Frank and Palladini, Giovanni: 2 shared corpus papers
- Bridoux, Frank and Fervenza, Fernando C: 2 shared corpus papers
- Chen, Helen X and Rini, Brian I: 2 shared corpus papers
- Cornell, Lynn D and Lacy, Martha Q: 2 shared corpus papers
- D'Agati, Vivette D and Wechalekar, Ashutosh D: 2 shared corpus papers
- Dimopoulos, Meletios A and Wechalekar, Ashutosh D: 2 shared corpus papers
- Dimopoulos, Meletios A and Gertz, Morie A: 2 shared corpus papers
- Dispenzieri, Angela and Herrmann, Sandra M: 2 shared corpus papers
- Fervenza, Fernando C and Kastritis, Efstathios: 2 shared corpus papers
- Fervenza, Fernando C and Merlini, Giampaolo: 2 shared corpus papers
- Fervenza, Fernando C and Wechalekar, Ashutosh D: 2 shared corpus papers
- Gertz, Morie A and Kastritis, Efstathios: 2 shared corpus papers
- Gertz, Morie A and Wechalekar, Ashutosh D: 2 shared corpus papers
- Gertz, Morie A and Herrmann, Sandra M: 2 shared corpus papers
- Gupta, Shruti and Leung, Nelson: 2 shared corpus papers
- Herrmann, Sandra M and Nasr, Samih H: 2 shared corpus papers
- Herrmann, Sandra M and Kumar, Shaji K: 2 shared corpus papers
- Herrmann, Sandra M and Perazella, Mark A: 2 shared corpus papers
- Herrmann, Sandra M and Lacy, Martha Q: 2 shared corpus papers
- Hutchison, Colin A and Nasr, Samih H: 2 shared corpus papers
- Hutchison, Colin A and Kastritis, Efstathios: 2 shared corpus papers
- Jhaveri, Kenar D and Leung, Nelson: 2 shared corpus papers
- Jhaveri, Kenar D and Kitchlu, Abhijat: 2 shared corpus papers
- Kastritis, Efstathios and Nasr, Samih H: 2 shared corpus papers
- Kastritis, Efstathios and Sethi, Sanjeev: 2 shared corpus papers
- Kumar, Shaji K and Palladini, Giovanni: 2 shared corpus papers
- Kumar, Shaji K and Richardson, Paul G: 2 shared corpus papers
- Leaf, David E and Perazella, Mark A: 2 shared corpus papers
- Leaf, David E and Rosner, Mitchell H: 2 shared corpus papers
- Leung, Nelson and Palladini, Giovanni: 2 shared corpus papers
- Nasr, Samih H and Wechalekar, Ashutosh D: 2 shared corpus papers
- Sethi, Sanjeev and Wechalekar, Ashutosh D: 2 shared corpus papers
- Anderson, Kenneth C and Leung, Nelson: 1 shared corpus paper
- Anderson, Kenneth C and Dispenzieri, Angela: 1 shared corpus paper
- Anderson, Kenneth C and Kastritis, Efstathios: 1 shared corpus paper
- Anderson, Kenneth C and Merlini, Giampaolo: 1 shared corpus paper
- Anderson, Kenneth C and Gupta, Shruti: 1 shared corpus paper
- Bridoux, Frank and Richardson, Paul G: 1 shared corpus paper
- Cornell, Lynn D and Kumar, Shaji K: 1 shared corpus paper
- Cornell, Lynn D and Kyle, Robert A: 1 shared corpus paper
- Cornell, Lynn D and Herrmann, Sandra M: 1 shared corpus paper
- Cornell, Lynn D and Gupta, Shruti: 1 shared corpus paper
- Cornell, Lynn D and Sise, Meghan E: 1 shared corpus paper
- Cornell, Lynn D and Leaf, David E: 1 shared corpus paper
- D'Agati, Vivette D and Dispenzieri, Angela: 1 shared corpus paper
- D'Agati, Vivette D and Kumar, Shaji K: 1 shared corpus paper
- D'Agati, Vivette D and Kyle, Robert A: 1 shared corpus paper
- D'Agati, Vivette D and Kastritis, Efstathios: 1 shared corpus paper
- D'Agati, Vivette D and Merlini, Giampaolo: 1 shared corpus paper
- Dimopoulos, Meletios A and Jhaveri, Kenar D: 1 shared corpus paper
- Dimopoulos, Meletios A and Lacy, Martha Q: 1 shared corpus paper
- Dimopoulos, Meletios A and Kyle, Robert A: 1 shared corpus paper
- Dispenzieri, Angela and Richardson, Paul G: 1 shared corpus paper
- Dispenzieri, Angela and Terpos, Evangelos: 1 shared corpus paper
- Fervenza, Fernando C and Hutchison, Colin A: 1 shared corpus paper
- Gertz, Morie A and Hutchison, Colin A: 1 shared corpus paper
- Herrmann, Sandra M and Kyle, Robert A: 1 shared corpus paper
- Hutchison, Colin A and Sethi, Sanjeev: 1 shared corpus paper
- Hutchison, Colin A and Kumar, Shaji K: 1 shared corpus paper
- Hutchison, Colin A and Merlini, Giampaolo: 1 shared corpus paper
- Jhaveri, Kenar D and Nasr, Samih H: 1 shared corpus paper
- Jhaveri, Kenar D and Terpos, Evangelos: 1 shared corpus paper
- Jhaveri, Kenar D and Kastritis, Efstathios: 1 shared corpus paper
- Kitchlu, Abhijat and Perazella, Mark A: 1 shared corpus paper
- Kumar, Shaji K and Terpos, Evangelos: 1 shared corpus paper
- Kyle, Robert A and Terpos, Evangelos: 1 shared corpus paper
- Kyle, Robert A and Wechalekar, Ashutosh D: 1 shared corpus paper
- Kyle, Robert A and Palladini, Giovanni: 1 shared corpus paper
- Kyle, Robert A and Richardson, Paul G: 1 shared corpus paper
- Palladini, Giovanni and Terpos, Evangelos: 1 shared corpus paper
- Onco-nephrology (general)
- Anticancer drug nephrotoxicity
- MGRS & paraprotein kidney disease
- Myeloma cast nephropathy
- Anti-VEGF / TKI renal effects
- Tumor lysis & electrolytes
- Cellular therapy renal effects
Hover, tap, or focus a node to trace its co-authorship links and reach the contributor page.
Arcs and co-author counts are drawn only between recognized contributors, and papers with more than 40 authors are left out of the pair tally — a lower bound on the full collaboration graph, not a complete count.
FAERS & real-world signals
What spontaneous reporting shows — disproportionate reporting, never incidence.
Each agent's acute-kidney-injury reporting odds ratio (horizontal, log) against its AKI report count (vertical, log). A dot right of the ROR = 1 line has a point estimate above 1; it reports AKI disproportionately only when its whisker clears the line too (filled). Size = total report volume.
245 agents plotted — every ROR rests on at least 50 total reports (its AKI count, on the vertical axis, can still be 1 or 2 — hence the widest whiskers at the bottom) · whisker = ROR 95% CI · filled = significant renal signal (CI lower bound > 1 — whisker clears the ROR = 1 line) · faint = no signal · dashed ring = a signal whose IC025 does not clear 0 (4 of 95) · 3 of the signals rest in part on one case filed repeatedly (named in each mark's label; the drug page gives the ratio without it) · size = total FAERS reports · color = signature injury. Reporting, not incidence. 6 agents queried but not plotted — under 50 total reports the ratio's own denominator is too thin to divide. FAERS snapshot 2026-11-15.
- Lifileucel (Prerenal / Hemodynamic AKI): ROR 8.22 (95% CI 5.37–12.58), 23 AKI reports of 285 total — signal; IC025 2.09
- Clofarabine (Prerenal / Hemodynamic AKI): ROR 5.51 (95% CI 4.60–6.58), 127 AKI reports of 2,287 total — signal; IC025 2.11
- Interleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): ROR 5.41 (95% CI 4.24–6.90), 69 AKI reports of 1,263 total — signal; IC025 1.97
- Trabectedin (Acute Tubular Necrosis): ROR 4.69 (95% CI 3.88–5.67), 112 AKI reports of 2,350 total — signal; IC025 1.87
- Tagraxofusp (Prerenal / Hemodynamic AKI): ROR 4.37 (95% CI 2.90–6.58), 24 AKI reports of 538 total — signal; IC025 1.35
- Streptozocin (Fanconi Syndrome): ROR 4.04 (95% CI 2.08–7.87), 9 AKI reports of 245 total — signal; IC025 0.67
- Pemetrexed (Chronic Interstitial Nephropathy): ROR 3.88 (95% CI 3.69–4.08), 1,547 AKI reports of 39,105 total — signal; IC025 1.83
- Idecabtagene vicleucel (Prerenal / Hemodynamic AKI): ROR 3.77 (95% CI 2.82–5.03), 48 AKI reports of 1,241 total — signal; IC025 1.40
- Sirolimus (Glomerular Injury / Proteinuria): ROR 3.65 (95% CI 3.34–3.98), 512 AKI reports of 13,673 total — signal; IC025 1.69
- Adagrasib (Prerenal / Hemodynamic AKI): ROR 3.48 (95% CI 2.49–4.84), 36 AKI reports of 1,134 total — signal; IC025 1.21
- Cisplatin (Acute Tubular Necrosis): ROR 3.43 (95% CI 3.30–3.56), 2,766 AKI reports of 79,025 total — signal; IC025 1.67
- Retifanlimab (Acute Interstitial Nephritis): ROR 3.40 (95% CI 1.51–7.67), 6 AKI reports of 193 total — signal; IC025 0.12
- Pamidronate (Glomerular Injury / Proteinuria): ROR 3.16 (95% CI 2.65–3.77), 127 AKI reports of 4,390 total — signal; IC025 1.36
- Carfilzomib (Thrombotic Microangiopathy): ROR 3.11 (95% CI 2.91–3.32), 909 AKI reports of 28,379 total — signal; IC025 1.50
- Cobimetinib (Acute Tubular Necrosis): ROR 3.05 (95% CI 2.58–3.61), 140 AKI reports of 4,436 total — signal; IC025 1.32
- Inavolisib (Electrolyte Disturbance): ROR 3.03 (95% CI 1.96–4.68), 21 AKI reports of 670 total — signal; IC025 0.82
- Melphalan (SIADH / Hyponatremia): ROR 2.94 (95% CI 2.73–3.16), 768 AKI reports of 25,290 total — signal; IC025 1.42
- Gemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 2.82 (95% CI 2.32–3.41), 107 AKI reports of 3,665 total — signal; IC025 1.17
- Lurbinectedin (Acute Tubular Necrosis): ROR 2.78 (95% CI 1.93–3.99), 30 AKI reports of 1,175 total — signal; IC025 0.85
- Fludarabine (Crystal / Obstructive Nephropathy): ROR 2.66 (95% CI 2.51–2.83), 1,098 AKI reports of 39,838 total — signal; IC025 1.29
- Pembrolizumab (Acute Interstitial Nephritis): ROR 2.59 (95% CI 2.49–2.69), 2,572 AKI reports of 109,044 total — signal; IC025 1.28
- Isatuximab (Prerenal / Hemodynamic AKI): ROR 2.58 (95% CI 2.20–3.02), 157 AKI reports of 5,853 total — signal; IC025 1.10
- Cytarabine (Crystal / Obstructive Nephropathy): ROR 2.57 (95% CI 2.45–2.70), 1,679 AKI reports of 63,055 total — signal; IC025 1.26
- Ifosfamide (Fanconi Syndrome): ROR 2.50 (95% CI 2.29–2.72), 557 AKI reports of 21,470 total — signal; IC025 1.17
- Avelumab (Acute Interstitial Nephritis): ROR 2.42 (95% CI 1.97–2.97), 93 AKI reports of 4,169 total — signal; IC025 0.94
- Carboplatin (Acute Tubular Necrosis): ROR 2.41 (95% CI 2.33–2.50), 3,233 AKI reports of 130,075 total — signal; IC025 1.18
- Carmustine (BCNU) (Chronic Interstitial Nephropathy): ROR 2.38 (95% CI 1.98–2.86), 117 AKI reports of 4,718 total — signal; IC025 0.95; 14 of the AKI reports look like one case filed repeatedly
- Gemcitabine (Thrombotic Microangiopathy): ROR 2.36 (95% CI 2.24–2.50), 1,326 AKI reports of 54,066 total — signal; IC025 1.13
- Zanidatamab (Prerenal / Hemodynamic AKI): ROR 2.34 (95% CI 0.57–9.52), 2 AKI reports of 82 total; IC025 −1.72
- Etoposide (Crystal / Obstructive Nephropathy): ROR 2.33 (95% CI 2.23–2.45), 1,814 AKI reports of 74,949 total — signal; IC025 1.13
- Epcoritamab (Prerenal / Hemodynamic AKI): ROR 2.27 (95% CI 1.81–2.83), 79 AKI reports of 3,771 total — signal; IC025 0.82; 10 of the AKI reports look like one case filed repeatedly
- Thiotepa (Hemorrhagic Cystitis): ROR 2.27 (95% CI 1.99–2.59), 231 AKI reports of 9,762 total — signal; IC025 0.97
- Binimetinib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.93–2.58), 185 AKI reports of 7,953 total — signal; IC025 0.92
- Encorafenib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.96–2.54), 237 AKI reports of 10,191 total — signal; IC025 0.94
- Bendamustine (Crystal / Obstructive Nephropathy): ROR 2.19 (95% CI 2.01–2.38), 550 AKI reports of 24,082 total — signal; IC025 0.99
- Zoledronic acid (Acute Tubular Necrosis): ROR 2.13 (95% CI 2.02–2.25), 1,314 AKI reports of 66,922 total — signal; IC025 0.99
- Mogamulizumab (Prerenal / Hemodynamic AKI): ROR 2.10 (95% CI 1.51–2.90), 37 AKI reports of 1,908 total — signal; IC025 0.53
- Busulfan (Thrombotic Microangiopathy): ROR 2.09 (95% CI 1.88–2.32), 347 AKI reports of 15,927 total — signal; IC025 0.89
- Pirtobrutinib (Crystal / Obstructive Nephropathy): ROR 2.09 (95% CI 1.33–3.30), 19 AKI reports of 981 total — signal; IC025 0.29
- Ipilimumab (Acute Interstitial Nephritis): ROR 2.08 (95% CI 1.95–2.22), 951 AKI reports of 43,846 total — signal; IC025 0.94
- Temsirolimus (Glomerular Injury / Proteinuria): ROR 2.08 (95% CI 1.70–2.54), 98 AKI reports of 4,507 total — signal; IC025 0.73
- Enfortumab vedotin (Acute Tubular Necrosis): ROR 2.07 (95% CI 1.78–2.41), 170 AKI reports of 7,851 total — signal; IC025 0.80
- Vinorelbine (SIADH / Hyponatremia): ROR 2.05 (95% CI 1.74–2.41), 149 AKI reports of 6,966 total — signal; IC025 0.77
- Linvoseltamab (Prerenal / Hemodynamic AKI): ROR 2.04 (95% CI 0.28–14.74), 1 AKI reports of 53 total; IC025 −3.21
- Atezolizumab (Acute Interstitial Nephritis): ROR 2.03 (95% CI 1.89–2.19), 752 AKI reports of 40,046 total — signal; IC025 0.90
- Vemurafenib (Acute Tubular Necrosis): ROR 2.01 (95% CI 1.77–2.28), 252 AKI reports of 11,991 total — signal; IC025 0.80
- Oxaliplatin (Thrombotic Microangiopathy): ROR 2.00 (95% CI 1.90–2.10), 1,579 AKI reports of 75,953 total — signal; IC025 0.90
- Pegaspargase (Prerenal / Hemodynamic AKI): ROR 1.99 (95% CI 1.76–2.26), 258 AKI reports of 12,377 total — signal; IC025 0.80
- Inotuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 1.98 (95% CI 1.54–2.55), 62 AKI reports of 2,992 total — signal; IC025 0.58
- 5-Fluorouracil (Thrombotic Microangiopathy): ROR 1.96 (95% CI 1.86–2.06), 1,607 AKI reports of 78,755 total — signal; IC025 0.88
- Nelarabine (Crystal / Obstructive Nephropathy): ROR 1.96 (95% CI 1.26–3.06), 20 AKI reports of 974 total — signal; IC025 0.22
- Capivasertib (Prerenal / Hemodynamic AKI): ROR 1.94 (95% CI 1.48–2.53), 55 AKI reports of 3,064 total — signal; IC025 0.52
- Pentostatin (Acute Tubular Necrosis): ROR 1.94 (95% CI 1.04–3.63), 10 AKI reports of 555 total — signal; IC025 −0.15, which does not clear 0
- Raltitrexed (Acute Tubular Necrosis): ROR 1.93 (95% CI 1.09–3.41), 12 AKI reports of 672 total — signal; IC025 −0.05, which does not clear 0
- Relacorilant (Electrolyte Disturbance): ROR 1.93 (95% CI 0.48–7.83), 2 AKI reports of 99 total; IC025 −1.90
- Procarbazine (Acute Tubular Necrosis): ROR 1.92 (95% CI 1.61–2.28), 130 AKI reports of 7,315 total — signal; IC025 0.66
- Brentuximab vedotin (Prerenal / Hemodynamic AKI): ROR 1.91 (95% CI 1.67–2.19), 208 AKI reports of 10,402 total — signal; IC025 0.71
- Elotuzumab (Prerenal / Hemodynamic AKI): ROR 1.90 (95% CI 1.56–2.31), 103 AKI reports of 5,171 total — signal; IC025 0.62
- Vincristine (SIADH / Hyponatremia): ROR 1.90 (95% CI 1.75–2.07), 588 AKI reports of 29,521 total — signal; IC025 0.79
- Nivolumab (Acute Interstitial Nephritis): ROR 1.88 (95% CI 1.80–1.97), 1,935 AKI reports of 98,547 total — signal; IC025 0.83
- Idelalisib (Prerenal / Hemodynamic AKI): ROR 1.87 (95% CI 1.57–2.24), 124 AKI reports of 7,144 total — signal; IC025 0.62
- Amsacrine (Electrolyte Disturbance): ROR 1.80 (95% CI 0.93–3.48), 9 AKI reports of 538 total; IC025 −0.31
- Cyclophosphamide (SIADH / Hyponatremia): ROR 1.80 (95% CI 1.74–1.87), 3,364 AKI reports of 179,391 total — signal; IC025 0.78
- Denileukin diftitox (Prerenal / Hemodynamic AKI): ROR 1.80 (95% CI 0.25–12.96), 1 AKI reports of 60 total; IC025 −3.30
- Bortezomib (Thrombotic Microangiopathy): ROR 1.78 (95% CI 1.69–1.86), 1,669 AKI reports of 89,993 total — signal; IC025 0.74
- Tisotumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.78 (95% CI 1.08–2.91), 16 AKI reports of 971 total — signal; IC025 −0.01, which does not clear 0
- Gilteritinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.42–2.22), 78 AKI reports of 4,738 total — signal; IC025 0.47
- Neratinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.31–2.39), 43 AKI reports of 2,319 total — signal; IC025 0.33; 13 of the AKI reports look like one case filed repeatedly, and without them the ratio does not clear 1
- Lisocabtagene maraleucel (Prerenal / Hemodynamic AKI): ROR 1.74 (95% CI 1.06–2.85), 16 AKI reports of 876 total — signal; IC025 −0.04, which does not clear 0
- Arsenic trioxide (Prerenal / Hemodynamic AKI): ROR 1.70 (95% CI 1.34–2.14), 72 AKI reports of 4,043 total — signal; IC025 0.39
- Bicalutamide (Acute Interstitial Nephritis): ROR 1.69 (95% CI 1.50–1.90), 271 AKI reports of 15,311 total — signal; IC025 0.56
- Everolimus (Glomerular Injury / Proteinuria): ROR 1.69 (95% CI 1.58–1.81), 881 AKI reports of 49,667 total — signal; IC025 0.65
- Lenvatinib (Hypertension): ROR 1.69 (95% CI 1.56–1.83), 622 AKI reports of 39,694 total — signal; IC025 0.63
- Cabazitaxel (Prerenal / Hemodynamic AKI): ROR 1.68 (95% CI 1.31–2.16), 62 AKI reports of 3,517 total — signal; IC025 0.35
- Doxorubicin (Glomerular Injury / Proteinuria): ROR 1.68 (95% CI 1.60–1.76), 1,704 AKI reports of 97,231 total — signal; IC025 0.66
- Relatlimab (Acute Interstitial Nephritis): ROR 1.66 (95% CI 0.86–3.22), 9 AKI reports of 515 total; IC025 −0.42
- Tafasitamab (Prerenal / Hemodynamic AKI): ROR 1.65 (95% CI 1.21–2.25), 41 AKI reports of 2,675 total — signal; IC025 0.23
- Vinblastine (SIADH / Hyponatremia): ROR 1.65 (95% CI 1.18–2.32), 34 AKI reports of 1,961 total — signal; IC025 0.17
- Abemaciclib (Pseudo-AKI): ROR 1.63 (95% CI 1.47–1.82), 325 AKI reports of 21,412 total — signal; IC025 0.54
- Mitoxantrone (Crystal / Obstructive Nephropathy): ROR 1.60 (95% CI 1.32–1.95), 106 AKI reports of 6,289 total — signal; IC025 0.38
- Hydroxyurea (Crystal / Obstructive Nephropathy): ROR 1.58 (95% CI 1.42–1.75), 353 AKI reports of 21,340 total — signal; IC025 0.49
- Infigratinib (Electrolyte Disturbance): ROR 1.58 (95% CI 0.22–11.39), 1 AKI reports of 68 total; IC025 −3.40
- Daratumumab (Prerenal / Hemodynamic AKI): ROR 1.57 (95% CI 1.45–1.69), 655 AKI reports of 44,998 total — signal; IC025 0.53
- Decitabine (Crystal / Obstructive Nephropathy): ROR 1.57 (95% CI 1.27–1.94), 88 AKI reports of 5,334 total — signal; IC025 0.32
- Belantamab mafodotin (Glomerular Injury / Proteinuria): ROR 1.52 (95% CI 1.13–2.05), 44 AKI reports of 3,110 total — signal; IC025 0.13
- Paclitaxel (Prerenal / Hemodynamic AKI): ROR 1.52 (95% CI 1.45–1.60), 1,618 AKI reports of 101,259 total — signal; IC025 0.52
- Cemiplimab (Acute Interstitial Nephritis): ROR 1.51 (95% CI 1.07–2.13), 33 AKI reports of 2,083 total — signal; IC025 0.04
- Vandetanib (Hypertension): ROR 1.50 (95% CI 0.94–2.40), 18 AKI reports of 1,286 total; IC025 −0.18
- Irinotecan (Prerenal / Hemodynamic AKI): ROR 1.48 (95% CI 1.29–1.70), 205 AKI reports of 13,147 total — signal; IC025 0.35
- Momelotinib (Pseudo-AKI): ROR 1.48 (95% CI 0.98–2.23), 23 AKI reports of 1,481 total; IC025 −0.11
- Asparaginase (Prerenal / Hemodynamic AKI): ROR 1.47 (95% CI 0.96–2.26), 21 AKI reports of 1,533 total; IC025 −0.15
- Afatinib (Prerenal / Hemodynamic AKI): ROR 1.45 (95% CI 1.19–1.76), 101 AKI reports of 6,622 total — signal; IC025 0.23
- Necitumumab (Electrolyte Disturbance): ROR 1.43 (95% CI 0.64–3.21), 6 AKI reports of 450 total; IC025 −0.91
- Bleomycin (Prerenal / Hemodynamic AKI): ROR 1.42 (95% CI 1.21–1.67), 155 AKI reports of 10,369 total — signal; IC025 0.26
- Entrectinib (Pseudo-AKI): ROR 1.40 (95% CI 0.92–2.13), 22 AKI reports of 1,691 total; IC025 −0.20
- Glasdegib (Prerenal / Hemodynamic AKI): ROR 1.40 (95% CI 0.67–2.96), 7 AKI reports of 474 total; IC025 −0.82
- Rituximab (Crystal / Obstructive Nephropathy): ROR 1.38 (95% CI 1.34–1.43), 3,173 AKI reports of 218,782 total — signal; IC025 0.41
- Azacitidine (Fanconi Syndrome): ROR 1.37 (95% CI 1.25–1.51), 436 AKI reports of 30,141 total — signal; IC025 0.31
- Ibritumomab tiuxetan (Prerenal / Hemodynamic AKI): ROR 1.37 (95% CI 0.90–2.09), 22 AKI reports of 1,524 total; IC025 −0.23
- Tucatinib (Pseudo-AKI): ROR 1.37 (95% CI 1.12–1.69), 91 AKI reports of 7,112 total — signal; IC025 0.14
- Obecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): ROR 1.34 (95% CI 0.19–9.63), 1 AKI reports of 71 total; IC025 −3.53
- Copanlisib (Hypertension): ROR 1.33 (95% CI 0.55–3.22), 5 AKI reports of 403 total; IC025 −1.16
- Dinutuximab (Prerenal / Hemodynamic AKI): ROR 1.33 (95% CI 0.75–2.34), 12 AKI reports of 859 total; IC025 −0.55
- Cetuximab (Electrolyte Disturbance): ROR 1.32 (95% CI 1.20–1.45), 440 AKI reports of 31,704 total — signal; IC025 0.25
- Ceritinib (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.94–1.82), 36 AKI reports of 2,947 total; IC025 −0.13
- Talquetamab (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.90–1.90), 28 AKI reports of 2,290 total; IC025 −0.20
- Abiraterone (Electrolyte Disturbance): ROR 1.29 (95% CI 1.19–1.40), 559 AKI reports of 41,137 total — signal; IC025 0.24
- Iberdomide (Prerenal / Hemodynamic AKI): ROR 1.27 (95% CI 0.32–5.14), 2 AKI reports of 149 total; IC025 −2.32
- Temozolomide (SIADH / Hyponatremia): ROR 1.26 (95% CI 1.12–1.42), 283 AKI reports of 21,320 total — signal; IC025 0.15
- Obinutuzumab (Crystal / Obstructive Nephropathy): ROR 1.24 (95% CI 1.08–1.43), 206 AKI reports of 17,772 total — signal; IC025 0.11
- Panitumumab (Electrolyte Disturbance): ROR 1.24 (95% CI 1.08–1.42), 210 AKI reports of 16,107 total — signal; IC025 0.10
- Zolbetuximab (Prerenal / Hemodynamic AKI): ROR 1.24 (95% CI 0.80–1.93), 20 AKI reports of 1,525 total; IC025 −0.40
- Docetaxel (Prerenal / Hemodynamic AKI): ROR 1.19 (95% CI 1.12–1.28), 858 AKI reports of 68,125 total — signal; IC025 0.15
- Tretinoin (ATRA) (Prerenal / Hemodynamic AKI): ROR 1.18 (95% CI 0.97–1.42), 111 AKI reports of 8,951 total; IC025 −0.05
- Bevacizumab (Glomerular Injury / Proteinuria): ROR 1.18 (95% CI 1.13–1.24), 1,630 AKI reports of 130,956 total — signal; IC025 0.16
- Ixazomib (Thrombotic Microangiopathy): ROR 1.17 (95% CI 1.05–1.30), 354 AKI reports of 28,726 total — signal; IC025 0.07
- Mobocertinib (Prerenal / Hemodynamic AKI): ROR 1.17 (95% CI 0.58–2.34), 8 AKI reports of 735 total; IC025 −0.96
- Chlorambucil (SIADH / Hyponatremia): ROR 1.16 (95% CI 0.87–1.54), 48 AKI reports of 3,932 total; IC025 −0.23
- Imlunestrant (Pseudo-AKI): ROR 1.16 (95% CI 0.16–8.36), 1 AKI reports of 92 total; IC025 −3.66
- Selpercatinib (Hypertension): ROR 1.15 (95% CI 0.69–1.92), 15 AKI reports of 1,396 total; IC025 −0.63
- Idarubicin (Crystal / Obstructive Nephropathy): ROR 1.14 (95% CI 0.68–1.94), 14 AKI reports of 1,159 total; IC025 −0.67
- Polatuzumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.14 (95% CI 0.96–1.36), 123 AKI reports of 10,202 total; IC025 −0.08
- Glofitamab (Prerenal / Hemodynamic AKI): ROR 1.12 (95% CI 0.79–1.58), 32 AKI reports of 2,709 total; IC025 −0.39
- Ponatinib (Hypertension): ROR 1.12 (95% CI 0.93–1.34), 119 AKI reports of 11,399 total; IC025 −0.11
- Dostarlimab (Acute Interstitial Nephritis): ROR 1.11 (95% CI 0.76–1.64), 26 AKI reports of 2,502 total; IC025 −0.46
- Tepotinib (Pseudo-AKI): ROR 1.10 (95% CI 0.55–2.20), 8 AKI reports of 691 total; IC025 −1.05
- Dabrafenib (Acute Interstitial Nephritis): ROR 1.08 (95% CI 0.95–1.23), 241 AKI reports of 21,157 total; IC025 −0.08
- Dacarbazine (Prerenal / Hemodynamic AKI): ROR 1.08 (95% CI 0.87–1.33), 86 AKI reports of 7,561 total; IC025 −0.22
- Selinexor (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.89–1.32), 100 AKI reports of 8,763 total; IC025 −0.19
- Tamoxifen (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.85–1.38), 66 AKI reports of 5,782 total; IC025 −0.26
- Axitinib (Hypertension): ROR 1.07 (95% CI 0.94–1.22), 221 AKI reports of 19,550 total; IC025 −0.10
- Dactinomycin (actinomycin D) (Electrolyte Disturbance): ROR 1.07 (95% CI 0.72–1.59), 25 AKI reports of 2,211 total; IC025 −0.53
- Methotrexate (high-dose) (Crystal / Obstructive Nephropathy): ROR 1.07 (95% CI 1.04–1.10), 5,575 AKI reports of 494,382 total — signal; IC025 0.05
- Thalidomide (Prerenal / Hemodynamic AKI): ROR 1.05 (95% CI 0.91–1.21), 194 AKI reports of 19,824 total; IC025 −0.14
- Ribociclib (Pseudo-AKI): ROR 1.04 (95% CI 0.94–1.15), 359 AKI reports of 32,716 total; IC025 −0.10
- Capecitabine (Prerenal / Hemodynamic AKI): ROR 1.03 (95% CI 0.96–1.09), 999 AKI reports of 92,086 total; IC025 −0.05
- Belzutifan (Prerenal / Hemodynamic AKI): ROR 1.02 (95% CI 0.64–1.65), 17 AKI reports of 1,777 total; IC025 −0.73
- Crizotinib (Renal Cysts): ROR 1.02 (95% CI 0.84–1.24), 103 AKI reports of 10,760 total; IC025 −0.26
- Sorafenib (Hypertension): ROR 1.02 (95% CI 0.89–1.16), 223 AKI reports of 20,700 total; IC025 −0.17
- Topotecan (Prerenal / Hemodynamic AKI): ROR 1.01 (95% CI 0.80–1.27), 74 AKI reports of 6,940 total; IC025 −0.34
- Duvelisib (Prerenal / Hemodynamic AKI): ROR 1.00 (95% CI 0.52–1.93), 9 AKI reports of 853 total; IC025 −1.10
- Elranatamab (Prerenal / Hemodynamic AKI): ROR 0.98 (95% CI 0.65–1.50), 22 AKI reports of 2,391 total; IC025 −0.69
- Mitotane (Electrolyte Disturbance): ROR 0.98 (95% CI 0.63–1.54), 19 AKI reports of 1,830 total; IC025 −0.75
- Durvalumab (Acute Interstitial Nephritis): ROR 0.96 (95% CI 0.84–1.10), 220 AKI reports of 21,581 total; IC025 −0.25
- Trametinib (Prerenal / Hemodynamic AKI): ROR 0.94 (95% CI 0.83–1.07), 243 AKI reports of 24,319 total; IC025 −0.27
- Regorafenib (Hypertension): ROR 0.93 (95% CI 0.77–1.12), 114 AKI reports of 11,611 total; IC025 −0.38
- Imatinib (Electrolyte Disturbance): ROR 0.92 (95% CI 0.84–1.02), 408 AKI reports of 47,183 total; IC025 −0.26
- Loncastuximab tesirine (Prerenal / Hemodynamic AKI): ROR 0.92 (95% CI 0.34–2.47), 4 AKI reports of 410 total; IC025 −1.84
- Fedratinib (Electrolyte Disturbance): ROR 0.91 (95% CI 0.53–1.57), 13 AKI reports of 1,349 total; IC025 −1.02
- Melphalan flufenamide (melflufen) (Acute Tubular Necrosis): ROR 0.91 (95% CI 0.13–6.54), 1 AKI reports of 117 total; IC025 −3.88
- Taletrectinib (Pseudo-AKI): ROR 0.89 (95% CI 0.12–6.38), 1 AKI reports of 120 total; IC025 −3.91
- Eribulin (Prerenal / Hemodynamic AKI): ROR 0.88 (95% CI 0.63–1.23), 35 AKI reports of 3,739 total; IC025 −0.69
- Ramucirumab (Hypertension): ROR 0.88 (95% CI 0.68–1.14), 59 AKI reports of 6,320 total; IC025 −0.57
- Bosutinib (Pseudo-AKI): ROR 0.87 (95% CI 0.70–1.08), 83 AKI reports of 8,981 total; IC025 −0.52
- Lazertinib (SIADH / Hyponatremia): ROR 0.87 (95% CI 0.43–1.75), 8 AKI reports of 865 total; IC025 −1.35
- Sunitinib (Hypertension): ROR 0.87 (95% CI 0.78–0.96), 360 AKI reports of 39,148 total; IC025 −0.35
- Zanubrutinib (Prerenal / Hemodynamic AKI): ROR 0.86 (95% CI 0.62–1.19), 37 AKI reports of 4,598 total; IC025 −0.72
- Futibatinib (Electrolyte Disturbance): ROR 0.85 (95% CI 0.21–3.42), 2 AKI reports of 222 total; IC025 −2.78
- Octreotide (Electrolyte Disturbance): ROR 0.85 (95% CI 0.76–0.96), 279 AKI reports of 31,000 total; IC025 −0.41
- Mitomycin C (Thrombotic Microangiopathy): ROR 0.83 (95% CI 0.58–1.17), 32 AKI reports of 3,659 total; IC025 −0.81
- Venetoclax (Crystal / Obstructive Nephropathy): ROR 0.83 (95% CI 0.76–0.90), 551 AKI reports of 62,878 total; IC025 −0.39
- Pralatrexate (Crystal / Obstructive Nephropathy): ROR 0.81 (95% CI 0.30–2.16), 4 AKI reports of 529 total; IC025 −2.01
- Trifluridine/tipiracil (Prerenal / Hemodynamic AKI): ROR 0.81 (95% CI 0.67–0.99), 97 AKI reports of 11,253 total; IC025 −0.59
- Sacituzumab govitecan (Prerenal / Hemodynamic AKI): ROR 0.80 (95% CI 0.59–1.09), 41 AKI reports of 4,834 total; IC025 −0.79
- Blinatumomab (Prerenal / Hemodynamic AKI): ROR 0.79 (95% CI 0.64–0.97), 90 AKI reports of 10,722 total; IC025 −0.64
- Sonidegib (Acute Tubular Necrosis): ROR 0.79 (95% CI 0.47–1.33), 14 AKI reports of 1,679 total; IC025 −1.19
- Teniposide (Electrolyte Disturbance): ROR 0.79 (95% CI 0.25–2.46), 3 AKI reports of 405 total; IC025 −2.34
- Nedaplatin (Acute Tubular Necrosis): ROR 0.78 (95% CI 0.39–1.56), 8 AKI reports of 1,100 total; IC025 −1.51
- Tebentafusp (Prerenal / Hemodynamic AKI): ROR 0.78 (95% CI 0.33–1.89), 5 AKI reports of 602 total; IC025 −1.85
- Erdafitinib (Electrolyte Disturbance): ROR 0.76 (95% CI 0.41–1.41), 10 AKI reports of 1,247 total; IC025 −1.41
- Naxitamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.19–3.04), 2 AKI reports of 250 total; IC025 −2.92
- Pazopanib (Glomerular Injury / Proteinuria): ROR 0.75 (95% CI 0.66–0.86), 215 AKI reports of 26,971 total; IC025 −0.61
- Teclistamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.48–1.18), 19 AKI reports of 2,379 total; IC025 −1.12
- Capmatinib (Pseudo-AKI): ROR 0.74 (95% CI 0.46–1.20), 17 AKI reports of 2,444 total; IC025 −1.18
- Ivosidenib (Prerenal / Hemodynamic AKI): ROR 0.74 (95% CI 0.46–1.19), 17 AKI reports of 2,178 total; IC025 −1.19
- Larotrectinib (Pseudo-AKI): ROR 0.74 (95% CI 0.35–1.55), 7 AKI reports of 896 total; IC025 −1.67
- Rucaparib (Pseudo-AKI): ROR 0.74 (95% CI 0.57–0.95), 61 AKI reports of 8,832 total; IC025 −0.82
- Alpelisib (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.57–0.93), 62 AKI reports of 9,106 total; IC025 −0.84
- Asciminib (Hypertension): ROR 0.73 (95% CI 0.49–1.09), 24 AKI reports of 3,514 total; IC025 −1.08
- Ciltacabtagene autoleucel (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.56–0.96), 51 AKI reports of 6,566 total; IC025 −0.86
- Estramustine (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.23–2.28), 3 AKI reports of 437 total; IC025 −2.44
- Midostaurin (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.43–1.20), 15 AKI reports of 1,957 total; IC025 −1.27
- Tarlatamab (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.42–1.25), 13 AKI reports of 1,917 total; IC025 −1.34
- Gefitinib (Glomerular Injury / Proteinuria): ROR 0.70 (95% CI 0.55–0.89), 67 AKI reports of 8,990 total; IC025 −0.87
- Ibrutinib (Hypertension): ROR 0.70 (95% CI 0.65–0.76), 605 AKI reports of 80,997 total; IC025 −0.62
- Lenalidomide (Acute Tubular Necrosis): ROR 0.69 (95% CI 0.67–0.72), 3,147 AKI reports of 425,916 total; IC025 −0.57
- Repotrectinib (Pseudo-AKI): ROR 0.69 (95% CI 0.17–2.77), 2 AKI reports of 274 total; IC025 −3.03
- Ibandronate (Acute Tubular Necrosis): ROR 0.66 (95% CI 0.54–0.82), 92 AKI reports of 14,757 total; IC025 −0.89
- Pemigatinib (Electrolyte Disturbance): ROR 0.66 (95% CI 0.30–1.48), 6 AKI reports of 853 total; IC025 −1.93
- Pomalidomide (Prerenal / Hemodynamic AKI): ROR 0.66 (95% CI 0.61–0.71), 725 AKI reports of 103,640 total; IC025 −0.70
- Dasatinib (Glomerular Injury / Proteinuria): ROR 0.62 (95% CI 0.54–0.72), 191 AKI reports of 32,694 total; IC025 −0.89
- Lutetium-177 Dotatate (Chronic Interstitial Nephropathy): ROR 0.62 (95% CI 0.45–0.85), 38 AKI reports of 5,819 total; IC025 −1.18
- Darolutamide (Electrolyte Disturbance): ROR 0.61 (95% CI 0.44–0.86), 34 AKI reports of 5,924 total; IC025 −1.22
- Nirogacestat (Electrolyte Disturbance): ROR 0.61 (95% CI 0.27–1.37), 6 AKI reports of 923 total; IC025 −2.03
- Talazoparib (Pseudo-AKI): ROR 0.61 (95% CI 0.35–1.08), 12 AKI reports of 1,853 total; IC025 −1.61
- Tislelizumab (Acute Interstitial Nephritis): ROR 0.61 (95% CI 0.47–0.81), 51 AKI reports of 8,853 total; IC025 −1.12
- Mosunetuzumab (Prerenal / Hemodynamic AKI): ROR 0.60 (95% CI 0.28–1.25), 7 AKI reports of 1,107 total; IC025 −1.96
- Ruxolitinib (Prerenal / Hemodynamic AKI): ROR 0.58 (95% CI 0.53–0.63), 449 AKI reports of 73,257 total; IC025 −0.92
- Nintedanib (Hypertension): ROR 0.57 (95% CI 0.50–0.66), 199 AKI reports of 32,818 total; IC025 −1.01
- Zongertinib (Pseudo-AKI): ROR 0.56 (95% CI 0.08–4.03), 1 AKI reports of 167 total; IC025 −4.39
- Radium-223 dichloride (Prerenal / Hemodynamic AKI): ROR 0.54 (95% CI 0.38–0.78), 29 AKI reports of 5,055 total; IC025 −1.44
- Amivantamab (Electrolyte Disturbance): ROR 0.53 (95% CI 0.34–0.82), 20 AKI reports of 3,576 total; IC025 −1.60
- Erlotinib (Glomerular Injury / Proteinuria): ROR 0.53 (95% CI 0.44–0.64), 115 AKI reports of 22,936 total; IC025 −1.17
- Sotorasib (Prerenal / Hemodynamic AKI): ROR 0.52 (95% CI 0.33–0.81), 19 AKI reports of 3,470 total; IC025 −1.65
- Lomustine (CCNU) (Chronic Interstitial Nephropathy): ROR 0.51 (95% CI 0.30–0.86), 14 AKI reports of 2,597 total; IC025 −1.80
- Toripalimab (Acute Interstitial Nephritis): ROR 0.50 (95% CI 0.26–0.96), 9 AKI reports of 1,928 total; IC025 −2.06
- Acalabrutinib (Hypertension): ROR 0.49 (95% CI 0.38–0.62), 66 AKI reports of 12,744 total; IC025 −1.39
- Cabozantinib (Hypertension): ROR 0.49 (95% CI 0.43–0.55), 251 AKI reports of 48,250 total; IC025 −1.21
- Fruquintinib (Hypertension): ROR 0.48 (95% CI 0.31–0.74), 20 AKI reports of 3,941 total; IC025 −1.74
- Tivozanib (Hypertension): ROR 0.47 (95% CI 0.22–0.99), 7 AKI reports of 1,588 total; IC025 −2.29
- Brigatinib (Pseudo-AKI): ROR 0.46 (95% CI 0.29–0.74), 18 AKI reports of 3,655 total; IC025 −1.82
- Trastuzumab deruxtecan (Acute Tubular Necrosis): ROR 0.46 (95% CI 0.35–0.60), 53 AKI reports of 10,910 total; IC025 −1.53
- Trastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): ROR 0.44 (95% CI 0.33–0.61), 40 AKI reports of 8,459 total; IC025 −1.63
- Nilotinib (Prerenal / Hemodynamic AKI): ROR 0.43 (95% CI 0.36–0.50), 134 AKI reports of 29,571 total; IC025 −1.47
- Enzalutamide (Hypertension): ROR 0.42 (95% CI 0.37–0.47), 262 AKI reports of 58,866 total; IC025 −1.43
- Cladribine (Crystal / Obstructive Nephropathy): ROR 0.40 (95% CI 0.29–0.54), 42 AKI reports of 9,967 total; IC025 −1.79
- Denosumab (Electrolyte Disturbance): ROR 0.40 (95% CI 0.37–0.42), 864 AKI reports of 203,750 total; IC025 −1.42
- Lanreotide (Electrolyte Disturbance): ROR 0.39 (95% CI 0.28–0.55), 33 AKI reports of 7,953 total; IC025 −1.87
- Osimertinib (SIADH / Hyponatremia): ROR 0.39 (95% CI 0.33–0.47), 125 AKI reports of 33,803 total; IC025 −1.60
- Ziv-aflibercept (Hypertension): ROR 0.37 (95% CI 0.31–0.44), 130 AKI reports of 32,703 total; IC025 −1.67
- Palbociclib (Pseudo-AKI): ROR 0.36 (95% CI 0.33–0.40), 369 AKI reports of 95,562 total; IC025 −1.60
- Leuprolide (Hypertension): ROR 0.35 (95% CI 0.32–0.40), 300 AKI reports of 79,718 total; IC025 −1.66
- Lorlatinib (Pseudo-AKI): ROR 0.35 (95% CI 0.24–0.51), 28 AKI reports of 7,455 total; IC025 −2.06
- Alectinib (Pseudo-AKI): ROR 0.34 (95% CI 0.23–0.50), 27 AKI reports of 7,388 total; IC025 −2.11
- Selumetinib (Prerenal / Hemodynamic AKI): ROR 0.33 (95% CI 0.15–0.75), 6 AKI reports of 1,684 total; IC025 −2.87
- Fotemustine (Chronic Interstitial Nephropathy): ROR 0.32 (95% CI 0.04–2.29), 1 AKI reports of 331 total; IC025 −5.06
- Lutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): ROR 0.30 (95% CI 0.22–0.40), 44 AKI reports of 13,841 total; IC025 −2.18
- Olaparib (Pseudo-AKI): ROR 0.26 (95% CI 0.20–0.34), 60 AKI reports of 21,443 total; IC025 −2.30
- Vismodegib (SIADH / Hyponatremia): ROR 0.25 (95% CI 0.17–0.38), 24 AKI reports of 8,927 total; IC025 −2.59
- Niraparib (Hypertension): ROR 0.22 (95% CI 0.17–0.29), 53 AKI reports of 22,237 total; IC025 −2.55
- Pacritinib (Prerenal / Hemodynamic AKI): ROR 0.21 (95% CI 0.10–0.45), 7 AKI reports of 3,069 total; IC025 −3.40
- Pralsetinib (Hypertension): ROR 0.21 (95% CI 0.08–0.55), 4 AKI reports of 1,824 total; IC025 −3.87
- Enasidenib (Prerenal / Hemodynamic AKI): ROR 0.19 (95% CI 0.09–0.41), 7 AKI reports of 3,369 total; IC025 −3.53
- Tazemetostat (Prerenal / Hemodynamic AKI): ROR 0.17 (95% CI 0.06–0.54), 3 AKI reports of 1,622 total; IC025 −4.38
- Vorasidenib (Pseudo-AKI): ROR 0.17 (95% CI 0.02–1.23), 1 AKI reports of 612 total; IC025 −5.85
- Ripretinib (Hypertension): ROR 0.16 (95% CI 0.08–0.31), 9 AKI reports of 5,243 total; IC025 −3.65
- Pexidartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.93), 1 AKI reports of 717 total; IC025 −6.23
- Quizartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.95), 1 AKI reports of 702 total; IC025 −6.20
- Datopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): ROR 0.11 (95% CI 0.01–0.78), 1 AKI reports of 859 total; IC025 −6.47
- Mirvetuximab soravtansine (Prerenal / Hemodynamic AKI): ROR 0.10 (95% CI 0.03–0.41), 2 AKI reports of 1,814 total; IC025 −5.57
- Avapritinib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.05–0.17), 11 AKI reports of 12,654 total; IC025 −4.35
- Revumenib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.01–0.65), 1 AKI reports of 1,031 total; IC025 −6.72
- Avutometinib (Electrolyte Disturbance): ROR 0.08 (95% CI 0.01–0.59), 1 AKI reports of 1,125 total; IC025 −6.84
- Elacestrant (Prerenal / Hemodynamic AKI): ROR 0.07 (95% CI 0.03–0.16), 5 AKI reports of 7,181 total; IC025 −5.32
- Mechlorethamine (Electrolyte Disturbance): ROR 0.04 (95% CI 0.01–0.30), 1 AKI reports of 2,247 total; IC025 −7.81
Which kidney phenotypes each drug class actually gets reported for. A cell's depth of color counts agents with a significant FAERS signal (ROR 95% CI lower bound > 1, on at least 50 total reports) for that phenotype, out of the family's agents holding a FAERS matrix row — the number after each row label — so a deep cell in a 3-agent family is not the same claim as one in a 20-agent family. A reporting signal, not incidence or causation — and ATN/AIN undercount, since most true cases file as generic acute kidney injury. Where a phenotype's terms mix naming and merely-consistent ones (haematuria beside haemorrhagic cystitis; every crystal term), a cell also counts signals the naming terms alone do not carry — its readout says how many.
| Drug class family | ATNsignaling agents: 41 | AINsignaling agents: 46 | TMAsignaling agents: 80 | GLOMsignaling agents: 83 | LYTEsignaling agents: 161 | FANCsignaling agents: 23 | XTALsignaling agents: 48 | HTNsignaling agents: 63 | SIADHsignaling agents: 128 | CYSTsignaling agents: 82 |
|---|---|---|---|---|---|---|---|---|---|---|
| Antimetabolites — 20 agents in the FAERS matrix | Antimetabolites, Acute Tubular Necrosis: 7 agents — 5-Fluorouracil, Clofarabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Pemetrexed | Antimetabolites, Acute Interstitial Nephritis: 4 agents — Cytarabine, Fludarabine, Gemcitabine, Pemetrexed | Antimetabolites, Thrombotic Microangiopathy: 12 agents — 5-Fluorouracil, Azacitidine, Capecitabine, Cladribine, Clofarabine, Cytarabine, Decitabine, Fludarabine, Gemcitabine, Methotrexate (high-dose), Pemetrexed, Pentostatin | Antimetabolites, Glomerular Injury / Proteinuria: 10 agents (2 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Capecitabine, Cytarabine, Fludarabine, Gemcitabine, Pemetrexed, Pentostatin, Raltitrexed, Tegafur-uracil (UFT), Trifluridine/tipiracil | Antimetabolites, Electrolyte Disturbance: 14 agents (5 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Capecitabine, Clofarabine, Cytarabine, Decitabine, Fludarabine, Gemcitabine, Hydroxyurea, Nelarabine, Pemetrexed, Pentostatin, Pralatrexate, Tegafur-uracil (UFT) | Antimetabolites, Fanconi Syndrome: 3 agents (1 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Doxifluridine | Antimetabolites, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Cladribine, Hydroxyurea, Methotrexate (high-dose), Trifluridine/tipiracil | Antimetabolites, Hypertension: 3 agents — 5-Fluorouracil, Methotrexate (high-dose), Raltitrexed | Antimetabolites, SIADH / Hyponatremia: 10 agents (4 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Capecitabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Pemetrexed, Pentostatin, Pralatrexate | Antimetabolites, Hemorrhagic Cystitis: 10 agents — Azacitidine, Capecitabine, Clofarabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Methotrexate (high-dose), Nelarabine, Pentostatin |
| Alkylating agents — 21 agents in the FAERS matrix | Alkylating agents, Acute Tubular Necrosis: 6 agents — Bendamustine, Carmustine (BCNU), Cyclophosphamide, Ifosfamide, Melphalan, Trabectedin | Alkylating agents, Acute Interstitial Nephritis: 8 agents — Bendamustine, Busulfan, Carmustine (BCNU), Chlorambucil, Cyclophosphamide, Ifosfamide, Melphalan, Temozolomide | Alkylating agents, Thrombotic Microangiopathy: 9 agents — Bendamustine, Busulfan, Carmustine (BCNU), Cyclophosphamide, Dacarbazine, Ifosfamide, Melphalan, Thiotepa, Trabectedin | Alkylating agents, Glomerular Injury / Proteinuria: 11 agents (4 on terms only consistent with the lesion, not naming it) — Busulfan, Carmustine (BCNU), Chlorambucil, Cyclophosphamide, Fotemustine, Ifosfamide, Lomustine (CCNU), Melphalan, Streptozocin, Temozolomide, Thiotepa | Alkylating agents, Electrolyte Disturbance: 10 agents (5 on terms only consistent with the lesion, not naming it) — Bendamustine, Cyclophosphamide, Dacarbazine, Estramustine, Fotemustine, Ifosfamide, Melphalan, Streptozocin, Temozolomide, Trabectedin | Alkylating agents, Fanconi Syndrome: 4 agents — Busulfan, Cyclophosphamide, Ifosfamide, Melphalan | Alkylating agents, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Bendamustine | Alkylating agents, Hypertension: 1 agent — Busulfan | Alkylating agents, SIADH / Hyponatremia: 11 agents (4 on terms only consistent with the lesion, not naming it) — Busulfan, Cyclophosphamide, Dacarbazine, Ifosfamide, Lomustine (CCNU), Lurbinectedin, Melphalan, Nimustine (ACNU), Temozolomide, Thiotepa, Trabectedin | Alkylating agents, Hemorrhagic Cystitis: 8 agents (1 on terms only consistent with the lesion, not naming it) — Bendamustine, Busulfan, Carmustine (BCNU), Cyclophosphamide, Estramustine, Ifosfamide, Melphalan, Thiotepa |
| Anti-angiogenic (VEGF) — 14 agents in the FAERS matrix | Anti-angiogenic (VEGF), Acute Tubular Necrosis: no signal | Anti-angiogenic (VEGF), Acute Interstitial Nephritis: 1 agent — Axitinib | Anti-angiogenic (VEGF), Thrombotic Microangiopathy: 6 agents — Bevacizumab, Fruquintinib, Lenvatinib, Ramucirumab, Sorafenib, Sunitinib | Anti-angiogenic (VEGF), Glomerular Injury / Proteinuria: 14 agents (1 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Fruquintinib, Lenvatinib, Nintedanib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib, Ziv-aflibercept | Anti-angiogenic (VEGF), Electrolyte Disturbance: 11 agents (5 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Lenvatinib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib | Anti-angiogenic (VEGF), Fanconi Syndrome: no signal | Anti-angiogenic (VEGF), Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Bevacizumab, Nintedanib, Vandetanib | Anti-angiogenic (VEGF), Hypertension: 14 agents — Axitinib, Bevacizumab, Cabozantinib, Fruquintinib, Lenvatinib, Nintedanib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib, Ziv-aflibercept | Anti-angiogenic (VEGF), SIADH / Hyponatremia: 11 agents (9 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Lenvatinib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib | Anti-angiogenic (VEGF), Hemorrhagic Cystitis: 7 agents (5 on terms only consistent with the lesion, not naming it) — Bevacizumab, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib |
| Other targeted agents — 41 agents in the FAERS matrix | Other targeted agents, Acute Tubular Necrosis: 2 agents — Bortezomib, Thalidomide | Other targeted agents, Acute Interstitial Nephritis: 1 agent — Arsenic trioxide | Other targeted agents, Thrombotic Microangiopathy: 7 agents — Bortezomib, Carfilzomib, Denileukin diftitox, Ixazomib, Lifileucel, Moxetumomab pasudotox, Thalidomide | Other targeted agents, Glomerular Injury / Proteinuria: 3 agents (2 on terms only consistent with the lesion, not naming it) — Belzutifan, Bortezomib, Thalidomide | Other targeted agents, Electrolyte Disturbance: 20 agents (12 on terms only consistent with the lesion, not naming it) — Adagrasib, Arsenic trioxide, Belzutifan, Bortezomib, Carfilzomib, Denileukin diftitox, Glasdegib, Ivosidenib, Ixazomib, Lifileucel, Niraparib, Nirogacestat, Relacorilant, Selinexor, Sotorasib, Talazoparib, Thalidomide, Venetoclax, Vismodegib, Vorasidenib | Other targeted agents, Fanconi Syndrome: 1 agent — Tazemetostat | Other targeted agents, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Belzutifan, Niraparib, Relacorilant, Tretinoin (ATRA) | Other targeted agents, Hypertension: 4 agents (1 on terms only consistent with the lesion, not naming it) — Arsenic trioxide, Carfilzomib, Niraparib, Tretinoin (ATRA) | Other targeted agents, SIADH / Hyponatremia: 12 agents (10 on terms only consistent with the lesion, not naming it) — Belzutifan, Bortezomib, Denileukin diftitox, Glasdegib, Lifileucel, Niraparib, Relacorilant, Rucaparib, Selinexor, Talazoparib, Vismodegib, Vorasidenib | Other targeted agents, Hemorrhagic Cystitis: 5 agents (3 on terms only consistent with the lesion, not naming it) — Bortezomib, Niraparib, Sonidegib, Talazoparib, Thalidomide |
| Checkpoint inhibitors — 16 agents in the FAERS matrix | Checkpoint inhibitors, Acute Tubular Necrosis: 4 agents — Dostarlimab, Ipilimumab, Nivolumab, Pembrolizumab | Checkpoint inhibitors, Acute Interstitial Nephritis: 9 agents — Atezolizumab, Avelumab, Cemiplimab, Dostarlimab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Relatlimab | Checkpoint inhibitors, Thrombotic Microangiopathy: 4 agents — Atezolizumab, Dostarlimab, Durvalumab, Pembrolizumab | Checkpoint inhibitors, Glomerular Injury / Proteinuria: 9 agents (4 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Tislelizumab, Toripalimab | Checkpoint inhibitors, Electrolyte Disturbance: 10 agents (4 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Dostarlimab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Retifanlimab, Tislelizumab, Toripalimab | Checkpoint inhibitors, Fanconi Syndrome: 2 agents (2 on terms only consistent with the lesion, not naming it) — Nivolumab, Pembrolizumab | Checkpoint inhibitors, Crystal / Obstructive Nephropathy: no signal | Checkpoint inhibitors, Hypertension: 5 agents — Atezolizumab, Avelumab, Pembrolizumab, Penpulimab, Toripalimab | Checkpoint inhibitors, SIADH / Hyponatremia: 9 agents (2 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Retifanlimab, Tislelizumab, Toripalimab | Checkpoint inhibitors, Hemorrhagic Cystitis: 4 agents (2 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Pembrolizumab, Penpulimab |
| Monoclonal antibodies (other) — 16 agents in the FAERS matrix | Monoclonal antibodies (other), Acute Tubular Necrosis: 4 agents — Amivantamab, Cetuximab, Necitumumab, Rituximab | Monoclonal antibodies (other), Acute Interstitial Nephritis: 2 agents — Amivantamab, Mogamulizumab | Monoclonal antibodies (other), Thrombotic Microangiopathy: 10 agents — Cetuximab, Daratumumab, Dinutuximab, Elotuzumab, Isatuximab, Mogamulizumab, Naxitamab, Obinutuzumab, Rituximab, Tafasitamab | Monoclonal antibodies (other), Glomerular Injury / Proteinuria: 7 agents (1 on terms only consistent with the lesion, not naming it) — Cetuximab, Daratumumab, Dinutuximab, Mogamulizumab, Obinutuzumab, Panitumumab, Rituximab | Monoclonal antibodies (other), Electrolyte Disturbance: 14 agents (7 on terms only consistent with the lesion, not naming it) — Amivantamab, Cetuximab, Daratumumab, Dinutuximab, Elotuzumab, Isatuximab, Mogamulizumab, Naxitamab, Necitumumab, Obinutuzumab, Panitumumab, Rituximab, Tafasitamab, Zolbetuximab | Monoclonal antibodies (other), Fanconi Syndrome: 1 agent — Zolbetuximab | Monoclonal antibodies (other), Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Naxitamab, Rituximab | Monoclonal antibodies (other), Hypertension: 5 agents — Dinutuximab, Isatuximab, Naxitamab, Obinutuzumab, Rituximab | Monoclonal antibodies (other), SIADH / Hyponatremia: 5 agents (5 on terms only consistent with the lesion, not naming it) — Cetuximab, Dinutuximab, Naxitamab, Necitumumab, Tafasitamab | Monoclonal antibodies (other), Hemorrhagic Cystitis: 2 agents (1 on terms only consistent with the lesion, not naming it) — Obinutuzumab, Rituximab |
| Hormonal / endocrine — 13 agents in the FAERS matrix | Hormonal / endocrine, Acute Tubular Necrosis: no signal | Hormonal / endocrine, Acute Interstitial Nephritis: no signal | Hormonal / endocrine, Thrombotic Microangiopathy: no signal | Hormonal / endocrine, Glomerular Injury / Proteinuria: 1 agent — Bicalutamide | Hormonal / endocrine, Electrolyte Disturbance: 7 agents (5 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Imlunestrant, Lanreotide, Mitotane, Octreotide, Tamoxifen | Hormonal / endocrine, Fanconi Syndrome: 1 agent — Bicalutamide | Hormonal / endocrine, Crystal / Obstructive Nephropathy: 8 agents (8 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Lanreotide, Leuprolide, Octreotide, Tamoxifen | Hormonal / endocrine, Hypertension: 7 agents (1 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Lanreotide, Octreotide, Tamoxifen | Hormonal / endocrine, SIADH / Hyponatremia: 7 agents (6 on terms only consistent with the lesion, not naming it) — Bicalutamide, Darolutamide, Imlunestrant, Lanreotide, Mitotane, Octreotide, Tamoxifen | Hormonal / endocrine, Hemorrhagic Cystitis: 7 agents (7 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Leuprolide, Octreotide, Tamoxifen |
| Antibody-drug conjugates — 15 agents in the FAERS matrix | Antibody-drug conjugates, Acute Tubular Necrosis: 1 agent — Tisotumab vedotin | Antibody-drug conjugates, Acute Interstitial Nephritis: 3 agents — Brentuximab vedotin, Enfortumab vedotin, Loncastuximab tesirine | Antibody-drug conjugates, Thrombotic Microangiopathy: 2 agents — Gemtuzumab ozogamicin, Inotuzumab ozogamicin | Antibody-drug conjugates, Glomerular Injury / Proteinuria: 1 agent (1 on terms only consistent with the lesion, not naming it) — Belantamab mafodotin | Antibody-drug conjugates, Electrolyte Disturbance: 10 agents (2 on terms only consistent with the lesion, not naming it) — Belantamab mafodotin, Brentuximab vedotin, Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Sacituzumab govitecan, Tisotumab vedotin, Trastuzumab deruxtecan, Trastuzumab emtansine (T-DM1) | Antibody-drug conjugates, Fanconi Syndrome: no signal | Antibody-drug conjugates, Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Enfortumab vedotin, Polatuzumab vedotin, Tisotumab vedotin | Antibody-drug conjugates, Hypertension: 1 agent — Trastuzumab emtansine (T-DM1) | Antibody-drug conjugates, SIADH / Hyponatremia: 8 agents (7 on terms only consistent with the lesion, not naming it) — Brentuximab vedotin, Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Tisotumab vedotin, Trastuzumab deruxtecan, Trastuzumab emtansine (T-DM1) | Antibody-drug conjugates, Hemorrhagic Cystitis: 5 agents (1 on terms only consistent with the lesion, not naming it) — Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Tisotumab vedotin |
| Microtubule inhibitors — 8 agents in the FAERS matrix | Microtubule inhibitors, Acute Tubular Necrosis: 2 agents — Paclitaxel, Vinblastine | Microtubule inhibitors, Acute Interstitial Nephritis: 2 agents — Paclitaxel, Vinorelbine | Microtubule inhibitors, Thrombotic Microangiopathy: 4 agents — Docetaxel, Paclitaxel, Vincristine, Vinorelbine | Microtubule inhibitors, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Docetaxel, Paclitaxel | Microtubule inhibitors, Electrolyte Disturbance: 7 agents (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel, Docetaxel, Eribulin, Paclitaxel, Vinblastine, Vincristine, Vinorelbine | Microtubule inhibitors, Fanconi Syndrome: 1 agent — Vincristine | Microtubule inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel | Microtubule inhibitors, Hypertension: 1 agent — Paclitaxel | Microtubule inhibitors, SIADH / Hyponatremia: 6 agents (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel, Docetaxel, Paclitaxel, Vinblastine, Vincristine, Vinorelbine | Microtubule inhibitors, Hemorrhagic Cystitis: 4 agents — Cabazitaxel, Docetaxel, Paclitaxel, Vincristine |
| Platinum agents — 4 agents in the FAERS matrix | Platinum agents, Acute Tubular Necrosis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Acute Interstitial Nephritis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Thrombotic Microangiopathy: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Glomerular Injury / Proteinuria: 4 agents (2 on terms only consistent with the lesion, not naming it) — Carboplatin, Cisplatin, Nedaplatin, Oxaliplatin | Platinum agents, Electrolyte Disturbance: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Fanconi Syndrome: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Cisplatin | Platinum agents, Hypertension: 1 agent — Oxaliplatin | Platinum agents, SIADH / Hyponatremia: 3 agents — Carboplatin, Cisplatin, Oxaliplatin | Platinum agents, Hemorrhagic Cystitis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin |
| BRAF / MEK inhibitors — 10 agents in the FAERS matrix | BRAF / MEK inhibitors, Acute Tubular Necrosis: 2 agents — Binimetinib, Cobimetinib | BRAF / MEK inhibitors, Acute Interstitial Nephritis: 5 agents — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Trametinib | BRAF / MEK inhibitors, Thrombotic Microangiopathy: no signal | BRAF / MEK inhibitors, Glomerular Injury / Proteinuria: 3 agents (3 on terms only consistent with the lesion, not naming it) — Cobimetinib, Trametinib, Vemurafenib | BRAF / MEK inhibitors, Electrolyte Disturbance: 8 agents (6 on terms only consistent with the lesion, not naming it) — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Mirdametinib, Tovorafenib, Trametinib, Vemurafenib | BRAF / MEK inhibitors, Fanconi Syndrome: no signal | BRAF / MEK inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Selumetinib | BRAF / MEK inhibitors, Hypertension: no signal | BRAF / MEK inhibitors, SIADH / Hyponatremia: 7 agents (7 on terms only consistent with the lesion, not naming it) — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Tovorafenib, Trametinib, Vemurafenib | BRAF / MEK inhibitors, Hemorrhagic Cystitis: no signal |
| Antitumor antibiotics — 7 agents in the FAERS matrix | Antitumor antibiotics, Acute Tubular Necrosis: 1 agent — Bleomycin | Antitumor antibiotics, Acute Interstitial Nephritis: 2 agents — Dactinomycin (actinomycin D), Doxorubicin | Antitumor antibiotics, Thrombotic Microangiopathy: 6 agents — Bleomycin, Dactinomycin (actinomycin D), Doxorubicin, Idarubicin, Mitomycin C, Mitoxantrone | Antitumor antibiotics, Glomerular Injury / Proteinuria: 3 agents (2 on terms only consistent with the lesion, not naming it) — Dactinomycin (actinomycin D), Doxorubicin, Mitomycin C | Antitumor antibiotics, Electrolyte Disturbance: 4 agents (2 on terms only consistent with the lesion, not naming it) — Bleomycin, Doxorubicin, Idarubicin, Mitoxantrone | Antitumor antibiotics, Fanconi Syndrome: 2 agents — Dactinomycin (actinomycin D), Doxorubicin | Antitumor antibiotics, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Mitomycin C | Antitumor antibiotics, Hypertension: no signal | Antitumor antibiotics, SIADH / Hyponatremia: 2 agents — Bleomycin, Doxorubicin | Antitumor antibiotics, Hemorrhagic Cystitis: 4 agents — Dactinomycin (actinomycin D), Doxorubicin, Mitomycin C, Mitoxantrone |
| Bisphosphonates & bone — 4 agents in the FAERS matrix | Bisphosphonates & bone, Acute Tubular Necrosis: 1 agent — Zoledronic acid | Bisphosphonates & bone, Acute Interstitial Nephritis: 2 agents — Pamidronate, Zoledronic acid | Bisphosphonates & bone, Thrombotic Microangiopathy: no signal | Bisphosphonates & bone, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Pamidronate, Zoledronic acid | Bisphosphonates & bone, Electrolyte Disturbance: 4 agents — Denosumab, Ibandronate, Pamidronate, Zoledronic acid | Bisphosphonates & bone, Fanconi Syndrome: 2 agents — Ibandronate, Zoledronic acid | Bisphosphonates & bone, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Denosumab, Ibandronate, Pamidronate, Zoledronic acid | Bisphosphonates & bone, Hypertension: 3 agents — Ibandronate, Pamidronate, Zoledronic acid | Bisphosphonates & bone, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Pamidronate, Zoledronic acid | Bisphosphonates & bone, Hemorrhagic Cystitis: 4 agents (4 on terms only consistent with the lesion, not naming it) — Denosumab, Ibandronate, Pamidronate, Zoledronic acid |
| Topoisomerase inhibitors — 5 agents in the FAERS matrix | Topoisomerase inhibitors, Acute Tubular Necrosis: 2 agents — Etoposide, Topotecan | Topoisomerase inhibitors, Acute Interstitial Nephritis: 1 agent — Etoposide | Topoisomerase inhibitors, Thrombotic Microangiopathy: 3 agents — Amsacrine, Etoposide, Topotecan | Topoisomerase inhibitors, Glomerular Injury / Proteinuria: 4 agents (1 on terms only consistent with the lesion, not naming it) — Amsacrine, Etoposide, Irinotecan, Topotecan | Topoisomerase inhibitors, Electrolyte Disturbance: 3 agents — Etoposide, Irinotecan, Topotecan | Topoisomerase inhibitors, Fanconi Syndrome: 1 agent — Etoposide | Topoisomerase inhibitors, Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Irinotecan, Topotecan | Topoisomerase inhibitors, Hypertension: 1 agent — Irinotecan | Topoisomerase inhibitors, SIADH / Hyponatremia: 3 agents (1 on terms only consistent with the lesion, not naming it) — Etoposide, Irinotecan, Topotecan | Topoisomerase inhibitors, Hemorrhagic Cystitis: 3 agents — Etoposide, Teniposide, Topotecan |
| Other kinase inhibitors — 13 agents in the FAERS matrix | Other kinase inhibitors, Acute Tubular Necrosis: no signal | Other kinase inhibitors, Acute Interstitial Nephritis: no signal | Other kinase inhibitors, Thrombotic Microangiopathy: 3 agents — Gilteritinib, Ruxolitinib, Selpercatinib | Other kinase inhibitors, Glomerular Injury / Proteinuria: 1 agent — Selpercatinib | Other kinase inhibitors, Electrolyte Disturbance: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Pralsetinib, Selpercatinib | Other kinase inhibitors, Fanconi Syndrome: no signal | Other kinase inhibitors, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Avapritinib, Pacritinib, Pexidartinib, Ruxolitinib | Other kinase inhibitors, Hypertension: 5 agents — Pexidartinib, Pralsetinib, Ripretinib, Selpercatinib, Vimseltinib | Other kinase inhibitors, SIADH / Hyponatremia: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Pralsetinib, Selpercatinib | Other kinase inhibitors, Hemorrhagic Cystitis: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Ruxolitinib, Selpercatinib |
| mTOR inhibitors — 3 agents in the FAERS matrix | mTOR inhibitors, Acute Tubular Necrosis: 3 agents — Everolimus, Sirolimus, Temsirolimus | mTOR inhibitors, Acute Interstitial Nephritis: 1 agent — Sirolimus | mTOR inhibitors, Thrombotic Microangiopathy: 2 agents — Everolimus, Sirolimus | mTOR inhibitors, Glomerular Injury / Proteinuria: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus | mTOR inhibitors, Electrolyte Disturbance: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus | mTOR inhibitors, Fanconi Syndrome: 1 agent — Everolimus | mTOR inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Everolimus | mTOR inhibitors, Hypertension: 2 agents — Everolimus, Temsirolimus | mTOR inhibitors, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Everolimus, Temsirolimus | mTOR inhibitors, Hemorrhagic Cystitis: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus |
| EGFR / HER2 inhibitors — 11 agents in the FAERS matrix | EGFR / HER2 inhibitors, Acute Tubular Necrosis: 1 agent — Zongertinib | EGFR / HER2 inhibitors, Acute Interstitial Nephritis: no signal | EGFR / HER2 inhibitors, Thrombotic Microangiopathy: 1 agent — Erlotinib | EGFR / HER2 inhibitors, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Erlotinib, Gefitinib | EGFR / HER2 inhibitors, Electrolyte Disturbance: 6 agents (1 on terms only consistent with the lesion, not naming it) — Afatinib, Erlotinib, Gefitinib, Mobocertinib, Neratinib, Tucatinib | EGFR / HER2 inhibitors, Fanconi Syndrome: no signal | EGFR / HER2 inhibitors, Crystal / Obstructive Nephropathy: no signal | EGFR / HER2 inhibitors, Hypertension: no signal | EGFR / HER2 inhibitors, SIADH / Hyponatremia: 6 agents (5 on terms only consistent with the lesion, not naming it) — Afatinib, Erlotinib, Gefitinib, Mobocertinib, Osimertinib, Tucatinib | EGFR / HER2 inhibitors, Hemorrhagic Cystitis: 1 agent — Gefitinib |
| BTK inhibitors — 4 agents in the FAERS matrix | BTK inhibitors, Acute Tubular Necrosis: no signal | BTK inhibitors, Acute Interstitial Nephritis: no signal | BTK inhibitors, Thrombotic Microangiopathy: no signal | BTK inhibitors, Glomerular Injury / Proteinuria: no signal | BTK inhibitors, Electrolyte Disturbance: 3 agents (2 on terms only consistent with the lesion, not naming it) — Ibrutinib, Pirtobrutinib, Zanubrutinib | BTK inhibitors, Fanconi Syndrome: no signal | BTK inhibitors, Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Acalabrutinib, Ibrutinib, Zanubrutinib | BTK inhibitors, Hypertension: 2 agents — Ibrutinib, Zanubrutinib | BTK inhibitors, SIADH / Hyponatremia: 3 agents (3 on terms only consistent with the lesion, not naming it) — Acalabrutinib, Ibrutinib, Zanubrutinib | BTK inhibitors, Hemorrhagic Cystitis: 3 agents (2 on terms only consistent with the lesion, not naming it) — Ibrutinib, Pirtobrutinib, Zanubrutinib |
| BCR-ABL inhibitors — 7 agents in the FAERS matrix | BCR-ABL inhibitors, Acute Tubular Necrosis: 1 agent — Imatinib | BCR-ABL inhibitors, Acute Interstitial Nephritis: no signal | BCR-ABL inhibitors, Thrombotic Microangiopathy: 3 agents — Dasatinib, Imatinib, Ponatinib | BCR-ABL inhibitors, Glomerular Injury / Proteinuria: 2 agents — Dasatinib, Imatinib | BCR-ABL inhibitors, Electrolyte Disturbance: no signal | BCR-ABL inhibitors, Fanconi Syndrome: no signal | BCR-ABL inhibitors, Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Imatinib, Nilotinib | BCR-ABL inhibitors, Hypertension: 3 agents — Asciminib, Nilotinib, Ponatinib | BCR-ABL inhibitors, SIADH / Hyponatremia: no signal | BCR-ABL inhibitors, Hemorrhagic Cystitis: 2 agents (1 on terms only consistent with the lesion, not naming it) — Imatinib, Nilotinib |
| ALK / ROS1 / MET / TRK inhibitors — 13 agents in the FAERS matrix | ALK / ROS1 / MET / TRK inhibitors, Acute Tubular Necrosis: no signal | ALK / ROS1 / MET / TRK inhibitors, Acute Interstitial Nephritis: no signal | ALK / ROS1 / MET / TRK inhibitors, Thrombotic Microangiopathy: no signal | ALK / ROS1 / MET / TRK inhibitors, Glomerular Injury / Proteinuria: 1 agent — Lorlatinib | ALK / ROS1 / MET / TRK inhibitors, Electrolyte Disturbance: 3 agents (3 on terms only consistent with the lesion, not naming it) — Capmatinib, Ceritinib, Crizotinib | ALK / ROS1 / MET / TRK inhibitors, Fanconi Syndrome: no signal | ALK / ROS1 / MET / TRK inhibitors, Crystal / Obstructive Nephropathy: no signal | ALK / ROS1 / MET / TRK inhibitors, Hypertension: 2 agents (1 on terms only consistent with the lesion, not naming it) — Brigatinib, Lorlatinib | ALK / ROS1 / MET / TRK inhibitors, SIADH / Hyponatremia: 5 agents (4 on terms only consistent with the lesion, not naming it) — Capmatinib, Ceritinib, Crizotinib, Taletrectinib, Tepotinib | ALK / ROS1 / MET / TRK inhibitors, Hemorrhagic Cystitis: no signal |
| Bispecifics / T-cell engagers — 12 agents in the FAERS matrix | Bispecifics / T-cell engagers, Acute Tubular Necrosis: no signal | Bispecifics / T-cell engagers, Acute Interstitial Nephritis: 1 agent — Blinatumomab | Bispecifics / T-cell engagers, Thrombotic Microangiopathy: 2 agents — Blinatumomab, Epcoritamab | Bispecifics / T-cell engagers, Glomerular Injury / Proteinuria: no signal | Bispecifics / T-cell engagers, Electrolyte Disturbance: 5 agents (3 on terms only consistent with the lesion, not naming it) — Elranatamab, Epcoritamab, Glofitamab, Talquetamab, Tarlatamab | Bispecifics / T-cell engagers, Fanconi Syndrome: no signal | Bispecifics / T-cell engagers, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Epcoritamab | Bispecifics / T-cell engagers, Hypertension: no signal | Bispecifics / T-cell engagers, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Epcoritamab, Tarlatamab | Bispecifics / T-cell engagers, Hemorrhagic Cystitis: no signal |
| PI3K / AKT inhibitors — 7 agents in the FAERS matrix | PI3K / AKT inhibitors, Acute Tubular Necrosis: no signal | PI3K / AKT inhibitors, Acute Interstitial Nephritis: 1 agent — Copanlisib | PI3K / AKT inhibitors, Thrombotic Microangiopathy: no signal | PI3K / AKT inhibitors, Glomerular Injury / Proteinuria: no signal | PI3K / AKT inhibitors, Electrolyte Disturbance: 4 agents (4 on terms only consistent with the lesion, not naming it) — Alpelisib, Capivasertib, Copanlisib, Idelalisib | PI3K / AKT inhibitors, Fanconi Syndrome: no signal | PI3K / AKT inhibitors, Crystal / Obstructive Nephropathy: no signal | PI3K / AKT inhibitors, Hypertension: 1 agent — Copanlisib | PI3K / AKT inhibitors, SIADH / Hyponatremia: 3 agents (3 on terms only consistent with the lesion, not naming it) — Alpelisib, Capivasertib, Copanlisib | PI3K / AKT inhibitors, Hemorrhagic Cystitis: 1 agent — Capivasertib |
| Cytokines & enzymes — 4 agents in the FAERS matrix | Cytokines & enzymes, Acute Tubular Necrosis: no signal | Cytokines & enzymes, Acute Interstitial Nephritis: no signal | Cytokines & enzymes, Thrombotic Microangiopathy: 2 agents — Interleukin-2 (high-dose), Pegaspargase | Cytokines & enzymes, Glomerular Injury / Proteinuria: no signal | Cytokines & enzymes, Electrolyte Disturbance: 2 agents (1 on terms only consistent with the lesion, not naming it) — Interleukin-2 (high-dose), Pegaspargase | Cytokines & enzymes, Fanconi Syndrome: 1 agent (1 on terms only consistent with the lesion, not naming it) — Interleukin-2 (high-dose) | Cytokines & enzymes, Crystal / Obstructive Nephropathy: no signal | Cytokines & enzymes, Hypertension: 1 agent — Interleukin-2 (high-dose) | Cytokines & enzymes, SIADH / Hyponatremia: 2 agents — Interleukin-2 (high-dose), Pegaspargase | Cytokines & enzymes, Hemorrhagic Cystitis: 1 agent — Pegaspargase |
| CDK4/6 inhibitors — 3 agents in the FAERS matrix | CDK4/6 inhibitors, Acute Tubular Necrosis: 1 agent — Abemaciclib | CDK4/6 inhibitors, Acute Interstitial Nephritis: no signal | CDK4/6 inhibitors, Thrombotic Microangiopathy: no signal | CDK4/6 inhibitors, Glomerular Injury / Proteinuria: no signal | CDK4/6 inhibitors, Electrolyte Disturbance: 2 agents (2 on terms only consistent with the lesion, not naming it) — Abemaciclib, Ribociclib | CDK4/6 inhibitors, Fanconi Syndrome: no signal | CDK4/6 inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ribociclib | CDK4/6 inhibitors, Hypertension: 1 agent — Ribociclib | CDK4/6 inhibitors, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Abemaciclib, Ribociclib | CDK4/6 inhibitors, Hemorrhagic Cystitis: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ribociclib |
| FGFR inhibitors — 4 agents in the FAERS matrix | FGFR inhibitors, Acute Tubular Necrosis: no signal | FGFR inhibitors, Acute Interstitial Nephritis: no signal | FGFR inhibitors, Thrombotic Microangiopathy: no signal | FGFR inhibitors, Glomerular Injury / Proteinuria: no signal | FGFR inhibitors, Electrolyte Disturbance: 3 agents (2 on terms only consistent with the lesion, not naming it) — Futibatinib, Infigratinib, Pemigatinib | FGFR inhibitors, Fanconi Syndrome: no signal | FGFR inhibitors, Crystal / Obstructive Nephropathy: no signal | FGFR inhibitors, Hypertension: no signal | FGFR inhibitors, SIADH / Hyponatremia: 3 agents (2 on terms only consistent with the lesion, not naming it) — Erdafitinib, Futibatinib, Infigratinib | FGFR inhibitors, Hemorrhagic Cystitis: no signal |
| Radiopharmaceuticals — 4 agents in the FAERS matrix | Radiopharmaceuticals, Acute Tubular Necrosis: no signal | Radiopharmaceuticals, Acute Interstitial Nephritis: no signal | Radiopharmaceuticals, Thrombotic Microangiopathy: 1 agent — Ibritumomab tiuxetan | Radiopharmaceuticals, Glomerular Injury / Proteinuria: no signal | Radiopharmaceuticals, Electrolyte Disturbance: 2 agents (2 on terms only consistent with the lesion, not naming it) — Ibritumomab tiuxetan, Radium-223 dichloride | Radiopharmaceuticals, Fanconi Syndrome: no signal | Radiopharmaceuticals, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Radium-223 dichloride | Radiopharmaceuticals, Hypertension: no signal | Radiopharmaceuticals, SIADH / Hyponatremia: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ibritumomab tiuxetan | Radiopharmaceuticals, Hemorrhagic Cystitis: 1 agent (1 on terms only consistent with the lesion, not naming it) — Radium-223 dichloride |
| CAR-T cell therapy — 4 agents in the FAERS matrix | CAR-T cell therapy, Acute Tubular Necrosis: no signal | CAR-T cell therapy, Acute Interstitial Nephritis: no signal | CAR-T cell therapy, Thrombotic Microangiopathy: no signal | CAR-T cell therapy, Glomerular Injury / Proteinuria: no signal | CAR-T cell therapy, Electrolyte Disturbance: no signal | CAR-T cell therapy, Fanconi Syndrome: no signal | CAR-T cell therapy, Crystal / Obstructive Nephropathy: no signal | CAR-T cell therapy, Hypertension: no signal | CAR-T cell therapy, SIADH / Hyponatremia: no signal | CAR-T cell therapy, Hemorrhagic Cystitis: no signal |
Pick a kidney phenotype: of the 283 FAERS-covered agents, every one with a significant FAERS reporting signal for it on at least 50 total reports for the agent (a floor on the agent, not the phenotype: a row can still rest on one or two reports of the phenotype itself, which the dashed rows show), ranked by reporting odds ratio with its 95% CI and report count. Agents missing from that cohort are the class composites, which are never queried, and agents with no reports under either openFDA field the atlas asks — not checked and clean. A reporting signal, not incidence; every row clears significance (CI lower bound > 1) by construction. Dashed rows rest on fewer than 10 reports — a fragile signal. A * marks a signal carried only by terms consistent with the lesion, not naming it (haematuria rather than haemorrhagic cystitis).
- Necitumumab: ROR 23.34 (95% CI 18.19–29.94), 74 reports; IC025 3.78.
- Pamidronate: ROR 8.00 (95% CI 7.08–9.03), 277 reports; IC025 2.72.
- Panitumumab: ROR 7.65 (95% CI 7.20–8.12), 1,157 reports; IC025 2.75.
- Infigratinib: ROR 7.41 (95% CI 2.70–20.34), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.34.
- Futibatinib: ROR 7.12 (95% CI 4.21–12.02), 15 reports — rests on terms consistent with, not naming, the lesion; IC025 1.68.
- Dinutuximab: ROR 6.98 (95% CI 5.34–9.14), 57 reports; IC025 2.25.
- Interleukin-2 (high-dose): ROR 6.82 (95% CI 5.46–8.54), 82 reports; IC025 2.31.
- Retifanlimab: ROR 6.48 (95% CI 3.43–12.24), 10 reports; IC025 1.28.
- Denileukin diftitox: ROR 6.24 (95% CI 1.95–19.92), 3 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 −0.25, which does not clear 0.
- Vandetanib: ROR 6.21 (95% CI 4.83–7.98), 64 reports — rests on terms consistent with, not naming, the lesion; IC025 2.14; 24 of the reports look like one case filed repeatedly.
- Imlunestrant: ROR 5.39 (95% CI 1.98–14.67), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.09.
- Relacorilant: ROR 5.23 (95% CI 2.13–12.85), 5 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.35.
- Mitotane: ROR 5.14 (95% CI 4.17–6.35), 91 reports — rests on terms consistent with, not naming, the lesion; IC025 1.96.
- Cisplatin: ROR 4.87 (95% CI 4.71–5.04), 3,672 reports; IC025 2.16.
- Temsirolimus: ROR 4.73 (95% CI 4.12–5.44), 207 reports; IC025 1.97.
- Selinexor: ROR 4.65 (95% CI 4.20–5.14), 395 reports; IC025 2.01.
- Cetuximab: ROR 4.55 (95% CI 4.31–4.80), 1,395 reports; IC025 2.05.
- Neratinib: ROR 4.38 (95% CI 3.58–5.36), 99 reports; IC025 1.76; 15 of the reports look like one case filed repeatedly.
- Copanlisib: ROR 4.27 (95% CI 2.50–7.27), 14 reports — rests on terms consistent with, not naming, the lesion; IC025 1.05.
- Penpulimab: ROR 4.18 (95% CI 1.54–11.37), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 −0.14, which does not clear 0.
- Lifileucel: ROR 3.94 (95% CI 2.16–7.21), 11 reports — rests on terms consistent with, not naming, the lesion; IC025 0.79.
- Zoledronic acid: ROR 3.70 (95% CI 3.54–3.87), 2,004 reports; IC025 1.77.
- Pralatrexate: ROR 3.70 (95% CI 2.25–6.08), 16 reports — rests on terms consistent with, not naming, the lesion; IC025 0.95.
- Irinotecan: ROR 3.69 (95% CI 3.37–4.04), 475 reports; IC025 1.71.
- Zanubrutinib: ROR 3.67 (95% CI 3.10–4.35), 138 reports; IC025 1.58.
Electrolyte Disturbance: 161 of 283 FAERS-covered agents carry a significant signal, showing the 25 strongest by ROR · * 76 of 161 rest on terms consistent with, not naming, the lesion · † 8 of 161 have an IC025 that does not clear 0 (still signals) · ‡ 3 of 161 rest in part on one case filed repeatedly (the drug page gives the ratio without it) · whisker = 95% CI · n = reports carrying this phenotype for the agent (the ROR numerator) · reporting signal, not incidence · ATN/AIN undercount — most true cases file as generic AKI.
Where the curated atlas and the FAERS record agree, and why they appear not to. The documented lesion is the atlas's assertion; FAERS corroborates it or is silent. A bar spans only the agents carrying that injury in either source, not all 283 with FAERS data.
The middle bands need reading before they count against either source. Documented, FAERS-silent: 99 of 213 are expected — naming ATN or AIN takes a biopsy, so reporters file generic acute kidney injury, and some agents have too few reports to divide — while the other 114 sit on a reportable term with enough reports, the one silence that does count against corroboration. Not attributable: a real reporting signal the lesion's own MedDRA terms do not carry — either no term names it (stones and obstruction are not crystal nephropathy), or the naming terms asked alone came back flat and the signal rests on the merely-consistent half: haematuria rather than haemorrhagic cystitis, hyponatraemia rather than SIADH. In the last band the naming term itself is disproportionate and no profile claims the lesion — mostly a class echo (a same-family agent documents it, so the signal is likelier real), some a histological term reachable without the biopsy it implies. The 2026-08 review adjudicated every cell of the residue those explanations leave — reporters naming the lesion with nothing in the class behind it: 33 documented associations entered the profiles, cells the review attributed to the population, co-therapy, or class-level literature sit in the middle band, and reviewed open leads stay here. What shows as unreviewed is the next worklist. Full reasoning on methods.
| Injury signature | Concordance breakdown |
|---|---|
| Electrolyte Disturbance | Electrolyte Disturbance, Corroborated: 45 agents — Amivantamab, Arsenic trioxide, Azacitidine, Bendamustine, Brentuximab vedotin, Carboplatin, Cetuximab, Cisplatin, Cytarabine, Daratumumab, Decitabine, Denosumab, +33 more Electrolyte Disturbance, Documented, FAERS-silent: 61 agents — Afamitresgene autoleucel (Afami-cel), Amsacrine, Avapritinib, Avutometinib, Carmofur (HCFU), Catumaxomab, Chlorambucil, Ciltacabtagene autoleucel, Cladribine, Cosibelimab, Dactinomycin (actinomycin D), Daraxonrasib, Darolutamide, Doxifluridine, Enasidenib, Ensartinib, Enzalutamide, Erdafitinib, Gallium nitrate, Gedatolisib, Odronextamab, Pivekimab sunirine, Plicamycin (mithramycin), Sevabertinib, +37 more Electrolyte Disturbance, Not attributable: 76 agents — Abemaciclib, Abiraterone, Afatinib, Alpelisib, Axitinib, Belzutifan, Bicalutamide, Capivasertib, Capmatinib, Ceritinib, Clofarabine, Cobimetinib, Copanlisib, Crizotinib, Dabrafenib, Dacarbazine, Denileukin diftitox, Dostarlimab, Epcoritamab, Fotemustine, Futibatinib, Glasdegib, Glofitamab, Ibritumomab tiuxetan, +52 more Electrolyte Disturbance, Reported by name, undocumented: 40 agents — 5-Fluorouracil, Adagrasib, Atezolizumab, Avelumab, Belantamab mafodotin, Bevacizumab, Binimetinib, Bleomycin, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, +28 more |
| SIADH / Hyponatremia | SIADH / Hyponatremia, Corroborated: 14 agents — Atezolizumab, Carboplatin, Cisplatin, Cyclophosphamide, Cytarabine, Interleukin-2 (high-dose), Melphalan, Nivolumab, Osimertinib, Pemetrexed, Pentostatin, Selpercatinib, +2 more SIADH / Hyponatremia, Documented, FAERS-silent: 4 agents — Chlorambucil, Lazertinib, Sunvozertinib, Vinflunine SIADH / Hyponatremia, Not attributable: 90 agents — Abemaciclib, Acalabrutinib, Afatinib, Alpelisib, Axitinib, Azacitidine, Belzutifan, Bevacizumab, Bicalutamide, Binimetinib, Bleomycin, Brentuximab vedotin, Cabozantinib, Capecitabine, Capivasertib, Dabrafenib, Doxorubicin, Etoposide, Futibatinib, Selinexor, Tamoxifen, Temozolomide, Topotecan, Vinorelbine, Vismodegib, +65 more SIADH / Hyponatremia, Reported by name, undocumented: 24 agents — 5-Fluorouracil, Avelumab, Bortezomib, Busulfan, Cabazitaxel, Dacarbazine, Darolutamide, Docetaxel, Durvalumab, Fludarabine, Gemcitabine, Gilteritinib, Lenvatinib, Taletrectinib, +10 more |
| Acute Tubular Necrosis | Acute Tubular Necrosis, Corroborated: 14 agents — Binimetinib, Carboplatin, Cisplatin, Clofarabine, Cobimetinib, Ifosfamide, Imatinib, Nivolumab, Oxaliplatin, Pemetrexed, Rituximab, Sirolimus, +2 more Acute Tubular Necrosis, Documented, FAERS-silent: 56 agents — Afatinib, Alpelisib, Arsenic trioxide, Avutometinib, Azacitidine, Blinatumomab, Carfilzomib, Ciltacabtagene autoleucel, Dabrafenib, Datopotamab deruxtecan (Dato-DXd), Elranatamab, Enasidenib, +44 more Acute Tubular Necrosis, Reported by name, undocumented: 27 agents — 5-Fluorouracil, Abemaciclib, Amivantamab, Bendamustine, Bleomycin, Bortezomib, Carmustine (BCNU), Cetuximab, Cyclophosphamide, Cytarabine, Dostarlimab, Etoposide, Everolimus, Fludarabine, Paclitaxel, Topotecan, Vinblastine, +10 more |
| Thrombotic Microangiopathy | Thrombotic Microangiopathy, Corroborated: 26 agents — 5-Fluorouracil, Bendamustine, Bevacizumab, Bortezomib, Busulfan, Capecitabine, Carfilzomib, Carmustine (BCNU), Decitabine, Dinutuximab, Docetaxel, Doxorubicin, +14 more Thrombotic Microangiopathy, Documented, FAERS-silent: 16 agents — Axitinib, Carmofur (HCFU), Daraxonrasib, Doxifluridine, Ipilimumab, Ivonescimab, Lenalidomide, Lutetium-177 Dotatate, Nintedanib, Nivolumab, Olaparib, Pazopanib, Tegafur-uracil (UFT), Tislelizumab, Trastuzumab emtansine (T-DM1), +1 more Thrombotic Microangiopathy, Not attributable: 3 agents — Blinatumomab, Etoposide, Topotecan Thrombotic Microangiopathy, Reported by name, undocumented: 51 agents — Amsacrine, Atezolizumab, Azacitidine, Bleomycin, Carboplatin, Cetuximab, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin (actinomycin D), Epcoritamab, +37 more |
| Glomerular Injury / Proteinuria | Glomerular Injury / Proteinuria, Corroborated: 31 agents — Atezolizumab, Avelumab, Axitinib, Bevacizumab, Bortezomib, Cabozantinib, Cetuximab, Dasatinib, Everolimus, Fruquintinib, Gefitinib, Gemcitabine, +19 more Glomerular Injury / Proteinuria, Documented, FAERS-silent: 13 agents — Adagrasib, Carfilzomib, Cemiplimab, Clofarabine, Cosibelimab, Datopotamab deruxtecan (Dato-DXd), Dostarlimab, Ibandronate, Ibrutinib, Ivonescimab, Olverembatinib, Sugemalimab, Trastuzumab emtansine (T-DM1) Glomerular Injury / Proteinuria, Not attributable: 32 agents — Belantamab mafodotin, Belzutifan, Bicalutamide, Carboplatin, Chlorambucil, Cisplatin, Cobimetinib, Dactinomycin (actinomycin D), Dinutuximab, Docetaxel, Doxorubicin, Durvalumab, Erlotinib, Etoposide, Fotemustine, Irinotecan, Lomustine (CCNU), Nedaplatin, Oxaliplatin, Penpulimab, Pentostatin, Raltitrexed, Temsirolimus, Tislelizumab, Tivozanib, Toripalimab, Trametinib, +5 more Glomerular Injury / Proteinuria, Reported by name, undocumented: 20 agents — 5-Fluorouracil, Amsacrine, Busulfan, Capecitabine, Carmustine (BCNU), Cyclophosphamide, Cytarabine, Daratumumab, Fludarabine, Ifosfamide, Imatinib, Melphalan, Mogamulizumab, Obinutuzumab, Pemetrexed, Rituximab, Tegafur-uracil (UFT), Temozolomide, Thiotepa, Trifluridine/tipiracil |
| Crystal / Obstructive Nephropathy | Crystal / Obstructive Nephropathy, Documented, FAERS-silent: 36 agents — Amsacrine, Blinatumomab, Brentuximab vedotin, Ciltacabtagene autoleucel, Clofarabine, Cytarabine, Dactinomycin (actinomycin D), Decitabine, Elranatamab, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Odronextamab, Pivekimab sunirine, Sonrotoclax, +21 more Crystal / Obstructive Nephropathy, Not attributable: 48 agents — Abiraterone, Acalabrutinib, Avapritinib, Belzutifan, Bendamustine, Bevacizumab, Bicalutamide, Cabazitaxel, Cisplatin, Cladribine, Darolutamide, Denosumab, Enfortumab vedotin, Enzalutamide, Epcoritamab, Everolimus, Hydroxyurea, Methotrexate (high-dose), Polatuzumab vedotin, Rituximab, Zanubrutinib, +27 more |
| Hemorrhagic Cystitis | Hemorrhagic Cystitis, Corroborated: 15 agents — Atezolizumab, Cabazitaxel, Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Gefitinib, Gemcitabine, Ifosfamide, Mitomycin C, Mitoxantrone, +3 more Hemorrhagic Cystitis, Not attributable: 49 agents — Abiraterone, Avelumab, Bevacizumab, Bicalutamide, Bortezomib, Capivasertib, Darolutamide, Denosumab, Enfortumab vedotin, Enzalutamide, Estramustine, Etoposide, Everolimus, Gemtuzumab ozogamicin, Ibandronate, Ibrutinib, Imatinib, Inotuzumab ozogamicin, Lenvatinib, Leuprolide, Nilotinib, Pegaspargase, Polatuzumab vedotin, Rituximab, +25 more Hemorrhagic Cystitis, Reported by name, undocumented: 18 agents — Azacitidine, Bendamustine, Busulfan, Capecitabine, Carmustine (BCNU), Clofarabine, Cytarabine, Dactinomycin (actinomycin D), Fludarabine, Gilteritinib, Hydroxyurea, Melphalan, Methotrexate (high-dose), Teniposide, +4 more |
| Hypertension | Hypertension, Corroborated: 29 agents — Abiraterone, Asciminib, Axitinib, Bevacizumab, Brigatinib, Cabozantinib, Carfilzomib, Copanlisib, Dinutuximab, Enzalutamide, Fruquintinib, Ibrutinib, +17 more Hypertension, Documented, FAERS-silent: 7 agents — Acalabrutinib, Gemcitabine, Ivonescimab, Leuprolide, Olverembatinib, Relacorilant, Trametinib Hypertension, Not attributable: 14 agents — Arsenic trioxide, Busulfan, Darolutamide, Everolimus, Ibandronate, Interleukin-2 (high-dose), Irinotecan, Lorlatinib, Oxaliplatin, Paclitaxel, Pamidronate, Ribociclib, Temsirolimus, Zoledronic acid Hypertension, Reported by name, undocumented: 20 agents — 5-Fluorouracil, Atezolizumab, Avelumab, Bicalutamide, Isatuximab, Lanreotide, Methotrexate (high-dose), Nilotinib, Obinutuzumab, Octreotide, Pembrolizumab, Penpulimab, +8 more |
| Acute Interstitial Nephritis | Acute Interstitial Nephritis, Corroborated: 14 agents — Amivantamab, Atezolizumab, Avelumab, Cemiplimab, Cobimetinib, Dabrafenib, Dostarlimab, Durvalumab, Encorafenib, Ipilimumab, Nivolumab, Pembrolizumab, +2 more Acute Interstitial Nephritis, Documented, FAERS-silent: 14 agents — Bicalutamide, Cosibelimab, Duvelisib, Gefitinib, Ibrutinib, Idelalisib, Ivonescimab, Penpulimab, Procarbazine, Retifanlimab, Sacituzumab govitecan, Sugemalimab, +2 more Acute Interstitial Nephritis, Reported by name, undocumented: 32 agents — Arsenic trioxide, Axitinib, Bendamustine, Binimetinib, Blinatumomab, Brentuximab vedotin, Busulfan, Carboplatin, Carmustine (BCNU), Chlorambucil, Cisplatin, Copanlisib, Cyclophosphamide, Cytarabine, Dactinomycin (actinomycin D), Doxorubicin, Enfortumab vedotin, Etoposide, Fludarabine, Gemcitabine, Ifosfamide, Loncastuximab tesirine, Melphalan, Oxaliplatin, +8 more |
| Fanconi Syndrome | Fanconi Syndrome, Corroborated: 3 agents — Cisplatin, Ifosfamide, Zoledronic acid Fanconi Syndrome, Documented, FAERS-silent: 6 agents — Imatinib, Lenalidomide, Nirogacestat, Streptozocin, Trastuzumab deruxtecan, Vemurafenib Fanconi Syndrome, Not attributable: 10 agents — Azacitidine, Bicalutamide, Dactinomycin (actinomycin D), Doxorubicin, Etoposide, Everolimus, Interleukin-2 (high-dose), Nivolumab, Pembrolizumab, Vincristine Fanconi Syndrome, Reported by name, undocumented: 10 agents — 5-Fluorouracil, Busulfan, Carboplatin, Cyclophosphamide, Doxifluridine, Ibandronate, Melphalan, Oxaliplatin, Tazemetostat, Zolbetuximab |
Each agent's acute-kidney-injury reporting odds ratio (horizontal, log) against the share of its reports naming a death outcome (vertical). The upper-right quadrant holds agents right of ROR = 1 and above the cohort median death share; solid dots also clear the significance bar, faint ones do not. Both are REPORTING signals (notoriety, indication, reporting bias), not incidence or case fatality. Size = total report volume. 6 agents are queried but not plotted: under 50 reports a death share is noise and would move the median every other mark is read against.
245 agents plotted — both an AKI ROR and FAERS outcomes on at least 50 reports · filled = significant renal signal (CI lower bound > 1) · faint = no signal · size = total FAERS reports · color = signature injury. Reporting shares, not incidence or case fatality. FAERS snapshot 2026-11-15.
- Clofarabine (Prerenal / Hemodynamic AKI): AKI ROR 5.51 — signal, 39.6% of reports name a death outcome, 2,287 reports
- Lifileucel (Prerenal / Hemodynamic AKI): AKI ROR 8.22 — signal, 20.4% of reports name a death outcome, 285 reports
- Tagraxofusp (Prerenal / Hemodynamic AKI): AKI ROR 4.37 — signal, 29.9% of reports name a death outcome, 538 reports
- Adagrasib (Prerenal / Hemodynamic AKI): AKI ROR 3.48 — signal, 30.8% of reports name a death outcome, 1,134 reports
- Streptozocin (Fanconi Syndrome): AKI ROR 4.04 — signal, 25.3% of reports name a death outcome, 245 reports
- Trabectedin (Acute Tubular Necrosis): AKI ROR 4.69 — signal, 19.7% of reports name a death outcome, 2,350 reports
- Interleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): AKI ROR 5.41 — signal, 16.8% of reports name a death outcome, 1,263 reports
- Gemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 2.82 — signal, 30.9% of reports name a death outcome, 3,665 reports
- Fludarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.66 — signal, 30.5% of reports name a death outcome, 39,838 reports
- Pemetrexed (Chronic Interstitial Nephropathy): AKI ROR 3.88 — signal, 18.8% of reports name a death outcome, 39,105 reports
- Retifanlimab (Acute Interstitial Nephritis): AKI ROR 3.40 — signal, 21.2% of reports name a death outcome, 193 reports
- Melphalan (SIADH / Hyponatremia): AKI ROR 2.94 — signal, 23.7% of reports name a death outcome, 25,290 reports
- Lurbinectedin (Acute Tubular Necrosis): AKI ROR 2.78 — signal, 24.6% of reports name a death outcome, 1,175 reports
- Inotuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 1.98 — signal, 34% of reports name a death outcome, 2,992 reports
- Amsacrine (Electrolyte Disturbance): AKI ROR 1.80, 37% of reports name a death outcome, 538 reports
- Cisplatin (Acute Tubular Necrosis): AKI ROR 3.43 — signal, 19.1% of reports name a death outcome, 79,025 reports
- Thiotepa (Hemorrhagic Cystitis): AKI ROR 2.27 — signal, 28% of reports name a death outcome, 9,762 reports
- Carmustine (BCNU) (Chronic Interstitial Nephropathy): AKI ROR 2.38 — signal, 25.8% of reports name a death outcome, 4,718 reports
- Busulfan (Thrombotic Microangiopathy): AKI ROR 2.09 — signal, 29.3% of reports name a death outcome, 15,927 reports
- Epcoritamab (Prerenal / Hemodynamic AKI): AKI ROR 2.27 — signal, 26.5% of reports name a death outcome, 3,771 reports
- Cytarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.57 — signal, 23.1% of reports name a death outcome, 63,055 reports
- Sirolimus (Glomerular Injury / Proteinuria): AKI ROR 3.65 — signal, 15.9% of reports name a death outcome, 13,673 reports
- Glasdegib (Prerenal / Hemodynamic AKI): AKI ROR 1.40, 40.7% of reports name a death outcome, 474 reports
- Etoposide (Crystal / Obstructive Nephropathy): AKI ROR 2.33 — signal, 24.1% of reports name a death outcome, 74,949 reports
- Avelumab (Acute Interstitial Nephritis): AKI ROR 2.42 — signal, 22.9% of reports name a death outcome, 4,169 reports
- Idecabtagene vicleucel (Prerenal / Hemodynamic AKI): AKI ROR 3.77 — signal, 14.2% of reports name a death outcome, 1,241 reports
- Mobocertinib (Prerenal / Hemodynamic AKI): AKI ROR 1.17, 44.8% of reports name a death outcome, 735 reports
- Atezolizumab (Acute Interstitial Nephritis): AKI ROR 2.03 — signal, 25.3% of reports name a death outcome, 40,046 reports
- Belantamab mafodotin (Glomerular Injury / Proteinuria): AKI ROR 1.52 — signal, 33.5% of reports name a death outcome, 3,110 reports
- Ifosfamide (Fanconi Syndrome): AKI ROR 2.50 — signal, 20.1% of reports name a death outcome, 21,470 reports
- Azacitidine (Fanconi Syndrome): AKI ROR 1.37 — signal, 36.3% of reports name a death outcome, 30,141 reports
- Ibritumomab tiuxetan (Prerenal / Hemodynamic AKI): AKI ROR 1.37, 36.2% of reports name a death outcome, 1,524 reports
- Pirtobrutinib (Crystal / Obstructive Nephropathy): AKI ROR 2.09 — signal, 23.6% of reports name a death outcome, 981 reports
- Pamidronate (Glomerular Injury / Proteinuria): AKI ROR 3.16 — signal, 15.5% of reports name a death outcome, 4,390 reports
- Pentostatin (Acute Tubular Necrosis): AKI ROR 1.94 — signal, 25.2% of reports name a death outcome, 555 reports
- Carfilzomib (Thrombotic Microangiopathy): AKI ROR 3.11 — signal, 15.6% of reports name a death outcome, 28,379 reports
- Denileukin diftitox (Prerenal / Hemodynamic AKI): AKI ROR 1.80, 26.7% of reports name a death outcome, 60 reports
- Nivolumab (Acute Interstitial Nephritis): AKI ROR 1.88 — signal, 25.5% of reports name a death outcome, 98,547 reports
- Gilteritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 26.6% of reports name a death outcome, 4,738 reports
- Ipilimumab (Acute Interstitial Nephritis): AKI ROR 2.08 — signal, 22.4% of reports name a death outcome, 43,846 reports
- Pembrolizumab (Acute Interstitial Nephritis): AKI ROR 2.59 — signal, 17.8% of reports name a death outcome, 109,044 reports
- Bendamustine (Crystal / Obstructive Nephropathy): AKI ROR 2.19 — signal, 20.5% of reports name a death outcome, 24,082 reports
- Temsirolimus (Glomerular Injury / Proteinuria): AKI ROR 2.08 — signal, 21.5% of reports name a death outcome, 4,507 reports
- Gemcitabine (Thrombotic Microangiopathy): AKI ROR 2.36 — signal, 18.8% of reports name a death outcome, 54,066 reports
- Tafasitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.65 — signal, 26.5% of reports name a death outcome, 2,675 reports
- Vinorelbine (SIADH / Hyponatremia): AKI ROR 2.05 — signal, 21.2% of reports name a death outcome, 6,966 reports
- Nelarabine (Crystal / Obstructive Nephropathy): AKI ROR 1.96 — signal, 21.9% of reports name a death outcome, 974 reports
- Relacorilant (Electrolyte Disturbance): AKI ROR 1.93, 22.2% of reports name a death outcome, 99 reports
- Mitoxantrone (Crystal / Obstructive Nephropathy): AKI ROR 1.60 — signal, 26.6% of reports name a death outcome, 6,289 reports
- Idelalisib (Prerenal / Hemodynamic AKI): AKI ROR 1.87 — signal, 22.7% of reports name a death outcome, 7,144 reports
- Obecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): AKI ROR 1.34, 31% of reports name a death outcome, 71 reports
- Enfortumab vedotin (Acute Tubular Necrosis): AKI ROR 2.07 — signal, 19.9% of reports name a death outcome, 7,851 reports
- Cobimetinib (Acute Tubular Necrosis): AKI ROR 3.05 — signal, 13.3% of reports name a death outcome, 4,436 reports
- Decitabine (Crystal / Obstructive Nephropathy): AKI ROR 1.57 — signal, 25.4% of reports name a death outcome, 5,334 reports
- Mogamulizumab (Prerenal / Hemodynamic AKI): AKI ROR 2.10 — signal, 18.1% of reports name a death outcome, 1,908 reports
- Carboplatin (Acute Tubular Necrosis): AKI ROR 2.41 — signal, 15.7% of reports name a death outcome, 130,075 reports
- Capivasertib (Prerenal / Hemodynamic AKI): AKI ROR 1.94 — signal, 19.3% of reports name a death outcome, 3,064 reports
- Encorafenib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 16.7% of reports name a death outcome, 10,191 reports
- Ceritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 28% of reports name a death outcome, 2,947 reports
- Brentuximab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.91 — signal, 19.2% of reports name a death outcome, 10,402 reports
- Everolimus (Glomerular Injury / Proteinuria): AKI ROR 1.69 — signal, 21.6% of reports name a death outcome, 49,667 reports
- Cyclophosphamide (SIADH / Hyponatremia): AKI ROR 1.80 — signal, 20.2% of reports name a death outcome, 179,391 reports
- Binimetinib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 15.7% of reports name a death outcome, 7,953 reports
- Vemurafenib (Acute Tubular Necrosis): AKI ROR 2.01 — signal, 17.3% of reports name a death outcome, 11,991 reports
- Vincristine (SIADH / Hyponatremia): AKI ROR 1.90 — signal, 18.3% of reports name a death outcome, 29,521 reports
- Relatlimab (Acute Interstitial Nephritis): AKI ROR 1.66, 20.8% of reports name a death outcome, 515 reports
- Isatuximab (Prerenal / Hemodynamic AKI): AKI ROR 2.58 — signal, 13.2% of reports name a death outcome, 5,853 reports
- Elotuzumab (Prerenal / Hemodynamic AKI): AKI ROR 1.90 — signal, 17.8% of reports name a death outcome, 5,171 reports
- Cabazitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.68 — signal, 20% of reports name a death outcome, 3,517 reports
- Loncastuximab tesirine (Prerenal / Hemodynamic AKI): AKI ROR 0.92, 35.6% of reports name a death outcome, 410 reports
- Bleomycin (Prerenal / Hemodynamic AKI): AKI ROR 1.42 — signal, 23% of reports name a death outcome, 10,369 reports
- Afatinib (Prerenal / Hemodynamic AKI): AKI ROR 1.45 — signal, 22.3% of reports name a death outcome, 6,622 reports
- Crizotinib (Renal Cysts): AKI ROR 1.02, 31.7% of reports name a death outcome, 10,760 reports
- Glofitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.12, 28.8% of reports name a death outcome, 2,709 reports
- Ponatinib (Hypertension): AKI ROR 1.12, 28.4% of reports name a death outcome, 11,399 reports
- Cemiplimab (Acute Interstitial Nephritis): AKI ROR 1.51 — signal, 21% of reports name a death outcome, 2,083 reports
- Doxorubicin (Glomerular Injury / Proteinuria): AKI ROR 1.68 — signal, 18.7% of reports name a death outcome, 97,231 reports
- Trifluridine/tipiracil (Prerenal / Hemodynamic AKI): AKI ROR 0.81, 38.2% of reports name a death outcome, 11,253 reports
- Lisocabtagene maraleucel (Prerenal / Hemodynamic AKI): AKI ROR 1.74 — signal, 17.6% of reports name a death outcome, 876 reports
- Irinotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.48 — signal, 20.6% of reports name a death outcome, 13,147 reports
- Durvalumab (Acute Interstitial Nephritis): AKI ROR 0.96, 31.7% of reports name a death outcome, 21,581 reports
- Bicalutamide (Acute Interstitial Nephritis): AKI ROR 1.69 — signal, 18% of reports name a death outcome, 15,311 reports
- Oxaliplatin (Thrombotic Microangiopathy): AKI ROR 2.00 — signal, 14.4% of reports name a death outcome, 75,953 reports
- Zoledronic acid (Acute Tubular Necrosis): AKI ROR 2.13 — signal, 13.5% of reports name a death outcome, 66,922 reports
- Imatinib (Electrolyte Disturbance): AKI ROR 0.92, 31.1% of reports name a death outcome, 47,183 reports
- Bortezomib (Thrombotic Microangiopathy): AKI ROR 1.78 — signal, 15.8% of reports name a death outcome, 89,993 reports
- Raltitrexed (Acute Tubular Necrosis): AKI ROR 1.93 — signal, 14.4% of reports name a death outcome, 672 reports
- Neratinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 15.7% of reports name a death outcome, 2,319 reports
- Chlorambucil (SIADH / Hyponatremia): AKI ROR 1.16, 23.7% of reports name a death outcome, 3,932 reports
- 5-Fluorouracil (Thrombotic Microangiopathy): AKI ROR 1.96 — signal, 14% of reports name a death outcome, 78,755 reports
- Necitumumab (Electrolyte Disturbance): AKI ROR 1.43, 18.9% of reports name a death outcome, 450 reports
- Dinutuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.33, 20.1% of reports name a death outcome, 859 reports
- Temozolomide (SIADH / Hyponatremia): AKI ROR 1.26 — signal, 21.1% of reports name a death outcome, 21,320 reports
- Abiraterone (Electrolyte Disturbance): AKI ROR 1.29 — signal, 20.5% of reports name a death outcome, 41,137 reports
- Sunitinib (Hypertension): AKI ROR 0.87, 29.9% of reports name a death outcome, 39,148 reports
- Tepotinib (Pseudo-AKI): AKI ROR 1.10, 23.6% of reports name a death outcome, 691 reports
- Bevacizumab (Glomerular Injury / Proteinuria): AKI ROR 1.18 — signal, 22% of reports name a death outcome, 130,956 reports
- Pegaspargase (Prerenal / Hemodynamic AKI): AKI ROR 1.99 — signal, 12.9% of reports name a death outcome, 12,377 reports
- Infigratinib (Electrolyte Disturbance): AKI ROR 1.58, 16.2% of reports name a death outcome, 68 reports
- Procarbazine (Acute Tubular Necrosis): AKI ROR 1.92 — signal, 13.2% of reports name a death outcome, 7,315 reports
- Sorafenib (Hypertension): AKI ROR 1.02, 24.6% of reports name a death outcome, 20,700 reports
- Paclitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.52 — signal, 16.4% of reports name a death outcome, 101,259 reports
- Idarubicin (Crystal / Obstructive Nephropathy): AKI ROR 1.14, 21.8% of reports name a death outcome, 1,159 reports
- Rituximab (Crystal / Obstructive Nephropathy): AKI ROR 1.38 — signal, 17.5% of reports name a death outcome, 218,782 reports
- Melphalan flufenamide (melflufen) (Acute Tubular Necrosis): AKI ROR 0.91, 26.5% of reports name a death outcome, 117 reports
- Polatuzumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.14, 21.1% of reports name a death outcome, 10,202 reports
- Topotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.01, 23.8% of reports name a death outcome, 6,940 reports
- Elranatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.98, 24.2% of reports name a death outcome, 2,391 reports
- Ramucirumab (Hypertension): AKI ROR 0.88, 26.8% of reports name a death outcome, 6,320 reports
- Hydroxyurea (Crystal / Obstructive Nephropathy): AKI ROR 1.58 — signal, 14.9% of reports name a death outcome, 21,340 reports
- Venetoclax (Crystal / Obstructive Nephropathy): AKI ROR 0.83, 28.1% of reports name a death outcome, 62,878 reports
- Vinblastine (SIADH / Hyponatremia): AKI ROR 1.65 — signal, 14.1% of reports name a death outcome, 1,961 reports
- Momelotinib (Pseudo-AKI): AKI ROR 1.48, 15.5% of reports name a death outcome, 1,481 reports
- Zanidatamab (Prerenal / Hemodynamic AKI): AKI ROR 2.34, 9.8% of reports name a death outcome, 82 reports
- Entrectinib (Pseudo-AKI): AKI ROR 1.40, 16.3% of reports name a death outcome, 1,691 reports
- Lenvatinib (Hypertension): AKI ROR 1.69 — signal, 13.5% of reports name a death outcome, 39,694 reports
- Dabrafenib (Acute Interstitial Nephritis): AKI ROR 1.08, 20.9% of reports name a death outcome, 21,157 reports
- Axitinib (Hypertension): AKI ROR 1.07, 20.2% of reports name a death outcome, 19,550 reports
- Ixazomib (Thrombotic Microangiopathy): AKI ROR 1.17 — signal, 18.4% of reports name a death outcome, 28,726 reports
- Erdafitinib (Electrolyte Disturbance): AKI ROR 0.76, 28% of reports name a death outcome, 1,247 reports
- Duvelisib (Prerenal / Hemodynamic AKI): AKI ROR 1.00, 21.2% of reports name a death outcome, 853 reports
- Panitumumab (Electrolyte Disturbance): AKI ROR 1.24 — signal, 17% of reports name a death outcome, 16,107 reports
- Capecitabine (Prerenal / Hemodynamic AKI): AKI ROR 1.03, 20% of reports name a death outcome, 92,086 reports
- Pralatrexate (Crystal / Obstructive Nephropathy): AKI ROR 0.81, 25.1% of reports name a death outcome, 529 reports
- Estramustine (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 27.5% of reports name a death outcome, 437 reports
- Trametinib (Prerenal / Hemodynamic AKI): AKI ROR 0.94, 21.3% of reports name a death outcome, 24,319 reports
- Pazopanib (Glomerular Injury / Proteinuria): AKI ROR 0.75, 25.8% of reports name a death outcome, 26,971 reports
- Regorafenib (Hypertension): AKI ROR 0.93, 20.4% of reports name a death outcome, 11,611 reports
- Dactinomycin (actinomycin D) (Electrolyte Disturbance): AKI ROR 1.07, 17.7% of reports name a death outcome, 2,211 reports
- Dacarbazine (Prerenal / Hemodynamic AKI): AKI ROR 1.08, 17.4% of reports name a death outcome, 7,561 reports
- Daratumumab (Prerenal / Hemodynamic AKI): AKI ROR 1.57 — signal, 11.9% of reports name a death outcome, 44,998 reports
- Thalidomide (Prerenal / Hemodynamic AKI): AKI ROR 1.05, 17.6% of reports name a death outcome, 19,824 reports
- Capmatinib (Pseudo-AKI): AKI ROR 0.74, 24.9% of reports name a death outcome, 2,444 reports
- Selinexor (SIADH / Hyponatremia): AKI ROR 1.08, 17% of reports name a death outcome, 8,763 reports
- Cetuximab (Electrolyte Disturbance): AKI ROR 1.32 — signal, 13.4% of reports name a death outcome, 31,704 reports
- Midostaurin (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 24.1% of reports name a death outcome, 1,957 reports
- Teniposide (Electrolyte Disturbance): AKI ROR 0.79, 21.7% of reports name a death outcome, 405 reports
- Selpercatinib (Hypertension): AKI ROR 1.15, 14.8% of reports name a death outcome, 1,396 reports
- Octreotide (Electrolyte Disturbance): AKI ROR 0.85, 19.8% of reports name a death outcome, 31,000 reports
- Sacituzumab govitecan (Prerenal / Hemodynamic AKI): AKI ROR 0.80, 21% of reports name a death outcome, 4,834 reports
- Osimertinib (SIADH / Hyponatremia): AKI ROR 0.39, 42.8% of reports name a death outcome, 33,803 reports
- Obinutuzumab (Crystal / Obstructive Nephropathy): AKI ROR 1.24 — signal, 13.1% of reports name a death outcome, 17,772 reports
- Copanlisib (Hypertension): AKI ROR 1.33, 12.2% of reports name a death outcome, 403 reports
- Futibatinib (Electrolyte Disturbance): AKI ROR 0.85, 18.9% of reports name a death outcome, 222 reports
- Docetaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.19 — signal, 13.2% of reports name a death outcome, 68,125 reports
- Erlotinib (Glomerular Injury / Proteinuria): AKI ROR 0.53, 29.5% of reports name a death outcome, 22,936 reports
- Eribulin (Prerenal / Hemodynamic AKI): AKI ROR 0.88, 17.7% of reports name a death outcome, 3,739 reports
- Fruquintinib (Hypertension): AKI ROR 0.48, 32.2% of reports name a death outcome, 3,941 reports
- Linvoseltamab (Prerenal / Hemodynamic AKI): AKI ROR 2.04, 7.5% of reports name a death outcome, 53 reports
- Gefitinib (Glomerular Injury / Proteinuria): AKI ROR 0.70, 21.7% of reports name a death outcome, 8,990 reports
- Talquetamab (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 11.4% of reports name a death outcome, 2,290 reports
- Ribociclib (Pseudo-AKI): AKI ROR 1.04, 14.3% of reports name a death outcome, 32,716 reports
- Tisotumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.78 — signal, 8.3% of reports name a death outcome, 971 reports
- Inavolisib (Electrolyte Disturbance): AKI ROR 3.03 — signal, 4.8% of reports name a death outcome, 670 reports
- Zolbetuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.24, 11.7% of reports name a death outcome, 1,525 reports
- Blinatumomab (Prerenal / Hemodynamic AKI): AKI ROR 0.79, 18% of reports name a death outcome, 10,722 reports
- Tucatinib (Pseudo-AKI): AKI ROR 1.37 — signal, 10.3% of reports name a death outcome, 7,112 reports
- Teclistamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 18.7% of reports name a death outcome, 2,379 reports
- Tebentafusp (Prerenal / Hemodynamic AKI): AKI ROR 0.78, 17.8% of reports name a death outcome, 602 reports
- Larotrectinib (Pseudo-AKI): AKI ROR 0.74, 18.2% of reports name a death outcome, 896 reports
- Dostarlimab (Acute Interstitial Nephritis): AKI ROR 1.11, 11.9% of reports name a death outcome, 2,502 reports
- Fedratinib (Electrolyte Disturbance): AKI ROR 0.91, 14.2% of reports name a death outcome, 1,349 reports
- Mitotane (Electrolyte Disturbance): AKI ROR 0.98, 13% of reports name a death outcome, 1,830 reports
- Asparaginase (Prerenal / Hemodynamic AKI): AKI ROR 1.47, 8.4% of reports name a death outcome, 1,533 reports
- Sotorasib (Prerenal / Hemodynamic AKI): AKI ROR 0.52, 23.7% of reports name a death outcome, 3,470 reports
- Ibrutinib (Hypertension): AKI ROR 0.70, 17.1% of reports name a death outcome, 80,997 reports
- Tretinoin (ATRA) (Prerenal / Hemodynamic AKI): AKI ROR 1.18, 10% of reports name a death outcome, 8,951 reports
- Trastuzumab deruxtecan (Acute Tubular Necrosis): AKI ROR 0.46, 25.6% of reports name a death outcome, 10,910 reports
- Vandetanib (Hypertension): AKI ROR 1.50, 7.8% of reports name a death outcome, 1,286 reports
- Pemigatinib (Electrolyte Disturbance): AKI ROR 0.66, 17.6% of reports name a death outcome, 853 reports
- Abemaciclib (Pseudo-AKI): AKI ROR 1.63 — signal, 7.1% of reports name a death outcome, 21,412 reports
- Lomustine (CCNU) (Chronic Interstitial Nephropathy): AKI ROR 0.51, 22.6% of reports name a death outcome, 2,597 reports
- Nintedanib (Hypertension): AKI ROR 0.57, 19.8% of reports name a death outcome, 32,818 reports
- Talazoparib (Pseudo-AKI): AKI ROR 0.61, 18.5% of reports name a death outcome, 1,853 reports
- Arsenic trioxide (Prerenal / Hemodynamic AKI): AKI ROR 1.70 — signal, 6.6% of reports name a death outcome, 4,043 reports
- Taletrectinib (Pseudo-AKI): AKI ROR 0.89, 12.5% of reports name a death outcome, 120 reports
- Radium-223 dichloride (Prerenal / Hemodynamic AKI): AKI ROR 0.54, 20.5% of reports name a death outcome, 5,055 reports
- Alpelisib (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 14.6% of reports name a death outcome, 9,106 reports
- Acalabrutinib (Hypertension): AKI ROR 0.49, 21.2% of reports name a death outcome, 12,744 reports
- Iberdomide (Prerenal / Hemodynamic AKI): AKI ROR 1.27, 8.1% of reports name a death outcome, 149 reports
- Ziv-aflibercept (Hypertension): AKI ROR 0.37, 27.8% of reports name a death outcome, 32,703 reports
- Tarlatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 13.9% of reports name a death outcome, 1,917 reports
- Brigatinib (Pseudo-AKI): AKI ROR 0.46, 21.6% of reports name a death outcome, 3,655 reports
- Lorlatinib (Pseudo-AKI): AKI ROR 0.35, 27.8% of reports name a death outcome, 7,455 reports
- Belzutifan (Prerenal / Hemodynamic AKI): AKI ROR 1.02, 9.4% of reports name a death outcome, 1,777 reports
- Ciltacabtagene autoleucel (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 13.1% of reports name a death outcome, 6,566 reports
- Zanubrutinib (Prerenal / Hemodynamic AKI): AKI ROR 0.86, 11.1% of reports name a death outcome, 4,598 reports
- Nedaplatin (Acute Tubular Necrosis): AKI ROR 0.78, 11.6% of reports name a death outcome, 1,100 reports
- Mitomycin C (Thrombotic Microangiopathy): AKI ROR 0.83, 10.9% of reports name a death outcome, 3,659 reports
- Pomalidomide (Prerenal / Hemodynamic AKI): AKI ROR 0.66, 13.7% of reports name a death outcome, 103,640 reports
- Repotrectinib (Pseudo-AKI): AKI ROR 0.69, 13.1% of reports name a death outcome, 274 reports
- Tamoxifen (SIADH / Hyponatremia): AKI ROR 1.08, 8.2% of reports name a death outcome, 5,782 reports
- Lenalidomide (Acute Tubular Necrosis): AKI ROR 0.69, 12.7% of reports name a death outcome, 425,916 reports
- Mosunetuzumab (Prerenal / Hemodynamic AKI): AKI ROR 0.60, 14.1% of reports name a death outcome, 1,107 reports
- Methotrexate (high-dose) (Crystal / Obstructive Nephropathy): AKI ROR 1.07 — signal, 7.8% of reports name a death outcome, 494,382 reports
- Nilotinib (Prerenal / Hemodynamic AKI): AKI ROR 0.43, 19.1% of reports name a death outcome, 29,571 reports
- Asciminib (Hypertension): AKI ROR 0.73, 11.2% of reports name a death outcome, 3,514 reports
- Enzalutamide (Hypertension): AKI ROR 0.42, 19.4% of reports name a death outcome, 58,866 reports
- Ruxolitinib (Prerenal / Hemodynamic AKI): AKI ROR 0.58, 13.6% of reports name a death outcome, 73,257 reports
- Ivosidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.74, 10.5% of reports name a death outcome, 2,178 reports
- Bosutinib (Pseudo-AKI): AKI ROR 0.87, 8.9% of reports name a death outcome, 8,981 reports
- Zongertinib (Pseudo-AKI): AKI ROR 0.56, 13.8% of reports name a death outcome, 167 reports
- Lutetium-177 Dotatate (Chronic Interstitial Nephropathy): AKI ROR 0.62, 12.2% of reports name a death outcome, 5,819 reports
- Sonidegib (Acute Tubular Necrosis): AKI ROR 0.79, 9.4% of reports name a death outcome, 1,679 reports
- Olaparib (Pseudo-AKI): AKI ROR 0.26, 28.3% of reports name a death outcome, 21,443 reports
- Darolutamide (Electrolyte Disturbance): AKI ROR 0.61, 12% of reports name a death outcome, 5,924 reports
- Lanreotide (Electrolyte Disturbance): AKI ROR 0.39, 18.7% of reports name a death outcome, 7,953 reports
- Trastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): AKI ROR 0.44, 13.8% of reports name a death outcome, 8,459 reports
- Dasatinib (Glomerular Injury / Proteinuria): AKI ROR 0.62, 9.2% of reports name a death outcome, 32,694 reports
- Fotemustine (Chronic Interstitial Nephropathy): AKI ROR 0.32, 17.8% of reports name a death outcome, 331 reports
- Cabozantinib (Hypertension): AKI ROR 0.49, 11.3% of reports name a death outcome, 48,250 reports
- Leuprolide (Hypertension): AKI ROR 0.35, 15.6% of reports name a death outcome, 79,718 reports
- Denosumab (Electrolyte Disturbance): AKI ROR 0.40, 12.8% of reports name a death outcome, 203,750 reports
- Enasidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.19, 24.9% of reports name a death outcome, 3,369 reports
- Tivozanib (Hypertension): AKI ROR 0.47, 9.9% of reports name a death outcome, 1,588 reports
- Alectinib (Pseudo-AKI): AKI ROR 0.34, 12.9% of reports name a death outcome, 7,388 reports
- Rucaparib (Pseudo-AKI): AKI ROR 0.74, 5.9% of reports name a death outcome, 8,832 reports
- Palbociclib (Pseudo-AKI): AKI ROR 0.36, 11.2% of reports name a death outcome, 95,562 reports
- Amivantamab (Electrolyte Disturbance): AKI ROR 0.53, 7.6% of reports name a death outcome, 3,576 reports
- Imlunestrant (Pseudo-AKI): AKI ROR 1.16, 3.3% of reports name a death outcome, 92 reports
- Lutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): AKI ROR 0.30, 12.1% of reports name a death outcome, 13,841 reports
- Lazertinib (SIADH / Hyponatremia): AKI ROR 0.87, 4% of reports name a death outcome, 865 reports
- Naxitamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 4.4% of reports name a death outcome, 250 reports
- Toripalimab (Acute Interstitial Nephritis): AKI ROR 0.50, 6% of reports name a death outcome, 1,928 reports
- Pralsetinib (Hypertension): AKI ROR 0.21, 14.2% of reports name a death outcome, 1,824 reports
- Cladribine (Crystal / Obstructive Nephropathy): AKI ROR 0.40, 7.2% of reports name a death outcome, 9,967 reports
- Vismodegib (SIADH / Hyponatremia): AKI ROR 0.25, 11.2% of reports name a death outcome, 8,927 reports
- Ibandronate (Acute Tubular Necrosis): AKI ROR 0.66, 4% of reports name a death outcome, 14,757 reports
- Pacritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.21, 11.4% of reports name a death outcome, 3,069 reports
- Tazemetostat (Prerenal / Hemodynamic AKI): AKI ROR 0.17, 13.3% of reports name a death outcome, 1,622 reports
- Datopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): AKI ROR 0.11, 20.1% of reports name a death outcome, 859 reports
- Selumetinib (Prerenal / Hemodynamic AKI): AKI ROR 0.33, 6.1% of reports name a death outcome, 1,684 reports
- Quizartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 15.2% of reports name a death outcome, 702 reports
- Ripretinib (Hypertension): AKI ROR 0.16, 9.5% of reports name a death outcome, 5,243 reports
- Niraparib (Hypertension): AKI ROR 0.22, 6.6% of reports name a death outcome, 22,237 reports
- Tislelizumab (Acute Interstitial Nephritis): AKI ROR 0.61, 2.2% of reports name a death outcome, 8,853 reports
- Mirvetuximab soravtansine (Prerenal / Hemodynamic AKI): AKI ROR 0.10, 13% of reports name a death outcome, 1,814 reports
- Revumenib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 13.3% of reports name a death outcome, 1,031 reports
- Nirogacestat (Electrolyte Disturbance): AKI ROR 0.61, 0.9% of reports name a death outcome, 923 reports
- Elacestrant (Prerenal / Hemodynamic AKI): AKI ROR 0.07, 7.7% of reports name a death outcome, 7,181 reports
- Vorasidenib (Pseudo-AKI): AKI ROR 0.17, 2% of reports name a death outcome, 612 reports
- Mechlorethamine (Electrolyte Disturbance): AKI ROR 0.04, 6.9% of reports name a death outcome, 2,247 reports
- Avapritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 3% of reports name a death outcome, 12,654 reports
- Avutometinib (Electrolyte Disturbance): AKI ROR 0.08, 3.3% of reports name a death outcome, 1,125 reports
- Pexidartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 2% of reports name a death outcome, 717 reports
Horizontal = citation staleness (years behind the freshest-cited agent); vertical = FAERS AKI reporting odds ratio (log). Color = the atlas's severity grade, size = evidence depth. The upper-right — stale & high-ROR — is the neglected-signal corner.
245 of 245 agents shown · filled = significant renal signal (CI lower bound > 1) · faint = no signal · color = severity grade · size = citation count. Reporting, not incidence. FAERS snapshot 2026-11-15.
- Lifileucel: ROR 8.22 (95% CI 5.37–12.58), 1 y behind the freshest-cited agent, 6 citations, Moderate — signal
- Clofarabine: ROR 5.51 (95% CI 4.60–6.58), 6 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Interleukin-2 (high-dose): ROR 5.41 (95% CI 4.24–6.90), 15 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Trabectedin: ROR 4.69 (95% CI 3.88–5.67), 7 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Tagraxofusp: ROR 4.37 (95% CI 2.90–6.58), 0 y behind the freshest-cited agent, 7 citations, Moderate — signal
- Streptozocin: ROR 4.04 (95% CI 2.08–7.87), 0 y behind the freshest-cited agent, 10 citations, Severe — signal
- Pemetrexed: ROR 3.88 (95% CI 3.69–4.08), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Idecabtagene vicleucel: ROR 3.77 (95% CI 2.82–5.03), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Sirolimus: ROR 3.65 (95% CI 3.34–3.98), 7 y behind the freshest-cited agent, 13 citations, Moderate — signal
- Adagrasib: ROR 3.48 (95% CI 2.49–4.84), 1 y behind the freshest-cited agent, 6 citations, Mild — signal
- Cisplatin: ROR 3.43 (95% CI 3.30–3.56), 1 y behind the freshest-cited agent, 21 citations, Severe — signal
- Retifanlimab: ROR 3.40 (95% CI 1.51–7.67), 1 y behind the freshest-cited agent, 6 citations, Moderate — signal
- Pamidronate: ROR 3.16 (95% CI 2.65–3.77), 15 y behind the freshest-cited agent, 6 citations, Severe — signal
- Carfilzomib: ROR 3.11 (95% CI 2.91–3.32), 1 y behind the freshest-cited agent, 13 citations, Severe — signal
- Cobimetinib: ROR 3.05 (95% CI 2.58–3.61), 4 y behind the freshest-cited agent, 7 citations, Mild — signal
- Inavolisib: ROR 3.03 (95% CI 1.96–4.68), 2 y behind the freshest-cited agent, 4 citations, Moderate — signal
- Melphalan: ROR 2.94 (95% CI 2.73–3.16), 1 y behind the freshest-cited agent, 8 citations, Mild — signal
- Gemtuzumab ozogamicin: ROR 2.82 (95% CI 2.32–3.41), 6 y behind the freshest-cited agent, 4 citations, Moderate — signal
- Lurbinectedin: ROR 2.78 (95% CI 1.93–3.99), 1 y behind the freshest-cited agent, 8 citations, Mild — signal
- Fludarabine: ROR 2.66 (95% CI 2.51–2.83), 9 y behind the freshest-cited agent, 11 citations, Moderate — signal
- Pembrolizumab: ROR 2.59 (95% CI 2.49–2.69), 0 y behind the freshest-cited agent, 15 citations, Moderate — signal
- Isatuximab: ROR 2.58 (95% CI 2.20–3.02), 1 y behind the freshest-cited agent, 7 citations, Mild — signal
- Cytarabine: ROR 2.57 (95% CI 2.45–2.70), 3 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Ifosfamide: ROR 2.50 (95% CI 2.29–2.72), 0 y behind the freshest-cited agent, 16 citations, Severe — signal
- Avelumab: ROR 2.42 (95% CI 1.97–2.97), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Carboplatin: ROR 2.41 (95% CI 2.33–2.50), 2 y behind the freshest-cited agent, 12 citations, Mild — signal
- Carmustine (BCNU): ROR 2.38 (95% CI 1.98–2.86), 14 y behind the freshest-cited agent, 7 citations, Moderate — signal
- Gemcitabine: ROR 2.36 (95% CI 2.24–2.50), 0 y behind the freshest-cited agent, 14 citations, Severe — signal
- Zanidatamab: ROR 2.34 (95% CI 0.57–9.52), 1 y behind the freshest-cited agent, 5 citations, Mild
- Etoposide: ROR 2.33 (95% CI 2.23–2.45), 5 y behind the freshest-cited agent, 9 citations, Mild — signal
- Epcoritamab: ROR 2.27 (95% CI 1.81–2.83), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Thiotepa: ROR 2.27 (95% CI 1.99–2.59), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
- Binimetinib: ROR 2.23 (95% CI 1.93–2.58), 4 y behind the freshest-cited agent, 9 citations, Mild — signal
- Encorafenib: ROR 2.23 (95% CI 1.96–2.54), 4 y behind the freshest-cited agent, 9 citations, Mild — signal
- Bendamustine: ROR 2.19 (95% CI 2.01–2.38), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Zoledronic acid: ROR 2.13 (95% CI 2.02–2.25), 0 y behind the freshest-cited agent, 11 citations, Moderate — signal
- Mogamulizumab: ROR 2.10 (95% CI 1.51–2.90), 5 y behind the freshest-cited agent, 6 citations, Mild — signal
- Busulfan: ROR 2.09 (95% CI 1.88–2.32), 7 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Pirtobrutinib: ROR 2.09 (95% CI 1.33–3.30), 2 y behind the freshest-cited agent, 6 citations, Mild — signal
- Ipilimumab: ROR 2.08 (95% CI 1.95–2.22), 0 y behind the freshest-cited agent, 13 citations, Severe — signal
- Temsirolimus: ROR 2.08 (95% CI 1.70–2.54), 10 y behind the freshest-cited agent, 10 citations, Mild — signal
- Enfortumab vedotin: ROR 2.07 (95% CI 1.78–2.41), 1 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Vinorelbine: ROR 2.05 (95% CI 1.74–2.41), 2 y behind the freshest-cited agent, 7 citations, Mild — signal
- Linvoseltamab: ROR 2.04 (95% CI 0.28–14.74), 1 y behind the freshest-cited agent, 6 citations, Mild
- Atezolizumab: ROR 2.03 (95% CI 1.89–2.19), 1 y behind the freshest-cited agent, 15 citations, Moderate — signal
- Vemurafenib: ROR 2.01 (95% CI 1.77–2.28), 5 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Oxaliplatin: ROR 2.00 (95% CI 1.90–2.10), 0 y behind the freshest-cited agent, 10 citations, Mild — signal
- Pegaspargase: ROR 1.99 (95% CI 1.76–2.26), 6 y behind the freshest-cited agent, 8 citations, Mild — signal
- Inotuzumab ozogamicin: ROR 1.98 (95% CI 1.54–2.55), 3 y behind the freshest-cited agent, 4 citations, Moderate — signal
- 5-Fluorouracil: ROR 1.96 (95% CI 1.86–2.06), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
- Nelarabine: ROR 1.96 (95% CI 1.26–3.06), 6 y behind the freshest-cited agent, 6 citations, Mild — signal
- Capivasertib: ROR 1.94 (95% CI 1.48–2.53), 0 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Pentostatin: ROR 1.94 (95% CI 1.04–3.63), 13 y behind the freshest-cited agent, 11 citations, Moderate — signal
- Raltitrexed: ROR 1.93 (95% CI 1.09–3.41), 5 y behind the freshest-cited agent, 4 citations, Moderate — signal
- Relacorilant: ROR 1.93 (95% CI 0.48–7.83), 1 y behind the freshest-cited agent, 3 citations, Mild
- Procarbazine: ROR 1.92 (95% CI 1.61–2.28), 5 y behind the freshest-cited agent, 4 citations, Moderate — signal
- Brentuximab vedotin: ROR 1.91 (95% CI 1.67–2.19), 2 y behind the freshest-cited agent, 5 citations, Mild — signal
- Elotuzumab: ROR 1.90 (95% CI 1.56–2.31), 9 y behind the freshest-cited agent, 4 citations, Mild — signal
- Vincristine: ROR 1.90 (95% CI 1.75–2.07), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
- Nivolumab: ROR 1.88 (95% CI 1.80–1.97), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Idelalisib: ROR 1.87 (95% CI 1.57–2.24), 5 y behind the freshest-cited agent, 6 citations, Mild — signal
- Amsacrine: ROR 1.80 (95% CI 0.93–3.48), 9 y behind the freshest-cited agent, 4 citations, Moderate
- Cyclophosphamide: ROR 1.80 (95% CI 1.74–1.87), 3 y behind the freshest-cited agent, 8 citations, Mild — signal
- Denileukin diftitox: ROR 1.80 (95% CI 0.25–12.96), 1 y behind the freshest-cited agent, 8 citations, Moderate
- Bortezomib: ROR 1.78 (95% CI 1.69–1.86), 1 y behind the freshest-cited agent, 7 citations, Moderate — signal
- Tisotumab vedotin: ROR 1.78 (95% CI 1.08–2.91), 2 y behind the freshest-cited agent, 4 citations, Mild — signal
- Gilteritinib: ROR 1.77 (95% CI 1.42–2.22), 0 y behind the freshest-cited agent, 7 citations, Moderate — signal
- Neratinib: ROR 1.77 (95% CI 1.31–2.39), 4 y behind the freshest-cited agent, 6 citations, Moderate — signal
- Lisocabtagene maraleucel: ROR 1.74 (95% CI 1.06–2.85), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Arsenic trioxide: ROR 1.70 (95% CI 1.34–2.14), 1 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Bicalutamide: ROR 1.69 (95% CI 1.50–1.90), 6 y behind the freshest-cited agent, 4 citations, Mild — signal
- Everolimus: ROR 1.69 (95% CI 1.58–1.81), 1 y behind the freshest-cited agent, 12 citations, Moderate — signal
- Lenvatinib: ROR 1.69 (95% CI 1.56–1.83), 0 y behind the freshest-cited agent, 13 citations, Moderate — signal
- Cabazitaxel: ROR 1.68 (95% CI 1.31–2.16), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
- Doxorubicin: ROR 1.68 (95% CI 1.60–1.76), 0 y behind the freshest-cited agent, 12 citations, Mild — signal
- Relatlimab: ROR 1.66 (95% CI 0.86–3.22), 0 y behind the freshest-cited agent, 7 citations, Moderate
- Tafasitamab: ROR 1.65 (95% CI 1.21–2.25), 2 y behind the freshest-cited agent, 6 citations, Mild — signal
- Vinblastine: ROR 1.65 (95% CI 1.18–2.32), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
- Abemaciclib: ROR 1.63 (95% CI 1.47–1.82), 0 y behind the freshest-cited agent, 8 citations, Mild — signal
- Mitoxantrone: ROR 1.60 (95% CI 1.32–1.95), 10 y behind the freshest-cited agent, 9 citations, Mild — signal
- Hydroxyurea: ROR 1.58 (95% CI 1.42–1.75), 6 y behind the freshest-cited agent, 7 citations, Mild — signal
- Infigratinib: ROR 1.58 (95% CI 0.22–11.39), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Daratumumab: ROR 1.57 (95% CI 1.45–1.69), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
- Decitabine: ROR 1.57 (95% CI 1.27–1.94), 3 y behind the freshest-cited agent, 6 citations, Mild — signal
- Belantamab mafodotin: ROR 1.52 (95% CI 1.13–2.05), 0 y behind the freshest-cited agent, 6 citations, Mild — signal
- Paclitaxel: ROR 1.52 (95% CI 1.45–1.60), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
- Cemiplimab: ROR 1.51 (95% CI 1.07–2.13), 0 y behind the freshest-cited agent, 11 citations, Moderate — signal
- Vandetanib: ROR 1.50 (95% CI 0.94–2.40), 3 y behind the freshest-cited agent, 6 citations, Moderate
- Irinotecan: ROR 1.48 (95% CI 1.29–1.70), 2 y behind the freshest-cited agent, 5 citations, Mild — signal
- Momelotinib: ROR 1.48 (95% CI 0.98–2.23), 0 y behind the freshest-cited agent, 7 citations, Mild
- Asparaginase: ROR 1.47 (95% CI 0.96–2.26), 1 y behind the freshest-cited agent, 6 citations, Mild
- Afatinib: ROR 1.45 (95% CI 1.19–1.76), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
- Necitumumab: ROR 1.43 (95% CI 0.64–3.21), 5 y behind the freshest-cited agent, 9 citations, Moderate
- Bleomycin: ROR 1.42 (95% CI 1.21–1.67), 5 y behind the freshest-cited agent, 7 citations, Mild — signal
- Entrectinib: ROR 1.40 (95% CI 0.92–2.13), 2 y behind the freshest-cited agent, 7 citations, Mild
- Glasdegib: ROR 1.40 (95% CI 0.67–2.96), 3 y behind the freshest-cited agent, 6 citations, Mild
- Rituximab: ROR 1.38 (95% CI 1.34–1.43), 2 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Azacitidine: ROR 1.37 (95% CI 1.25–1.51), 2 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Ibritumomab tiuxetan: ROR 1.37 (95% CI 0.90–2.09), 22 y behind the freshest-cited agent, 6 citations, Mild
- Tucatinib: ROR 1.37 (95% CI 1.12–1.69), 2 y behind the freshest-cited agent, 4 citations, Mild — signal
- Obecabtagene autoleucel (Obe-cel): ROR 1.34 (95% CI 0.19–9.63), 1 y behind the freshest-cited agent, 5 citations, Moderate
- Copanlisib: ROR 1.33 (95% CI 0.55–3.22), 5 y behind the freshest-cited agent, 6 citations, Moderate
- Dinutuximab: ROR 1.33 (95% CI 0.75–2.34), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Cetuximab: ROR 1.32 (95% CI 1.20–1.45), 4 y behind the freshest-cited agent, 13 citations, Mild — signal
- Ceritinib: ROR 1.31 (95% CI 0.94–1.82), 1 y behind the freshest-cited agent, 6 citations, Mild
- Talquetamab: ROR 1.31 (95% CI 0.90–1.90), 0 y behind the freshest-cited agent, 7 citations, Moderate
- Abiraterone: ROR 1.29 (95% CI 1.19–1.40), 1 y behind the freshest-cited agent, 11 citations, Moderate — signal
- Iberdomide: ROR 1.27 (95% CI 0.32–5.14), 1 y behind the freshest-cited agent, 7 citations, Mild
- Temozolomide: ROR 1.26 (95% CI 1.12–1.42), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
- Obinutuzumab: ROR 1.24 (95% CI 1.08–1.43), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Panitumumab: ROR 1.24 (95% CI 1.08–1.42), 0 y behind the freshest-cited agent, 10 citations, Mild — signal
- Zolbetuximab: ROR 1.24 (95% CI 0.80–1.93), 1 y behind the freshest-cited agent, 4 citations, Moderate
- Docetaxel: ROR 1.19 (95% CI 1.12–1.28), 1 y behind the freshest-cited agent, 10 citations, Mild — signal
- Tretinoin (ATRA): ROR 1.18 (95% CI 0.97–1.42), 1 y behind the freshest-cited agent, 10 citations, Moderate
- Bevacizumab: ROR 1.18 (95% CI 1.13–1.24), 7 y behind the freshest-cited agent, 9 citations, Moderate — signal
- Ixazomib: ROR 1.17 (95% CI 1.05–1.30), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
- Mobocertinib: ROR 1.17 (95% CI 0.58–2.34), 1 y behind the freshest-cited agent, 7 citations, Mild
- Chlorambucil: ROR 1.16 (95% CI 0.87–1.54), 5 y behind the freshest-cited agent, 3 citations, Mild
- Imlunestrant: ROR 1.16 (95% CI 0.16–8.36), 1 y behind the freshest-cited agent, 2 citations, Mild
- Selpercatinib: ROR 1.15 (95% CI 0.69–1.92), 0 y behind the freshest-cited agent, 11 citations, Moderate
- Idarubicin: ROR 1.14 (95% CI 0.68–1.94), 3 y behind the freshest-cited agent, 8 citations, Mild
- Polatuzumab vedotin: ROR 1.14 (95% CI 0.96–1.36), 2 y behind the freshest-cited agent, 4 citations, Mild
- Glofitamab: ROR 1.12 (95% CI 0.79–1.58), 2 y behind the freshest-cited agent, 6 citations, Moderate
- Ponatinib: ROR 1.12 (95% CI 0.93–1.34), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Dostarlimab: ROR 1.11 (95% CI 0.76–1.64), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Tepotinib: ROR 1.10 (95% CI 0.55–2.20), 1 y behind the freshest-cited agent, 8 citations, Mild
- Dabrafenib: ROR 1.08 (95% CI 0.95–1.23), 4 y behind the freshest-cited agent, 9 citations, Mild
- Dacarbazine: ROR 1.08 (95% CI 0.87–1.33), 25 y behind the freshest-cited agent, 2 citations, Mild
- Selinexor: ROR 1.08 (95% CI 0.89–1.32), 2 y behind the freshest-cited agent, 10 citations, Moderate
- Tamoxifen: ROR 1.08 (95% CI 0.85–1.38), 3 y behind the freshest-cited agent, 6 citations, Mild
- Axitinib: ROR 1.07 (95% CI 0.94–1.22), 3 y behind the freshest-cited agent, 7 citations, Moderate
- Dactinomycin (actinomycin D): ROR 1.07 (95% CI 0.72–1.59), 9 y behind the freshest-cited agent, 4 citations, Moderate
- Methotrexate (high-dose): ROR 1.07 (95% CI 1.04–1.10), 1 y behind the freshest-cited agent, 10 citations, Moderate — signal
- Thalidomide: ROR 1.05 (95% CI 0.91–1.21), 9 y behind the freshest-cited agent, 6 citations, Mild
- Ribociclib: ROR 1.04 (95% CI 0.94–1.15), 0 y behind the freshest-cited agent, 9 citations, Mild
- Capecitabine: ROR 1.03 (95% CI 0.96–1.09), 1 y behind the freshest-cited agent, 9 citations, Mild
- Belzutifan: ROR 1.02 (95% CI 0.64–1.65), 1 y behind the freshest-cited agent, 7 citations, Mild
- Crizotinib: ROR 1.02 (95% CI 0.84–1.24), 1 y behind the freshest-cited agent, 10 citations, Mild
- Sorafenib: ROR 1.02 (95% CI 0.89–1.16), 5 y behind the freshest-cited agent, 11 citations, Moderate
- Topotecan: ROR 1.01 (95% CI 0.80–1.27), 4 y behind the freshest-cited agent, 4 citations, Mild
- Duvelisib: ROR 1.00 (95% CI 0.52–1.93), 1 y behind the freshest-cited agent, 7 citations, Mild
- Elranatamab: ROR 0.98 (95% CI 0.65–1.50), 0 y behind the freshest-cited agent, 10 citations, Moderate
- Mitotane: ROR 0.98 (95% CI 0.63–1.54), 1 y behind the freshest-cited agent, 6 citations, Moderate
- Durvalumab: ROR 0.96 (95% CI 0.84–1.10), 0 y behind the freshest-cited agent, 11 citations, Moderate
- Trametinib: ROR 0.94 (95% CI 0.83–1.07), 2 y behind the freshest-cited agent, 10 citations, Moderate
- Regorafenib: ROR 0.93 (95% CI 0.77–1.12), 1 y behind the freshest-cited agent, 10 citations, Moderate
- Imatinib: ROR 0.92 (95% CI 0.84–1.02), 2 y behind the freshest-cited agent, 9 citations, Mild
- Loncastuximab tesirine: ROR 0.92 (95% CI 0.34–2.47), 2 y behind the freshest-cited agent, 5 citations, Moderate
- Fedratinib: ROR 0.91 (95% CI 0.53–1.57), 6 y behind the freshest-cited agent, 7 citations, Mild
- Melphalan flufenamide (melflufen): ROR 0.91 (95% CI 0.13–6.54), 0 y behind the freshest-cited agent, 4 citations, Moderate
- Taletrectinib: ROR 0.89 (95% CI 0.12–6.38), 0 y behind the freshest-cited agent, 4 citations, Mild
- Eribulin: ROR 0.88 (95% CI 0.63–1.23), 4 y behind the freshest-cited agent, 6 citations, Mild
- Ramucirumab: ROR 0.88 (95% CI 0.68–1.14), 1 y behind the freshest-cited agent, 11 citations, Moderate
- Bosutinib: ROR 0.87 (95% CI 0.70–1.08), 1 y behind the freshest-cited agent, 9 citations, Mild
- Lazertinib: ROR 0.87 (95% CI 0.43–1.75), 2 y behind the freshest-cited agent, 6 citations, Mild
- Sunitinib: ROR 0.87 (95% CI 0.78–0.96), 0 y behind the freshest-cited agent, 8 citations, Moderate
- Zanubrutinib: ROR 0.86 (95% CI 0.62–1.19), 2 y behind the freshest-cited agent, 7 citations, Mild
- Futibatinib: ROR 0.85 (95% CI 0.21–3.42), 2 y behind the freshest-cited agent, 6 citations, Moderate
- Octreotide: ROR 0.85 (95% CI 0.76–0.96), 2 y behind the freshest-cited agent, 7 citations, Mild
- Mitomycin C: ROR 0.83 (95% CI 0.58–1.17), 1 y behind the freshest-cited agent, 13 citations, Severe
- Venetoclax: ROR 0.83 (95% CI 0.76–0.90), 1 y behind the freshest-cited agent, 12 citations, Severe
- Pralatrexate: ROR 0.81 (95% CI 0.30–2.16), 4 y behind the freshest-cited agent, 8 citations, Moderate
- Trifluridine/tipiracil: ROR 0.81 (95% CI 0.67–0.99), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Sacituzumab govitecan: ROR 0.80 (95% CI 0.59–1.09), 0 y behind the freshest-cited agent, 5 citations, Moderate
- Blinatumomab: ROR 0.79 (95% CI 0.64–0.97), 4 y behind the freshest-cited agent, 8 citations, Moderate
- Sonidegib: ROR 0.79 (95% CI 0.47–1.33), 3 y behind the freshest-cited agent, 6 citations, Mild
- Teniposide: ROR 0.79 (95% CI 0.25–2.46), 5 y behind the freshest-cited agent, 5 citations, Mild
- Nedaplatin: ROR 0.78 (95% CI 0.39–1.56), 3 y behind the freshest-cited agent, 11 citations, Moderate
- Tebentafusp: ROR 0.78 (95% CI 0.33–1.89), 3 y behind the freshest-cited agent, 4 citations, Moderate
- Erdafitinib: ROR 0.76 (95% CI 0.41–1.41), 2 y behind the freshest-cited agent, 7 citations, Moderate
- Naxitamab: ROR 0.75 (95% CI 0.19–3.04), 1 y behind the freshest-cited agent, 8 citations, Moderate
- Pazopanib: ROR 0.75 (95% CI 0.66–0.86), 2 y behind the freshest-cited agent, 9 citations, Moderate
- Teclistamab: ROR 0.75 (95% CI 0.48–1.18), 0 y behind the freshest-cited agent, 9 citations, Moderate
- Capmatinib: ROR 0.74 (95% CI 0.46–1.20), 1 y behind the freshest-cited agent, 8 citations, Mild
- Ivosidenib: ROR 0.74 (95% CI 0.46–1.19), 2 y behind the freshest-cited agent, 6 citations, Moderate
- Larotrectinib: ROR 0.74 (95% CI 0.35–1.55), 6 y behind the freshest-cited agent, 7 citations, Mild
- Rucaparib: ROR 0.74 (95% CI 0.57–0.95), 0 y behind the freshest-cited agent, 7 citations, Mild
- Alpelisib: ROR 0.73 (95% CI 0.57–0.93), 2 y behind the freshest-cited agent, 7 citations, Moderate
- Asciminib: ROR 0.73 (95% CI 0.49–1.09), 0 y behind the freshest-cited agent, 7 citations, Mild
- Ciltacabtagene autoleucel: ROR 0.73 (95% CI 0.56–0.96), 0 y behind the freshest-cited agent, 10 citations, Moderate
- Estramustine: ROR 0.73 (95% CI 0.23–2.28), 11 y behind the freshest-cited agent, 7 citations, Mild
- Midostaurin: ROR 0.72 (95% CI 0.43–1.20), 3 y behind the freshest-cited agent, 7 citations, Mild
- Tarlatamab: ROR 0.72 (95% CI 0.42–1.25), 0 y behind the freshest-cited agent, 8 citations, Moderate
- Gefitinib: ROR 0.70 (95% CI 0.55–0.89), 8 y behind the freshest-cited agent, 12 citations, Mild
- Ibrutinib: ROR 0.70 (95% CI 0.65–0.76), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Lenalidomide: ROR 0.69 (95% CI 0.67–0.72), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Repotrectinib: ROR 0.69 (95% CI 0.17–2.77), 1 y behind the freshest-cited agent, 6 citations, Mild
- Ibandronate: ROR 0.66 (95% CI 0.54–0.82), 2 y behind the freshest-cited agent, 9 citations, Mild
- Pemigatinib: ROR 0.66 (95% CI 0.30–1.48), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Pomalidomide: ROR 0.66 (95% CI 0.61–0.71), 1 y behind the freshest-cited agent, 7 citations, Mild
- Dasatinib: ROR 0.62 (95% CI 0.54–0.72), 1 y behind the freshest-cited agent, 9 citations, Moderate
- Lutetium-177 Dotatate: ROR 0.62 (95% CI 0.45–0.85), 1 y behind the freshest-cited agent, 19 citations, Moderate
- Darolutamide: ROR 0.61 (95% CI 0.44–0.86), 1 y behind the freshest-cited agent, 5 citations, Mild
- Nirogacestat: ROR 0.61 (95% CI 0.27–1.37), 2 y behind the freshest-cited agent, 7 citations, Mild
- Talazoparib: ROR 0.61 (95% CI 0.35–1.08), 0 y behind the freshest-cited agent, 6 citations, Mild
- Tislelizumab: ROR 0.61 (95% CI 0.47–0.81), 0 y behind the freshest-cited agent, 8 citations, Moderate
- Mosunetuzumab: ROR 0.60 (95% CI 0.28–1.25), 2 y behind the freshest-cited agent, 8 citations, Moderate
- Ruxolitinib: ROR 0.58 (95% CI 0.53–0.63), 0 y behind the freshest-cited agent, 7 citations, Mild
- Nintedanib: ROR 0.57 (95% CI 0.50–0.66), 0 y behind the freshest-cited agent, 9 citations, Mild
- Zongertinib: ROR 0.56 (95% CI 0.08–4.03), 1 y behind the freshest-cited agent, 4 citations, Mild
- Radium-223 dichloride: ROR 0.54 (95% CI 0.38–0.78), 4 y behind the freshest-cited agent, 8 citations, Mild
- Amivantamab: ROR 0.53 (95% CI 0.34–0.82), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Erlotinib: ROR 0.53 (95% CI 0.44–0.64), 2 y behind the freshest-cited agent, 9 citations, Mild
- Sotorasib: ROR 0.52 (95% CI 0.33–0.81), 1 y behind the freshest-cited agent, 6 citations, Mild
- Lomustine (CCNU): ROR 0.51 (95% CI 0.30–0.86), 7 y behind the freshest-cited agent, 9 citations, Moderate
- Toripalimab: ROR 0.50 (95% CI 0.26–0.96), 2 y behind the freshest-cited agent, 7 citations, Moderate
- Acalabrutinib: ROR 0.49 (95% CI 0.38–0.62), 1 y behind the freshest-cited agent, 8 citations, Mild
- Cabozantinib: ROR 0.49 (95% CI 0.43–0.55), 0 y behind the freshest-cited agent, 10 citations, Moderate
- Fruquintinib: ROR 0.48 (95% CI 0.31–0.74), 1 y behind the freshest-cited agent, 10 citations, Moderate
- Tivozanib: ROR 0.47 (95% CI 0.22–0.99), 5 y behind the freshest-cited agent, 5 citations, Moderate
- Brigatinib: ROR 0.46 (95% CI 0.29–0.74), 1 y behind the freshest-cited agent, 9 citations, Mild
- Trastuzumab deruxtecan: ROR 0.46 (95% CI 0.35–0.60), 0 y behind the freshest-cited agent, 6 citations, Moderate
- Trastuzumab emtansine (T-DM1): ROR 0.44 (95% CI 0.33–0.61), 0 y behind the freshest-cited agent, 7 citations, Moderate
- Nilotinib: ROR 0.43 (95% CI 0.36–0.50), 1 y behind the freshest-cited agent, 8 citations, Mild
- Enzalutamide: ROR 0.42 (95% CI 0.37–0.47), 2 y behind the freshest-cited agent, 9 citations, Mild
- Cladribine: ROR 0.40 (95% CI 0.29–0.54), 3 y behind the freshest-cited agent, 10 citations, Mild
- Denosumab: ROR 0.40 (95% CI 0.37–0.42), 1 y behind the freshest-cited agent, 10 citations, Moderate
- Lanreotide: ROR 0.39 (95% CI 0.28–0.55), 8 y behind the freshest-cited agent, 6 citations, Mild
- Osimertinib: ROR 0.39 (95% CI 0.33–0.47), 0 y behind the freshest-cited agent, 9 citations, Mild
- Ziv-aflibercept: ROR 0.37 (95% CI 0.31–0.44), 4 y behind the freshest-cited agent, 8 citations, Moderate
- Palbociclib: ROR 0.36 (95% CI 0.33–0.40), 0 y behind the freshest-cited agent, 8 citations, Mild
- Leuprolide: ROR 0.35 (95% CI 0.32–0.40), 2 y behind the freshest-cited agent, 8 citations, Mild
- Lorlatinib: ROR 0.35 (95% CI 0.24–0.51), 1 y behind the freshest-cited agent, 8 citations, Mild
- Alectinib: ROR 0.34 (95% CI 0.23–0.50), 0 y behind the freshest-cited agent, 9 citations, Mild
- Selumetinib: ROR 0.33 (95% CI 0.15–0.75), 3 y behind the freshest-cited agent, 6 citations, Mild
- Fotemustine: ROR 0.32 (95% CI 0.04–2.29), 11 y behind the freshest-cited agent, 4 citations, Moderate
- Lutetium-177 PSMA-617 (vipivotide): ROR 0.30 (95% CI 0.22–0.40), 0 y behind the freshest-cited agent, 12 citations, Moderate
- Olaparib: ROR 0.26 (95% CI 0.20–0.34), 0 y behind the freshest-cited agent, 8 citations, Mild
- Vismodegib: ROR 0.25 (95% CI 0.17–0.38), 3 y behind the freshest-cited agent, 6 citations, Mild
- Niraparib: ROR 0.22 (95% CI 0.17–0.29), 0 y behind the freshest-cited agent, 8 citations, Mild
- Pacritinib: ROR 0.21 (95% CI 0.10–0.45), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Pralsetinib: ROR 0.21 (95% CI 0.08–0.55), 1 y behind the freshest-cited agent, 6 citations, Mild
- Enasidenib: ROR 0.19 (95% CI 0.09–0.41), 1 y behind the freshest-cited agent, 8 citations, Moderate
- Tazemetostat: ROR 0.17 (95% CI 0.06–0.54), 4 y behind the freshest-cited agent, 7 citations, Mild
- Vorasidenib: ROR 0.17 (95% CI 0.02–1.23), 0 y behind the freshest-cited agent, 4 citations, Mild
- Ripretinib: ROR 0.16 (95% CI 0.08–0.31), 0 y behind the freshest-cited agent, 7 citations, Mild
- Pexidartinib: ROR 0.13 (95% CI 0.02–0.93), 3 y behind the freshest-cited agent, 5 citations, Mild
- Quizartinib: ROR 0.13 (95% CI 0.02–0.95), 1 y behind the freshest-cited agent, 6 citations, Mild
- Datopotamab deruxtecan (Dato-DXd): ROR 0.11 (95% CI 0.01–0.78), 1 y behind the freshest-cited agent, 6 citations, Moderate
- Mirvetuximab soravtansine: ROR 0.10 (95% CI 0.03–0.41), 2 y behind the freshest-cited agent, 4 citations, Mild
- Avapritinib: ROR 0.09 (95% CI 0.05–0.17), 5 y behind the freshest-cited agent, 5 citations, Mild
- Revumenib: ROR 0.09 (95% CI 0.01–0.65), 2 y behind the freshest-cited agent, 6 citations, Moderate
- Avutometinib: ROR 0.08 (95% CI 0.01–0.59), 1 y behind the freshest-cited agent, 7 citations, Moderate
- Elacestrant: ROR 0.07 (95% CI 0.03–0.16), 2 y behind the freshest-cited agent, 4 citations, Mild
- Mechlorethamine: ROR 0.04 (95% CI 0.01–0.30), 5 y behind the freshest-cited agent, 4 citations, Moderate
Timing, regimen & era
When injury declares, how combinations compound it, and how the phenotype shifted by drug generation.
When each agent's kidney injury tends to surface, on a log time axis from one hour to two years. A solid bar with end-caps marks an explicit reported earliest→latest range; a lighter cap-less bar is a window estimate only (no dated range); a dot is a single reported day (a dashed tail marks a lone bound — onset can fall later → or earlier ←); and a faint dashed band is a genuinely variable course. Colored by signature injury and grouped beneath it — distilled from each drug's own cited onset prose.
- Prerenal / Hemodynamic AKI — Naxitamab: Hyperacute (<24 h), from about day 0
- Prerenal / Hemodynamic AKI — Paclitaxel: Hyperacute (<24 h), no explicit day range
- Prerenal / Hemodynamic AKI — Catumaxomab: Acute (~1–7 days), from about day 0
- Prerenal / Hemodynamic AKI — Ibritumomab tiuxetan: Acute (~1–7 days), from about day 0
- Prerenal / Hemodynamic AKI — Lifileucel: Acute (~1–7 days), from about day 0
- Prerenal / Hemodynamic AKI — Afamitresgene autoleucel (Afami-cel): Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Blinatumomab: Acute (~1–7 days), from about day 1
- Prerenal / Hemodynamic AKI — CAR-T Cell Therapy: Acute (~1–7 days), from about day 1
- Prerenal / Hemodynamic AKI — Ciltacabtagene autoleucel: Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Idecabtagene vicleucel: Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Linvoseltamab: Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Mosunetuzumab: Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Obecabtagene autoleucel (Obe-cel): Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Pivekimab sunirine: Acute (~1–7 days), day 1–21
- Prerenal / Hemodynamic AKI — Pomalidomide: Acute (~1–7 days), from about day 1
- Prerenal / Hemodynamic AKI — Tagraxofusp: Acute (~1–7 days), from about day 1
- Prerenal / Hemodynamic AKI — Tasonermin: Acute (~1–7 days), day 1–2
- Prerenal / Hemodynamic AKI — Tebentafusp: Acute (~1–7 days), day 1–21
- Prerenal / Hemodynamic AKI — Teclistamab: Acute (~1–7 days), day 1–14
- Prerenal / Hemodynamic AKI — Lisocabtagene maraleucel: Acute (~1–7 days), around day 10
- Prerenal / Hemodynamic AKI — Afatinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Brentuximab vedotin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Capecitabine: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Capivasertib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Clofarabine: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Denileukin diftitox: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Dinutuximab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Elranatamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Epcoritamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Gemtuzumab ozogamicin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Gilteritinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Glofitamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Imetelstat: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Inotuzumab ozogamicin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Interleukin-2 (high-dose): Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Irinotecan: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Midostaurin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Mobocertinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Mogamulizumab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Olutasidenib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Pegaspargase: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Polatuzumab vedotin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Quizartinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Revumenib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Sevabertinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Tafasitamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Talquetamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Tarlatamab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Tazemetostat: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Thalidomide: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Tisotumab vedotin: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Zanubrutinib: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Zenocutuzumab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Zolbetuximab: Acute (~1–7 days), no explicit day range
- Prerenal / Hemodynamic AKI — Enasidenib: Subacute (~1–6 weeks), day 1–150
- Prerenal / Hemodynamic AKI — Tretinoin (ATRA): Subacute (~1–6 weeks), by about day 21
- Prerenal / Hemodynamic AKI — Pacritinib: Subacute (~1–6 weeks), by about day 56
- Prerenal / Hemodynamic AKI — Estramustine: Subacute (~1–6 weeks), by about day 60
- Prerenal / Hemodynamic AKI — Adagrasib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Alpelisib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Arsenic trioxide: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Belzutifan: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Ivosidenib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Loncastuximab tesirine: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Neratinib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Sotorasib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Trifluridine/tipiracil: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Ziftomenib: Subacute (~1–6 weeks), no explicit day range
- Prerenal / Hemodynamic AKI — Docetaxel: Delayed (>6 weeks / cumulative), no explicit day range
- Prerenal / Hemodynamic AKI — Duvelisib: Delayed (>6 weeks / cumulative), no explicit day range
- Prerenal / Hemodynamic AKI — Idelalisib: Delayed (>6 weeks / cumulative), no explicit day range
- Prerenal / Hemodynamic AKI — Nilotinib: Delayed (>6 weeks / cumulative), no explicit day range
- Prerenal / Hemodynamic AKI — Bleomycin: Variable / unpredictable, from about day 0
- Prerenal / Hemodynamic AKI — Elotuzumab: Variable / unpredictable, around day 0
- Prerenal / Hemodynamic AKI — Altretamine (hexamethylmelamine): Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Asparaginase: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Avapritinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Cabazitaxel: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Casdatifan: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Ceritinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Dacarbazine: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Daratumumab: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Elacestrant: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Eribulin: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Glasdegib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Isatuximab: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Mirdametinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Mirvetuximab soravtansine: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Pexidartinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Radium-223 dichloride: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Ruxolitinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Sacituzumab govitecan: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Selumetinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Topotecan: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Tovorafenib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Trametinib: Variable / unpredictable, no explicit day range
- Prerenal / Hemodynamic AKI — Zanidatamab: Variable / unpredictable, no explicit day range
- Electrolyte Disturbance — Inavolisib: Hyperacute (<24 h), around day 0
- Electrolyte Disturbance — Amsacrine: Acute (~1–7 days), from about day 0
- Electrolyte Disturbance — Dactinomycin (actinomycin D): Acute (~1–7 days), from about day 0
- Electrolyte Disturbance — Mechlorethamine: Acute (~1–7 days), from about day 0
- Electrolyte Disturbance — Strontium-89 chloride: Acute (~1–7 days), from about day 0
- Electrolyte Disturbance — Vinflunine: Acute (~1–7 days), no explicit day range
- Electrolyte Disturbance — Avutometinib: Subacute (~1–6 weeks), by about day 90
- Electrolyte Disturbance — Abiraterone: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Amivantamab: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Cetuximab: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Denosumab: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Erdafitinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Fedratinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Futibatinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Gedatolisib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Infigratinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Mitotane: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Necitumumab: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Panitumumab: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Pemigatinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Sunvozertinib: Subacute (~1–6 weeks), no explicit day range
- Electrolyte Disturbance — Imatinib: Delayed (>6 weeks / cumulative), no explicit day range
- Electrolyte Disturbance — Relacorilant: Delayed (>6 weeks / cumulative), no explicit day range
- Electrolyte Disturbance — Darolutamide: Variable / unpredictable, day 0–2
- Electrolyte Disturbance — Lanreotide: Variable / unpredictable, no explicit day range
- Electrolyte Disturbance — Nirogacestat: Variable / unpredictable, no explicit day range
- Electrolyte Disturbance — Octreotide: Variable / unpredictable, no explicit day range
- Electrolyte Disturbance — Teniposide: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Cisplatin: Acute (~1–7 days), by about day 7
- Acute Tubular Necrosis — Gallium nitrate: Acute (~1–7 days), by about day 7
- Acute Tubular Necrosis — BRAF / MEK Inhibitors: Acute (~1–7 days), no explicit day range
- Acute Tubular Necrosis — Carboplatin: Acute (~1–7 days), no explicit day range
- Acute Tubular Necrosis — Ibandronate: Acute (~1–7 days), no explicit day range
- Acute Tubular Necrosis — Nedaplatin: Acute (~1–7 days), no explicit day range
- Acute Tubular Necrosis — Zoledronic acid: Acute (~1–7 days), no explicit day range
- Acute Tubular Necrosis — Vemurafenib: Subacute (~1–6 weeks), by about day 90
- Acute Tubular Necrosis — Binimetinib: Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Cobimetinib: Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Datopotamab deruxtecan (Dato-DXd): Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Encorafenib: Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Melphalan flufenamide (melflufen): Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Plicamycin (mithramycin): Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Raltitrexed: Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Sonidegib: Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Telisotuzumab vedotin (Teliso-V): Subacute (~1–6 weeks), no explicit day range
- Acute Tubular Necrosis — Iobenguane I-131: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Tubular Necrosis — Trabectedin: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Tubular Necrosis — Enfortumab vedotin: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Lenalidomide: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Lurbinectedin: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Pentostatin: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Procarbazine: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Samarium-153 lexidronam: Variable / unpredictable, no explicit day range
- Acute Tubular Necrosis — Trastuzumab deruxtecan: Variable / unpredictable, no explicit day range
- Hypertension — Copanlisib: Hyperacute (<24 h), from about day 0
- Hypertension — Acalabrutinib: Acute (~1–7 days), no explicit day range
- Hypertension — Axitinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Cabozantinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Enzalutamide: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Fruquintinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Lenvatinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Niraparib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Pralsetinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Ramucirumab: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Regorafenib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Ripretinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Selpercatinib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Sorafenib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Tivozanib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Vandetanib: Subacute (~1–6 weeks), no explicit day range
- Hypertension — VEGFR Tyrosine Kinase Inhibitors: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Ziv-aflibercept: Subacute (~1–6 weeks), no explicit day range
- Hypertension — Leuprolide: Delayed (>6 weeks / cumulative), no explicit day range
- Hypertension — Nintedanib: Delayed (>6 weeks / cumulative), no explicit day range
- Hypertension — Asciminib: Variable / unpredictable, no explicit day range
- Hypertension — Ibrutinib: Variable / unpredictable, no explicit day range
- Hypertension — Ponatinib: Variable / unpredictable, no explicit day range
- Hypertension — Sunitinib: Variable / unpredictable, no explicit day range
- Pseudo-AKI — Repotrectinib: Acute (~1–7 days), no explicit day range
- Pseudo-AKI — Taletrectinib: Acute (~1–7 days), no explicit day range
- Pseudo-AKI — Vimseltinib: Subacute (~1–6 weeks), day 1–56
- Pseudo-AKI — Abemaciclib: Subacute (~1–6 weeks), around day 21
- Pseudo-AKI — Palbociclib: Subacute (~1–6 weeks), around day 32
- Pseudo-AKI — Ribociclib: Subacute (~1–6 weeks), around day 42
- Pseudo-AKI — Alectinib: Subacute (~1–6 weeks), by about day 90
- Pseudo-AKI — Brigatinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Capmatinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Entrectinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Larotrectinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Lorlatinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Olaparib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Rucaparib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Tepotinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Tucatinib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Vorasidenib: Subacute (~1–6 weeks), no explicit day range
- Pseudo-AKI — Bosutinib: Delayed (>6 weeks / cumulative), no explicit day range
- Pseudo-AKI — Ensartinib: Variable / unpredictable, no explicit day range
- Pseudo-AKI — Momelotinib: Variable / unpredictable, no explicit day range
- Pseudo-AKI — Talazoparib: Variable / unpredictable, no explicit day range
- Pseudo-AKI — Zongertinib: Variable / unpredictable, no explicit day range
- Acute Interstitial Nephritis — Bicalutamide: Subacute (~1–6 weeks), no explicit day range
- Acute Interstitial Nephritis — Retifanlimab: Delayed (>6 weeks / cumulative), around day 90
- Acute Interstitial Nephritis — Immune Checkpoint Inhibitors: Delayed (>6 weeks / cumulative), around day 98
- Acute Interstitial Nephritis — Nivolumab: Delayed (>6 weeks / cumulative), around day 98
- Acute Interstitial Nephritis — Sugemalimab: Delayed (>6 weeks / cumulative), around day 98
- Acute Interstitial Nephritis — Pembrolizumab: Delayed (>6 weeks / cumulative), around day 105
- Acute Interstitial Nephritis — Penpulimab: Delayed (>6 weeks / cumulative), around day 105
- Acute Interstitial Nephritis — Cosibelimab: Delayed (>6 weeks / cumulative), around day 108
- Acute Interstitial Nephritis — Atezolizumab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Avelumab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Cemiplimab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Dostarlimab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Durvalumab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Relatlimab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Tislelizumab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Toripalimab: Delayed (>6 weeks / cumulative), no explicit day range
- Acute Interstitial Nephritis — Ipilimumab: Variable / unpredictable, around day 91
- Acute Interstitial Nephritis — Dabrafenib: Variable / unpredictable, no explicit day range
- Crystal / Obstructive Nephropathy — Hydroxyurea: Hyperacute (<24 h), day 0–1
- Crystal / Obstructive Nephropathy — Bendamustine: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Cytarabine: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Etoposide: Acute (~1–7 days), day 0–3
- Crystal / Obstructive Nephropathy — Idarubicin: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Methotrexate (high-dose): Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Mitoxantrone: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Obinutuzumab: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Rituximab: Acute (~1–7 days), day 0–3
- Crystal / Obstructive Nephropathy — Venetoclax: Acute (~1–7 days), from about day 0
- Crystal / Obstructive Nephropathy — Cladribine: Acute (~1–7 days), day 1–3
- Crystal / Obstructive Nephropathy — Odronextamab: Acute (~1–7 days), day 1–14
- Crystal / Obstructive Nephropathy — Sonrotoclax: Acute (~1–7 days), day 1–3
- Crystal / Obstructive Nephropathy — Fludarabine: Acute (~1–7 days), no explicit day range
- Crystal / Obstructive Nephropathy — Nelarabine: Acute (~1–7 days), no explicit day range
- Crystal / Obstructive Nephropathy — Pirtobrutinib: Acute (~1–7 days), no explicit day range
- Crystal / Obstructive Nephropathy — Decitabine: Variable / unpredictable, no explicit day range
- Crystal / Obstructive Nephropathy — Pralatrexate: Variable / unpredictable, no explicit day range
- Glomerular Injury / Proteinuria — Bevacizumab: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Dasatinib: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Doxorubicin: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Erlotinib: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Everolimus: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Gefitinib: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Interferon-α: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — mTOR Inhibitors: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Pazopanib: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Temsirolimus: Subacute (~1–6 weeks), no explicit day range
- Glomerular Injury / Proteinuria — Pamidronate: Delayed (>6 weeks / cumulative), day 450–1,440
- Glomerular Injury / Proteinuria — Belantamab mafodotin: Variable / unpredictable, no explicit day range
- Glomerular Injury / Proteinuria — Ivonescimab: Variable / unpredictable, no explicit day range
- Glomerular Injury / Proteinuria — Olverembatinib: Variable / unpredictable, no explicit day range
- Glomerular Injury / Proteinuria — Sirolimus: Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Oxaliplatin: Acute (~1–7 days), no explicit day range
- Thrombotic Microangiopathy — Busulfan: Subacute (~1–6 weeks), no explicit day range
- Thrombotic Microangiopathy — 5-Fluorouracil: Delayed (>6 weeks / cumulative), no explicit day range
- Thrombotic Microangiopathy — Doxifluridine: Delayed (>6 weeks / cumulative), no explicit day range
- Thrombotic Microangiopathy — Gemcitabine: Delayed (>6 weeks / cumulative), no explicit day range
- Thrombotic Microangiopathy — Mitomycin C: Delayed (>6 weeks / cumulative), no explicit day range
- Thrombotic Microangiopathy — Tegafur-uracil (UFT): Delayed (>6 weeks / cumulative), no explicit day range
- Thrombotic Microangiopathy — Bortezomib: Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Carfilzomib: Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Carmofur (HCFU): Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Ixazomib: Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Moxetumomab pasudotox: Variable / unpredictable, no explicit day range
- Thrombotic Microangiopathy — Trastuzumab emtansine (T-DM1): Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Cyclophosphamide: Hyperacute (<24 h), from about day 0
- SIADH / Hyponatremia — Melphalan: Acute (~1–7 days), no explicit day range
- SIADH / Hyponatremia — Vinblastine: Acute (~1–7 days), no explicit day range
- SIADH / Hyponatremia — Vincristine: Acute (~1–7 days), no explicit day range
- SIADH / Hyponatremia — Selinexor: Subacute (~1–6 weeks), no explicit day range
- SIADH / Hyponatremia — Osimertinib: Delayed (>6 weeks / cumulative), around day 60
- SIADH / Hyponatremia — Chlorambucil: Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Lazertinib: Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Tamoxifen: Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Temozolomide: Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Vinorelbine: Variable / unpredictable, no explicit day range
- SIADH / Hyponatremia — Vismodegib: Variable / unpredictable, no explicit day range
- Chronic Interstitial Nephropathy — Carmustine (BCNU): Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Fotemustine: Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Lomustine (CCNU): Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Lutetium-177 Dotatate: Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Lutetium-177 PSMA-617 (vipivotide): Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Nimustine (ACNU): Delayed (>6 weeks / cumulative), no explicit day range
- Chronic Interstitial Nephropathy — Pemetrexed: Delayed (>6 weeks / cumulative), no explicit day range
- Fanconi Syndrome — Azacitidine: Acute (~1–7 days), no explicit day range
- Fanconi Syndrome — Streptozocin: Subacute (~1–6 weeks), no explicit day range
- Fanconi Syndrome — Ifosfamide: Variable / unpredictable, no explicit day range
- Hemorrhagic Cystitis — Thiotepa: Variable / unpredictable, no explicit day range
- Renal Cysts — Crizotinib: Delayed (>6 weeks / cumulative), no explicit day range
Background bands mark the named onset windows on the log time axis: hyperacute (under 24 hours), acute (about 1–7 days), subacute (about 1–6 weeks), and delayed (beyond 6 weeks).
285 agents carrying a structured onset overlay, 65 with explicit day numbers · solid capped bar = reported earliest→latest days · light cap-less bar = window estimate only (no dated range) · dot = single reported day (dashed tail = a lone earliest/latest bound) · hollow dot = typical within a range · dashed band = variable course · › = extends beyond the 2-year axis · faint background bands mark the named onset windows (hyperacute / acute / subacute / delayed). Log time axis (1 h → 2 yr). Distilled from each drug's own cited onset prose — clinical timing, not a guarantee.
How soon after dosing each drug-class family's kidney injury tends to declare. Read across a row for a family's onset spread, down a column for the classes that share a tempo.
| Drug-class family | Hyperacute<24 hcolumn total: 6 | Acute1–7 dcolumn total: 87 | Subacute1–6 wkcolumn total: 84 | Delayed>6 wkcolumn total: 41 | Variablespreadcolumn total: 67 |
|---|---|---|---|---|---|
| Other targeted agents, row total 38 | Other targeted agents, Hyperacute: 0 agents (0% of row) | Other targeted agents, Acute: 13 agents (34% of row) | Other targeted agents, Subacute: 14 agents (37% of row) | Other targeted agents, Delayed: 1 agent (3% of row) | Other targeted agents, Variable: 10 agents (26% of row) |
| Alkylating agents, row total 21 | Alkylating agents, Hyperacute: 1 agent (5% of row) | Alkylating agents, Acute: 3 agents (14% of row) | Alkylating agents, Subacute: 4 agents (19% of row) | Alkylating agents, Delayed: 5 agents (24% of row) | Alkylating agents, Variable: 8 agents (38% of row) |
| Antimetabolites, row total 20 | Antimetabolites, Hyperacute: 1 agent (5% of row) | Antimetabolites, Acute: 8 agents (40% of row) | Antimetabolites, Subacute: 2 agents (10% of row) | Antimetabolites, Delayed: 5 agents (25% of row) | Antimetabolites, Variable: 4 agents (20% of row) |
| Checkpoint inhibitors, row total 17 | Checkpoint inhibitors, Hyperacute: 0 agents (0% of row) | Checkpoint inhibitors, Acute: 0 agents (0% of row) | Checkpoint inhibitors, Subacute: 0 agents (0% of row) | Checkpoint inhibitors, Delayed: 15 agents (88% of row) | Checkpoint inhibitors, Variable: 2 agents (12% of row) |
| Monoclonal antibodies (other), row total 16 | Monoclonal antibodies (other), Hyperacute: 1 agent (6% of row) | Monoclonal antibodies (other), Acute: 7 agents (44% of row) | Monoclonal antibodies (other), Subacute: 4 agents (25% of row) | Monoclonal antibodies (other), Delayed: 0 agents (0% of row) | Monoclonal antibodies (other), Variable: 4 agents (25% of row) |
| Anti-angiogenic (VEGF), row total 15 | Anti-angiogenic (VEGF), Hyperacute: 0 agents (0% of row) | Anti-angiogenic (VEGF), Acute: 0 agents (0% of row) | Anti-angiogenic (VEGF), Subacute: 13 agents (87% of row) | Anti-angiogenic (VEGF), Delayed: 1 agent (7% of row) | Anti-angiogenic (VEGF), Variable: 1 agent (7% of row) |
| Antibody-drug conjugates, row total 15 | Antibody-drug conjugates, Hyperacute: 0 agents (0% of row) | Antibody-drug conjugates, Acute: 6 agents (40% of row) | Antibody-drug conjugates, Subacute: 3 agents (20% of row) | Antibody-drug conjugates, Delayed: 0 agents (0% of row) | Antibody-drug conjugates, Variable: 6 agents (40% of row) |
| Other kinase inhibitors, row total 13 | Other kinase inhibitors, Hyperacute: 0 agents (0% of row) | Other kinase inhibitors, Acute: 3 agents (23% of row) | Other kinase inhibitors, Subacute: 6 agents (46% of row) | Other kinase inhibitors, Delayed: 0 agents (0% of row) | Other kinase inhibitors, Variable: 4 agents (31% of row) |
| ALK / ROS1 / MET / TRK inhibitors, row total 12 | ALK / ROS1 / MET / TRK inhibitors, Hyperacute: 0 agents (0% of row) | ALK / ROS1 / MET / TRK inhibitors, Acute: 2 agents (17% of row) | ALK / ROS1 / MET / TRK inhibitors, Subacute: 7 agents (58% of row) | ALK / ROS1 / MET / TRK inhibitors, Delayed: 1 agent (8% of row) | ALK / ROS1 / MET / TRK inhibitors, Variable: 2 agents (17% of row) |
| Bispecifics / T-cell engagers, row total 12 | Bispecifics / T-cell engagers, Hyperacute: 0 agents (0% of row) | Bispecifics / T-cell engagers, Acute: 12 agents (100% of row) | Bispecifics / T-cell engagers, Subacute: 0 agents (0% of row) | Bispecifics / T-cell engagers, Delayed: 0 agents (0% of row) | Bispecifics / T-cell engagers, Variable: 0 agents (0% of row) |
| BRAF / MEK inhibitors, row total 11 | BRAF / MEK inhibitors, Hyperacute: 0 agents (0% of row) | BRAF / MEK inhibitors, Acute: 1 agent (9% of row) | BRAF / MEK inhibitors, Subacute: 5 agents (45% of row) | BRAF / MEK inhibitors, Delayed: 0 agents (0% of row) | BRAF / MEK inhibitors, Variable: 5 agents (45% of row) |
| EGFR / HER2 inhibitors, row total 11 | EGFR / HER2 inhibitors, Hyperacute: 0 agents (0% of row) | EGFR / HER2 inhibitors, Acute: 3 agents (27% of row) | EGFR / HER2 inhibitors, Subacute: 5 agents (45% of row) | EGFR / HER2 inhibitors, Delayed: 1 agent (9% of row) | EGFR / HER2 inhibitors, Variable: 2 agents (18% of row) |
| Hormonal / endocrine, row total 10 | Hormonal / endocrine, Hyperacute: 0 agents (0% of row) | Hormonal / endocrine, Acute: 0 agents (0% of row) | Hormonal / endocrine, Subacute: 4 agents (40% of row) | Hormonal / endocrine, Delayed: 1 agent (10% of row) | Hormonal / endocrine, Variable: 5 agents (50% of row) |
| Microtubule inhibitors, row total 8 | Microtubule inhibitors, Hyperacute: 1 agent (13% of row) | Microtubule inhibitors, Acute: 3 agents (38% of row) | Microtubule inhibitors, Subacute: 0 agents (0% of row) | Microtubule inhibitors, Delayed: 1 agent (13% of row) | Microtubule inhibitors, Variable: 3 agents (38% of row) |
| Antitumor antibiotics, row total 7 | Antitumor antibiotics, Hyperacute: 0 agents (0% of row) | Antitumor antibiotics, Acute: 3 agents (43% of row) | Antitumor antibiotics, Subacute: 2 agents (29% of row) | Antitumor antibiotics, Delayed: 1 agent (14% of row) | Antitumor antibiotics, Variable: 1 agent (14% of row) |
| BCR-ABL inhibitors, row total 7 | BCR-ABL inhibitors, Hyperacute: 0 agents (0% of row) | BCR-ABL inhibitors, Acute: 0 agents (0% of row) | BCR-ABL inhibitors, Subacute: 1 agent (14% of row) | BCR-ABL inhibitors, Delayed: 3 agents (43% of row) | BCR-ABL inhibitors, Variable: 3 agents (43% of row) |
| PI3K / AKT inhibitors, row total 7 | PI3K / AKT inhibitors, Hyperacute: 2 agents (29% of row) | PI3K / AKT inhibitors, Acute: 1 agent (14% of row) | PI3K / AKT inhibitors, Subacute: 2 agents (29% of row) | PI3K / AKT inhibitors, Delayed: 2 agents (29% of row) | PI3K / AKT inhibitors, Variable: 0 agents (0% of row) |
| Radiopharmaceuticals, row total 7 | Radiopharmaceuticals, Hyperacute: 0 agents (0% of row) | Radiopharmaceuticals, Acute: 2 agents (29% of row) | Radiopharmaceuticals, Subacute: 0 agents (0% of row) | Radiopharmaceuticals, Delayed: 3 agents (43% of row) | Radiopharmaceuticals, Variable: 2 agents (29% of row) |
| CAR-T cell therapy, row total 5 | CAR-T cell therapy, Hyperacute: 0 agents (0% of row) | CAR-T cell therapy, Acute: 5 agents (100% of row) | CAR-T cell therapy, Subacute: 0 agents (0% of row) | CAR-T cell therapy, Delayed: 0 agents (0% of row) | CAR-T cell therapy, Variable: 0 agents (0% of row) |
| Cytokines & enzymes, row total 5 | Cytokines & enzymes, Hyperacute: 0 agents (0% of row) | Cytokines & enzymes, Acute: 3 agents (60% of row) | Cytokines & enzymes, Subacute: 1 agent (20% of row) | Cytokines & enzymes, Delayed: 0 agents (0% of row) | Cytokines & enzymes, Variable: 1 agent (20% of row) |
| Topoisomerase inhibitors, row total 5 | Topoisomerase inhibitors, Hyperacute: 0 agents (0% of row) | Topoisomerase inhibitors, Acute: 3 agents (60% of row) | Topoisomerase inhibitors, Subacute: 0 agents (0% of row) | Topoisomerase inhibitors, Delayed: 0 agents (0% of row) | Topoisomerase inhibitors, Variable: 2 agents (40% of row) |
| Bisphosphonates & bone, row total 4 | Bisphosphonates & bone, Hyperacute: 0 agents (0% of row) | Bisphosphonates & bone, Acute: 2 agents (50% of row) | Bisphosphonates & bone, Subacute: 1 agent (25% of row) | Bisphosphonates & bone, Delayed: 1 agent (25% of row) | Bisphosphonates & bone, Variable: 0 agents (0% of row) |
| BTK inhibitors, row total 4 | BTK inhibitors, Hyperacute: 0 agents (0% of row) | BTK inhibitors, Acute: 3 agents (75% of row) | BTK inhibitors, Subacute: 0 agents (0% of row) | BTK inhibitors, Delayed: 0 agents (0% of row) | BTK inhibitors, Variable: 1 agent (25% of row) |
| FGFR inhibitors, row total 4 | FGFR inhibitors, Hyperacute: 0 agents (0% of row) | FGFR inhibitors, Acute: 0 agents (0% of row) | FGFR inhibitors, Subacute: 4 agents (100% of row) | FGFR inhibitors, Delayed: 0 agents (0% of row) | FGFR inhibitors, Variable: 0 agents (0% of row) |
| mTOR inhibitors, row total 4 | mTOR inhibitors, Hyperacute: 0 agents (0% of row) | mTOR inhibitors, Acute: 0 agents (0% of row) | mTOR inhibitors, Subacute: 3 agents (75% of row) | mTOR inhibitors, Delayed: 0 agents (0% of row) | mTOR inhibitors, Variable: 1 agent (25% of row) |
| Platinum agents, row total 4 | Platinum agents, Hyperacute: 0 agents (0% of row) | Platinum agents, Acute: 4 agents (100% of row) | Platinum agents, Subacute: 0 agents (0% of row) | Platinum agents, Delayed: 0 agents (0% of row) | Platinum agents, Variable: 0 agents (0% of row) |
| CDK4/6 inhibitors, row total 3 | CDK4/6 inhibitors, Hyperacute: 0 agents (0% of row) | CDK4/6 inhibitors, Acute: 0 agents (0% of row) | CDK4/6 inhibitors, Subacute: 3 agents (100% of row) | CDK4/6 inhibitors, Delayed: 0 agents (0% of row) | CDK4/6 inhibitors, Variable: 0 agents (0% of row) |
Agent counts per class family × onset window · color depth scales within the grid · column totals above each window.
How the count of agents per drug generation distributes across kidney injuries — a composition view by era (left), not calendar year. Each ribbon's width is the number of agents from that era carrying that signature injury (right). What the ribbons actually show: the established generation spreads across the structural lesions — tubular necrosis, thrombotic microangiopathy, crystal and chronic interstitial disease — while the frontier concentrates into prerenal/hemodynamic AKI above all, with electrolyte disturbance and pseudo-AKI its next-widest ribbons, and carries no TMA agent at all. Hover or tap a node to isolate its flows.
- Established era → Acute Tubular Necrosis: 6 agents
- Established era → Acute Interstitial Nephritis: 5 agents
- Established era → Thrombotic Microangiopathy: 3 agents
- Established era → Glomerular Injury / Proteinuria: 3 agents
- Established era → Electrolyte Disturbance: 9 agents
- Established era → Crystal / Obstructive Nephropathy: 3 agents
- Established era → Hypertension: 3 agents
- Established era → Prerenal / Hemodynamic AKI: 13 agents
- Established era → SIADH / Hyponatremia: 2 agents
- Established era → Chronic Interstitial Nephropathy: 2 agents
- Recent era → Acute Tubular Necrosis: 7 agents
- Recent era → Acute Interstitial Nephritis: 7 agents
- Recent era → Thrombotic Microangiopathy: 2 agents
- Recent era → Glomerular Injury / Proteinuria: 1 agents
- Recent era → Electrolyte Disturbance: 6 agents
- Recent era → Crystal / Obstructive Nephropathy: 1 agents
- Recent era → Hypertension: 4 agents
- Recent era → Prerenal / Hemodynamic AKI: 21 agents
- Recent era → SIADH / Hyponatremia: 1 agents
- Recent era → Pseudo-AKI: 8 agents
- Recent era → Chronic Interstitial Nephropathy: 1 agents
- Frontier era → Acute Tubular Necrosis: 2 agents
- Frontier era → Acute Interstitial Nephritis: 1 agents
- Frontier era → Glomerular Injury / Proteinuria: 1 agents
- Frontier era → Electrolyte Disturbance: 6 agents
- Frontier era → Crystal / Obstructive Nephropathy: 2 agents
- Frontier era → Prerenal / Hemodynamic AKI: 27 agents
- Frontier era → SIADH / Hyponatremia: 1 agents
- Frontier era → Pseudo-AKI: 4 agents
- Frontier era → Chronic Interstitial Nephropathy: 1 agents
- Investigational era → Prerenal / Hemodynamic AKI: 1 agents
Ribbon width = agents flowing from each era to their signature injury · numbers = agents per era. A further 146 catalog agents carry no recorded era and are not in this figure — the ribbons total 154 agents, not the full catalog.
Assemble a regimen and see where kidney risk compounds. Each bar is a kidney injury; its length is how many of the chosen agents carry it, at any tier. Injuries two or more drugs carry, at least one above the rare tier, are the additive hazards to watch (⚠).
2 agents selected · bar segments = contributing drugs (opacity = injury tier: primary / secondary / rare) · ⚠ marks injuries two or more agents carry, at least one above the rare tier (compounding risk). Educational — not a dosing tool.
The documented anti-cancer combinations whose kidney risk compounds beyond either drug alone. Each arc joins two agents whose co-administration drives a kidney injury — colored by that phenotype — and a node grows with the number of combinations it anchors. Read the hubs that recur across regimens and the phenotype that dominates the synergies. Hover, tap, or focus a node for its combinations; the complementary agent-count view is the regimen injury-stacking figure above.
- Cisplatin + gemcitabine — synergistic thrombotic microangiopathy (PMID 33980166)
- Mitomycin C + 5-fluorouracil — carcinoma-associated TMA/HUS (PMID 36706238)
- Ipilimumab + nivolumab — dual checkpoint blockade, higher immune AIN (PMID 31896554)
- Cisplatin + ifosfamide — potentiated proximal-tubular injury / Fanconi (PMID 8232077)
- Cisplatin + pemetrexed — additive proximal-tubular ATN (PMID 32505078)
- Cisplatin + high-dose methotrexate — platinum tubular injury delays MTX clearance (PMID 31169759)
- Sunitinib + bevacizumab — dual VEGF blockade, MAHA/TMA plus hypertension & proteinuria (PMID 19402058)
- Acute Tubular Necrosis
- Acute Interstitial Nephritis
- Thrombotic Microangiopathy
- Fanconi Syndrome
7 verified combinations across 11 agents, thrombotic microangiopathy the most common synergy phenotype (3). Hover, tap, or focus a node to trace its combinations.
Node size = combinations anchored · arc color = the compounded kidney injury · every edge is PMID-grounded. Documented additive/synergistic risk, not a per-patient prediction.
Data Studio
Build your own view of the whole nephrotoxicity dataset. Pick a chart, choose the axes, color and group by any dimension, and filter to a slice — then read what falls out. Every field comes from the same citation-grounded catalog behind the rest of the atlas.
292 of 292 agents; charts omit any agent missing the plotted value. Exploratory view of documented data — not a statistical model or a clinical recommendation.
Covers the 292 cataloged agents. Exploratory teaching tool — read the shape, not a statistical model.
Go deeper
Figures are derived from the static, citation-grounded catalog. FAERS is a spontaneous-reporting system — reporting odds ratios reflect disproportionate reporting, not incidence or proven causation. Medical-education content only — not medical advice.